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Mutations in the ras genes are present in about 30% of all human cancers, but more 
than 90% of pancreatic ductal adenocarcinomas (PDACs) carry mutations in exon 1 of 
the KRAS gene: a genetic lesion that drives the malignant transformation of the cells. 
The main function of mutant KRAS in PDAC is to reprogram the metabolism in order to 
generate, from glucose and glutamine, the biomass and the reducing power necessary 
to fuel a high rate of proliferation. 
As pancreatic cancer cells are addicted to KRAS, this oncogene is considered the main 
target for the design of new and innovative therapeutic strategies. 
Recent studies have demonstrated that the promoter of KRAS contains a G- rich 
sequence motif located immediately upstream of the transcription start site (TSS). This 
sequence contains a non-canonical DNA structure, called G-quadruplex (G4). 
This discovery, which was carried out in our laboratory in 2006 1, raised many questions 
about the capacity of the G4 motif to form, under physiological conditions, a stable G4 
structure. As the G4 motif is located near to TSS, a challenging question is to know if this 
folded DNA conformation is somehow implicated in transcription regulation. Although 
this issue has been addressed by many studies, the role of the G4 DNA in gene 
expression is not yet clear. However, in our laboratory we found that the G4 of KRAS is 
recognized by several transcription factors (TFs), including MAZ, hnRNP A1, PARP-1 and 
OGG1. 
As PDAC cells have a high metabolic rate, they produce more reactive oxygen species 
(ROS) than healthy cells. A high intracellular level of ROS is toxic and oxidize lipids, 
proteins and DNA. These chemical modifications of the macromolecules, impair their 
function leading to cancer cells death by apoptosis. To avoid this unfavourable outcome, 
cancer cells have developed specific metabolic pathways, in order to control the redox 
homeostasis. The protein that behaves as a master regulator of oxidative stress is Nrf2, 
a transcription factor that, when ROS increases, migrates from the cytoplasm to the 
nucleus where it binds to a specific sequence of DNA, corresponding to the antioxidant 
response element (ARE). This stimulates the expression of several antioxidant genes that 





We found that in PDAC cells the ectopic expression of mutant KRAS G12D or G12V 
results in the upregulation of Nrf2, suggesting that the oncogenic KRAS controls the 
redox homeostasis through Nrf2 expression. Therefore, we also found that an increase 
of ROS upregulates KRAS. 
So, all the results taken together show that the redox balance in PDAC cells is maintained 
by an axis composed by ROS, KRAS and Nrf2. This axis has a function that goes beyond 
the control of the redox homeostasis, as it affects also the survival and apoptosis 
pathways involving Nf-B, Snail and RKIP. Our data show that low ROS levels result in 
the upregulation of NF-B and pro-survival Snail and the simultaneously downregulation 
of pro-apoptotic RKIP: this gene expression pattern favours cell proliferation. By 
contrast, high ROS favour apoptosis by upregulating pro-apoptotic RKIP and 
downregulating NF- B and pro-survival Snail. 
We then addressed the issue of how ROS upregulate KRAS. Evidence that ROS stimulate 
KRAS through a mechanism involving guanine oxidation in the G4 motif is provided. It 
should be noted that among the four DNA bases, guanine, having the lowest redox 
potential, is prone to oxidation to 7,8-dihydro-8-oxo-guanine (8OG). ChIP and qPCR-Real 
Time experiments showed that 8OG is more abundant in the G4 motif region of KRAS 
than in non-G4 regions, suggesting that the critical G4 motif is a hotspot for guanine 
oxidation. We hypothesised that this epigenetic modification plays a critical role in 
regulating the expression of KRAS. 
We moreover asked if 8OG affects the quadruplex structure formed in the promoter of 
the KRAS gene. In order to answer to this question, we designed a series of 
oligonucleotides mimicking the G4 motif, hosting 8OG in specific positions. By DMS 
footprinting, UV-spectroscopy and circular dichroism experiments, we analysed their 
capacity to fold into a stable G4. We found that 8OG has a strong impact on G4. When 
8OG is located in a loop of the G4, both topology and stability of the G4 structure do not 
change. In contrast, when it is located in a G-run forming a G-tetrad, the G4 motif folds 
in an alternative way and replaces the oxidized G-run with the extra G-run present in 
the G4 motif sequence. The resulting G4 has a different topology and a TM 10 °C lower 





Interestingly, we also found that the transcription factors MAZ, hnRNP A1 and PARP1 
are recruited more efficiently to the G4 motif when it hosts oxidized guanines. Thanks 
to the binding to G4, MAZ and hnRNP A1 unfold the structure and induce the G4 motif 
to assume the duplex conformation. Besides TFs, hOGG1 is also recruited to the oxidized 
G4 motif. This glycosylase recognizes the G4 motif in duplex and excises 8OG though the 
base excision repair (BER) process. The free-excised 8OG binds to hOGG1 and the 
complex behaves as guanine exchange factor activating the KRAS protein by 
transforming KRAS-GDP into KRAS-GTP. 
In the light of our findings, we have designed two anticancer strategies to inhibit KRAS 
in PDAC cells. 
The first is based on the use of photosensitizers generating ROS together with Nrf2 
inhibitors. Under these conditions, the photosensitizer produces high levels of ROS that 
trigger apoptosis. 
The second considers that in pancreatic cancer several microRNAs are aberrantly 
downregulated. We discovered that miR-216b is one of this microRNA aberrantly 
downregulated in PDAC. We thus designed miR-216b mimics with unlocked nucleic acids 
(UNA) modifications to make it more resistant to endogenous nucleases. We found that 
the designed UNA-modified miRNAs strongly suppressed KRAS gene in an 
AGO2- dependent manner. 
To conclude, although the research in oncology has made important achievements in 
the treatment of many human tumours, PDAC remains one of the deadliest disease with 
a poor prognosis. We think that our research may be useful in the rationale design of 







2.1 Pancreatic Cancer 
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease which represents one 
of the main causes of death in western countries 2. There are many risk factors leading 
to this malignant disease, including cigarette smoking, family history of pancreatic 
cancer and chronic pancreatitis 3,4. Generally, this type of tumour is asymptomatic and 
often, when diagnosed, it is untreatable, leading to a 5-year survival rate of only  5%  5,6. 
Since PDAC shows a little response to conventional chemotherapy, tumour resection 
remains the main option. Unfortunately, many patients are not eligible for resection 
and, even when the latter is carried out, the patients face problems of recurrence. 
PDAC is the most common form of pancreatic cancer, it arises in the exocrine part of the 
organ and starts from small non-invasive precursor lesions known as PanIN (Pancreatic 
Intraepithelial Neoplasia). 
As already known, cancer is a genetic disease due to accumulation of somatic mutations 
in both oncogenes and tumour suppressor genes. Four genes resulted to be directly 
involved in the development of PDAC and the activation or suppression of their 
downstream signals play an important role in the initiation and progression of the 
malignancy. These critical genes are KRAS, CDKN2A, TP53 and SMAD4. 
KRAS is a proto-oncogene and it is found to be altered in more than 90% of PDAC 
patients. Point mutations, occurring mainly at codon 12 or 13, result in the production 
of an activated protein that controls several signalling pathways. The other three critical 
genes are tumour suppressor genes implicated in the control of cell cycle regulation 
(CDKN2A), in cellular stress response (TP53) and in signalling mediated by transforming 






2.2 RAS family 
The role of the ras genes in the development of cancer was discovered in the mid-1960s, 
laying the molecular basis for cancer studies. 
By investigating transforming retroviruses isolated from mice, rats, monkeys or 
chickens, scientists found that these viruses were able to cause a rapid onset of sarcoma 
in infected animals and transformation of cultured cells 7. The first two viruses were 
discovered in rats by Jennifer Harvey 8 and Werner Kirsten 9 and were therefore called 
Harvey and Kirsten murine sarcoma viruses 8,10,11. The ability of these genes to cause 
sarcoma in rats is the reason of their name (RAS derives from RAT Sarcoma), but at the 
beginning ras genes were considered variants of src genes 12,13. In 1974, Scolnick and his 
collaborators speculated that the oncogenic potential of the sarcoma viruses were 
linked to their capacity to transduce normal cellular rat sequences into their own 
genomes 14, but years later other studies found out that tumours can be caused by 
mutations occurring in proto-oncogenes. In 1982, Geoffrey Cooper and his group 
published a study on human bladder and human lung carcinoma cell lines in which they 
found that the transforming genes in these cell lines were homologs of the ras genes of 
Harvey and Kirsten sarcoma viruses 15, and other works reported the presence of other 
homologous genes in human genome 16. 
 
2.2.1 RAS proteins 
The ras genes encode for low molecular weight GTPases (guanosine triphosphatesis) 
involved in signal transduction pathways which control proliferation, survival, growth, 
differentiation and other related important functions. The ras family includes three 
genes HRAS, KRAS and NRAS, encoding for highly homologous proteins of 21 KDa. There 
are two different isoforms for the KRAS protein, namely KRAS4A and KRAS4B, which 
derive from alternative splicing. 
These proteins contain two functional domains: the membrane targeting domain and 






Figure 1. Representation of the two functional domains of RAS proteins: the G-domain shows a 
high similarity between different RAS isoforms and contains the two regions Switch I (SI) and 
Switch II (SII) important for the binding with protein effectors; the membrane targeting domain 
is the hypervariable region. (Zeitouni D., 2016) 
 
The membrane targeting domain, located in the C-terminal domain of the protein, is a 
hypervariable region (HVR) and the three RAS isoforms show in this region the greatest 
diversity in amino acid sequence 17. The C-terminal domain undergoes post-translational 
modifications, which make the RAS proteins functionally active. The first step consists in 
the lipid modification of the Cys186 in the “CAAX box”, that is an important process 
driving the RAS localization 18. In the CAAX motif, C represent cysteine, A is an aliphatic 
amino acid and X denote the terminal amino acid, which can be serine, methionine, 
glutamine or leucine and plays an important role in determining the type of lipid 
modification: farnesylation or geranylgeranylation. The farnesylation process consists in 
the binding of 15-carbon farnesyl group by the enzyme farnesyl transferase (FTase), 
whereas in the geranylgeranylation process, the Leu in CAAL allows the linkage of a 
20- carbon geranylgeranyl chain by geranylgeranyl transferase 7,19,20. Thanks to these 
modifications the immature proteins become more hydrophobic and show a higher 
affinity for the endoplasmic reticulum (ER) membrane 18. In ER, the last three amino 
acids of either CAAX or CAAL are proteolytically cleaved by the RAS - converting 
enzyme  1  (Rce1) and the carboxyl terminal group is methylated. The final modification 
consists in the palmitoylation, which increases biological activity and membrane affinity 





The catalytic G-domain of 164 residues contains the regions of the protein responsible 
for binding to GTP and its hydrolysis to GDP. This domain is highly conserved in the three 
different isoforms (80% of sequence homology), even when the RAS mutations, that are 
critical for the catalytic activity of the protein, occur in the residues 12, 13 or 61 of this 
domain 21. 
RAS proteins’ activity is controlled by an on-off mechanism depending on GTP - GDP 
binding. The binding of GTP to the phosphate-binding loop present in the catalytic 
domain causes a conformational change in other two regions called Switch I and 
Switch  II and permits the interaction with effectors molecules 17. RAS proteins have a 
rather weak intrinsic capacity to hydrolyse GTP to GDP and their inactivation is mediated 
by a class of proteins called GAPs (GTPase activating proteins), which are able to speed 
up the hydrolysis. The two most studied GAPs proteins are p120GAP and NF1 10. 
p120GAP was the first identified RAS regulator and shows a catalytic domain that binds 
to the RAS effector domain in order to stop the RAS signalling. NF1 represents the 
tumour suppressor gene neurofibromatosis type I and contains a sequence homologous 
to p120GAP: this factor encodes for a protein that is responsible for the RAS inhibition, 
favouring the GTP hydrolysis. It has been reported that mutations or deletions of the 
NF1 gene are associated to an increased risk of cancer development 22–24. 
As RAS mutations are generally related to the loss of interaction between GAPs and RAS, 
these proteins are very important for the regulation of RAS hyperactivation and 
therefore for tumorigenesis prevention. 
Other important RAS regulators are represented by a group of proteins called GEFs, or 
guanine nucleotide exchange factors, which control the switch between the GDP- bound 
inactive state and the GTP-bound active state, catalysing the exchange of GDP with 
GTP  22. Since RAS proteins show a high affinity for both GDP and GTP, the nucleotide 
dissociation rate is slow and GEFs proteins play an important role, as the exchange of 
GDP for GTP is a rather fast process taking place within minutes or even less 25. These 
proteins are reported to increase the exchanging rate by several orders of magnitude  26. 
Three classes of GEF effectors containing the CDC25 catalytic domain and the 
N- terminal RAS exchange factor domain have been discovered: SOS, RAS-GRF and 





nucleotide binding is due to their capacity to modify Switch I and Switch II residues on 
RAS proteins, leading to GDP release and favouring GTP replacement 27 (Figure 2). 
 
 
Figure 2. RAS regulation mediated by GAPs and GEFs effectors (Malumbres M, 2003) 
 
 
2.2.2 KRAS and pancreatic cancer 
As before mentioned, the most frequent type of tumour in human pancreas is pancreatic 
ductal adenocarcinoma and the principal cause of its development and progression is 
represented by activating mutations in the KRAS oncogene. It has been found that 
human pancreatic cancers present predominantly three specific single point mutations 
in exon 1 at residues G12, G13 and Q61. In particular, mutations at G12 or G13 create 
steric hindrance that avoids the interaction between RAS and GAPs and leads to a 
constitutive RAS activation. On the other hand, substitutions at residue Q61 block the 
critical coordination of a water molecule for nucleotide hydrolysis 28. 
As all the mutations give RAS proteins constitutively active, the final result is the 
stimulation of downstream signalling pathways, leading to the increase of cell 
proliferation and survival, suppression of apoptosis, production of changes in tumour 
microenvironment, promotion of metabolic alterations and metastasis 






Figure 3. KRAS regulation in normal cells (left) and in pancreatic cancer cells (right). 
 
In past years it has been shown that KRAS G12D plays a critical role in the progression 
of pancreatic cancer and, using experimental models, it has been demonstrated that this 
particular mutation is fundamental for tumour cell survival 29–31. This point mutation 
consists in the substitution of glycine (G) with an aspartic acid (D) residue in exon 1, 
codon 12, leading to a constitutively active protein. As a result, constant KRAS G12D 
signalling brings to aberrant proliferation and increases the survival of cancer cells 
through the activation of downstream signalling pathways, as MAPK and 
PI3K- mTOR  (Figure 4). 
 
 





Starting from the observation that cancer is a genetic disease caused by alterations 
occurring in cells, we can affirm that pancreatic ductal adenocarcinoma development is 
the result of several mutagenic events occurring in normal pancreatic cells. 
In particular, KRAS mutations cause PanIN lesions that are small non- invasive precursor 
lesions. Then additional genetic alterations lead to the progression of the malignancy. 
Di Magliano and Logsdon, by studying the role of KRAS oncogene in pancreatic tumour 
development and progression, found that the effect of KRAS inactivation is time 
dependent  32. Oncogenic KRAS is important at early stages of lesion formation: indeed, 
the inactivation of the protein leads to apoptosis or cancer regression 33. Despite this, 
the transformation of PanIN lesions into adenocarcinoma requires additional mutations, 
such as loss of function of several tumour suppressor genes (p53 or p16) 34. Moreover, 
to highlight the critical role of the KRAS gene in PDAC, it has been reported that its 
inactivation in the advanced disease causes tumour regression but the specific 
mechanisms have not been yet identified. However, a small fraction of tumour cells, 
which conserves the mutations in KRAS gene and in other related genes, continues to 
proliferate leading to metastasis 32. These findings let to think that PDAC is closely 
related to KRAS activation. 
Other recent data have demonstrated that pancreatic cancer cells are addicted to 
oncogenic KRAS. This means that the cells, in order to support their enhanced metabolic 
rate, require a constitutive expression of KRAS. Cells with a high rate of division need 
energy and biomass (biosynthetic precursors): this is obtained by modifying the 
metabolism which is reprogrammed by oncogenes 31,35. In fact, DePinho and his group 
have recently found that oncogenic KRAS reprograms the glucose and glutamine (Gln) 
metabolism in PDAC, so as satisfy the high anabolic request typical of dividing cells. In 
particular they found that, when the KRAS activity is abolished in PDAC cells, a significant 
decrease of some glycolytic components is observed, such as glucose-6- phosphate 
(G6P), fructose-6-phospate (F6P) and fructose-1,6-bisphosphate (FBP). Authors also 
found that oncogenic KRAS increases the glycolytic flux, affecting glucose uptake and 
lactate production 31. Together, these metabolic changes are responsible for the 
so- called Warburg effect, according to which cancer cells consume big amount of 





that, in the presence of oxygen, cells can efficiently produce energy with a high 
ATP/glucose yield through the aerobic mitochondrial metabolism 36,37. 
So, why do cancer cells require glucose more than healthy cells? The answer to this 
question is quite simple: cancer cells require biomass to sustain a high rate of cell 
division. A high glycolytic flux provides the cells carbon atoms for the synthesis of 
essential molecules such as ribose, nucleotides, amino acids, phospholipids and many 
other essential compounds (Figure 5A) 38. As illustrated in Figure 5B, Serine plays a 
critical role in the generation of amino acids and nucleotides. KRAS increases the activity 
of enzyme phosphoglycerate dehydrogenase (PHGDH), which substracts 
3- phosphoglycerate (3PG) to the glycolytic flux, directing it towards the synthesis of 
Serine (Ser). This amino acid is essential for several anabolic pathways. For example, it 
is transformed into glycine (Gly) by providing a methyl group to folic acid (FA). By 
interacting with methionine, Ser can also provide cysteine (Cys). Methyl-THF is then 
























Figure 5. (A) The enhanced glycolytic flux in cancer cells fosters the synthesis of essential 
molecules. (Cell Rep. 2017 Jan 17; 18(3): 601–610.) (B) Serine biosynthesis and folate cycle are 
important pathways for the generation of amino acids and nucleotides (Luengo A, 2017) 
 
In addition to glycolysis, the metabolic rewiring caused by KRAS affects also the Gln fate, 
which does not follow the canonical oxidative pathway through the tricarboxylic acid 
(TCA) cycle 39,40. Gln is transformed into aspartate (Asp), and then translocated in the 
cytoplasm where it is converted to oxaloacetate (OOA). OOA is reduced to malate which 
is then decarboxylated to pyruvate: a process associated with the increase of 
NADPH/NADP+ ratio, i.e. an increasing of reductive power, which is important for the 
maintenance of the redox homeostasis 39. Moreover, Gln in PDAC is essential not only 
because it functions as a carbon source for the TCA cycle, but also because it supplies 
nitrogen for nucleotides, nonessential amino acids and hexosamine 







Figure 6. Effect of mutated KRAS on glucose metabolism and changes that happen upon KRASG12D 
withdrawal. (Ying H,2012) 
 
 
2.2.3 Targeting RAS as a therapeutic strategy 
As RAS proteins play a central role in the malignant transformation and progression of 
PDAC, it is of great therapeutic significance to find strategies for targeting these proteins 
in order to cure PDAC. It is known that ras are the most mutated genes in human 
cancer  42. The three ras isoforms are not equally mutated in human tumours: KRAS 
mutations are present in about 86% of human tumours, NRAS mutations in 11% of 
tumours and HRAS mutations only in about 3% of tumours. There are specific 
correlations between cancer and mutated ras isoforms: for example, PDAC and lung 
adenocarcinoma show preferentially KRAS mutations, whereas cutaneous melanoma 
and acute myelogenous leukaemias show preferentially mutations in NRAS gene. 
Mutations in both KRAS and NRAS can be found in colon and rectal carcinoma and also 
in multiple myeloma. Bladder cancer and head-neck squamous cell carcinoma show 
preferentially HRAS mutations 43. 
These different isoform mutations observed in human cancer suggest that every tumour 
may need to be targeted in a different way. Efforts done up to now by the scientific 
community and by private pharmaceutical industries have not produced effective 
anti- ras therapeutics. Target therapy against RAS protein did not give the expected 
results and the opinion that ras is “undruggable” has become widespread in the research 
field. Because of this, the search for new targets to cure PDAC is one of the biggest 





maintenance of PDAC, this critical oncogene remains the main target for the rational 
design of new therapeutic strategies. 
Several types of anti KRAS approaches have been tested: (i) development of inhibitors 
binding to the RAS protein; (ii) inhibitors against the RAS membrane association; 
(iii)  inhibitors capable to target downstream effectors of RAS signalling; (iv) synthetic 
lethality approach; (v) inhibitors against metabolic target; (vi) strategies against KRAS 
DNA and KRAS mRNA (Figure 7). 
The first approach, based on the development of inhibitors binding to the RAS protein, 
showed to be rather difficult to apply. Computational studies allow to identify potential 
binding sites, but the hydrophobic pockets on the surface of the RAS protein are not 
deep enough to host a therapeutic molecule 43–45. Several compounds were tested but 
all failed to give interesting results and showed in vivo toxicity. SCH-53239 was designed 
to compete with the binding of GDP 46 while other compounds based on non-steroidal 
anti-inflammatory drug (sulindac sulphide) were anticipated to inhibit RAS/RAF complex 
formation 47. 
In addition, other molecules have been developed to inhibit the interaction between 
RAS and other cellular factors. The RAS/RAF interaction is one of the most targeted: 
MCP1 and derivatives, in addition to the inhibition of RAS/RAF binding, showed the 
capacity to revert the malignant phenotype, even if they did not result strong 
enough  48,49. Genentech developed a compound called DCAI, which inhibits 
SOS- mediated nucleotide exchange by preventing the interaction between RAS and 
SOS  50. Unfortunately, this molecule binds weakly to KRAS. 
Because this first approach based on molecules designed to inhibit RAS proteins did not 
give promising results, the research concentrate the efforts to develop inhibitors against 
the RAS membrane association. The attention was focused on farnesyl transferase 
inhibitors (FITs) 51,52. FTase is the enzyme that catalyses the addiction of a 15-carbon 
farnesyl group to immature RAS protein. With this modification, the RAS protein become 
more hydrophobic and it is targeted to endoplasmic reticulum for the final 
modifications. FITs can prevent RAS protein activation and several studies showed that 
there are effective therapeutic molecules but they are not useful against all RAS 
isoforms. As a matter of fact, some FITs compounds, such as lonafarnib or tipifarnib, 





This happens because if FTase activity is blocked, KRAS and NRAS proteins become 
substrates for geranylgeranyltransferase, another enzyme that add a C-20 
geranylgeranyl isoprenoid group allowing the protein membrane association 53–55. 
To overcome the problems related to differences in the RAS maturation process, 
researchers focus their attention on another strategy to obtain RAS inhibition, designing 
molecules capable to target downstream effectors of RAS signalling. Many drugs 
targeting RAS effectors were developed and tested in clinical trials, but until now, all 
these compounds remain only in early phase trials 56,57. This strategy seems to be 
promising, but there are some problems to face: for example the cells are able to display 
some compensatory mechanisms when an important pathway is blocked, decreasing 
the efficacy of the treatment. Moreover, it could be necessary to inhibit not only one 
but several pathways that normally cross talk. This leads to the development of 
combining inhibitors against RAF and PI3K effectors that allow to obtain a greater 
outcome in terms of inhibition of RAS activity 57,58. However, this method shows an 
important side effect related to increased toxicity in normal cells 43. 
Because all these approaches, which target RAS proteins or their effectors, show several 
issues that need to be addressed and result to be a challenge for many reasons, it may 
be necessary to move to other directions. 
The fourth anti KRAS approach deals with the concept of synthetic lethality. This method 
suggests that the identification of specific targets showing synthetic lethal interaction 
with RAS could increase therapeutic selectivity. The synthetic lethality is described as 
the co-occurrence of two genetic events that can bring to cell death 59. The application 
of this approach is based on the discovery of genes whose inhibition would be lethal 
only when RAS is mutated 17,43. Although this approach has not been yet tested in human 
cancer therapy, several synthetic lethal targets have been identified and this strategy 
seems to provide a new therapeutic framework. 
In order to sustain the high metabolic rate, cancer cells enhance their metabolism and 
KRAS has been reported to be a key factor in promoting metabolic rewiring. Starting 
from this observation, it is easy to identify another anti KRAS approach based on the use 
of inhibitors directed against metabolic targets. Targeting metabolic pathways would be 
an interestingly anti-cancer strategy because normal cells, which are not KRAS-addicted, 





inhibitors have been tested in early phase clinical trials 60. These molecules are able to 
alter the redox balance in pancreatic cancer cells blocking the action of glutaminase, an 
enzyme that catalyses the conversion of glutamine to glutamate. Moreover, if in 
combination with treatments that increase ROS, the glutaminase inhibitors are able to 
reduce pancreatic cancer growth 39. 
Other drugs are used to obtain the inhibition of autophagy and macropynocitosis (HCQ), 
or to reduce glucose metabolism by blocking the mitochondrial complex  I or MEK 
(phenformin / metformin) 39,60,61. 
Findings demonstrating the importance of redox balance and the role of KRAS in 
maintaining ROS homeostasis through Nrf2 stimulation, suggest an interesting scenario: 
if controlled level of ROS promotes tumour development, the modification of redox 
balance in KRAS-driven tumours may represent an efficacy strategy to inhibit PDAC 
development  43,62. 
Even if these three decades of research have not given amazing results in the field of 
RAS-targeting molecules and pancreatic tumour strategies yet, a greater knowledge 
about RAS proteins, differences between three RAS isoforms, processes mediated by 










Finally, based on the fact that target therapy against the RAS proteins did not give the 
expected results, many scientists focused on the gene itself and hypothesised several 
strategies to directly suppress KRAS in PDAC cells 63–65. These strategies are based on the 
experimental findings that the suppression of KRAS in PDAC triggers a cell response, 
leading to apoptosis. 
To design molecular approaches aiming at the inhibition of gene expression at 
transcriptional or translational level, it is important to know the mechanisms of 
transcription and translation. The research so far done in this field, to which also the 
laboratory where I have worked for my PhD has contributed, has put in evidence that 
the ras gene has promoters characterized by a high C+G regions, in particular upstream 
of the transcription start site (TSS). These G-rich regions have two important 
characteristics: first, they are structurally polymorphic and can form unusual 
G- quadruplex structures; second, guanines present in clusters can easily undergo 
oxidation to 8-oxoguanine (8OG). As reported in the results of this PhD work, 
G- quadruplex and 8OG play a crucial role in the biology of KRAS in PDAC cells. 
Moreover, new therapeutic strategies are represented by microRNAs (miRNAs), which 
are small non-coding RNAs of approximately 20-22 nucleotides and act as 
post- transcriptional regulators. Immature miRNAs are initially transcribed as 
pre- miRNAs, then processed by Drosha in the nucleus and Dicer in the cytoplasm 66. 
MicroRNAs are not able to act by themselves and need to be incorporated with 
Argonaute (AGO) family of proteins in a complex called RISC (RNA-induced silencing 
complex) 67,68. Mature miRNAs in the RISC complex recognize complementary sequences 
on mRNA and cause mRNA degradation leading to the inhibition of translation. So, 
miRNAs can act as tumour suppressors. 
It was reported from several studies that different miRNAs resulted deregulated in 
tumours bearing ras mutated oncogenes. For example, it was found that let-7 miRNA 
family is implicated in the negative regulation of ras, both in C. Elegans tissues and in 
human cell lines 69. Moreover, its expression is higher in normal adult lung tissue than 
lung cancer tissue, suggesting a possible role of this miRNA as tumour suppressor. 
A Chinese group demonstrated that miR-96 targets the KRAS oncogene and acts as 
tumour suppressor gene in pancreatic cancer, leading human cells to apoptosis 63. 





and his collaborators found out that miR-216b is downregulated in NCP cell lines. They 
demonstrated that miR-216b binds to the 3’-UTR of KRAS mRNA and inhibits the 
expression of the gene leading to the suppression of tumour growth and invasion 70. 
As microRNAs act as tumour suppressors, they can be used as anti ras agents and may 





2.3 Quadruplex DNA: a non-canonical structure 
The common structure of DNA is a double helix, called B-DNA, which was discovered in 
1953 by James Watson and Francis Crick. In addition to the canonical structure, DNA can 
assume several other conformations called non-canonical DNA structures, which include 
G- quadruplexes, triplexes, cruciforms, hairpins, Z-DNA, i-motifs and RNA:DNA hybrids 
(Figure 8)  72–74. Recent studies showed that these structures can interact with specific 
proteins involved in transcription, translation, replication or recombination  75–78. 
Unusual DNA structures can have a role also on DNA damage and repair 75,79,80. In this 
work, as non- canonical DNA conformation, we focus on G- quadruplex DNA, since this 
structure has drawn the attention of many scientist in the last two decades and 
evidences that it occurs under in vivo conditions have been provided. 
 
 
Figure 8. Possible non-canonical conformations of B-DNA and their effects on DNA stability and 






2.3.1 DNA G-quadruplex 
The discovery that DNA can assume structures that differ from the canonical double 
helix started in 1910 when Bang reported a study about a jelly- like substance formed 
by a concentrated solution of guanylic acid. He observed that a concentrated solution 
of guanylic acid (25 mg/ml) at pH 5 becomes viscous and forms a gel, suggesting the 
formation of a high-order structure  81. The same author investigated the optical 
features of the gel and the structure of the fibres obtained from dried gel. He postulated 
that guanylic acid forms a helix type structure. About 50 years later, Gellert and 
collaborators reanalysed the fibres by X-ray diffraction and proposed the formation of a 
planar tetrameric structure, namely four guanines associated to form a planar structure 
called G-tetrad, stabilized by Hoogsteen hydrogen bonds  82. 
As illustrated in Figure 9, each guanine in the G-tetrad forms two H-bonds with the 
neighbouring bases: N1-H····O6 and N2-H····N7. Two or more G-tetrads can stack on top 
of each other allowing the formation of a G-quadruplex, characterized by a central cavity 
where free metal cations can locate: preferentially monovalent cations such as K+ (the 
major monovalent cation in the cells), Na+ or NH4+, but also bivalent cations like Mg2+ or 
Ca2+. The metal cations stabilize the structure by interacting with the O6 atoms of the 
four guanines of a G-tetrad. G4 structures can form spontaneously in physiological 
conditions and they are stabilized by K+ concentrations lower than that of mammalian 
cells (140 mM). 
 






Intramolecular G4 is obtained by the stacking of two or more G-tetrads kept together by 
loops constituted by nucleotides that are not involved in G-tetrad formation. The 
number of the stacks, the length and the nature of the loops are the key elements in 
influencing the thermal stability: it is reported that is possible to obtain G4 structures in 
vitro that are more thermodynamically stable than the duplex DNA, but the thermal 
stability in vitro may not correlate with effects obtained in vivo 83–85. G4 can have 
different topologies depending on the number of G-tetrads, the strand direction, the 
length of the loops, the sequence of the G4 motifs. It is possible to classify 
G- quadruplexes into: (i) intramolecular, when the quadruplex formation requires the 
presence of blocks of guanines in only one strand; (ii) intermolecular if the folding arise 
from two or more strands. G-quadruplex structures can be parallel, antiparallel or mixed 
parallel/antiparallel, depending on the direction of the strands: (i) in parallel G4 the 
strands run in the same direction; (ii) in antiparallel G4 at least one of the four stranded 
runs in the opposite direction compared to the others (Figure 10) 86,87. 
 
Figure 10. Schematic illustration of G-quadruplex structures. (a) Representation of intermolecular 
quadruplexes; (b) Representation of intramolecular quadruplexes and different types of DNA 
folding: parallel, antiparallel and mixed parallel/antiparallel. 
 
The 3D-conformation of G- quadruplex is useful for the design of molecules capable of 





replication and transcription 83,88. In human genome there are more than 300.000 
different G4-motifs that can potentially fold into a G4, but not all G-rich regions of the 
genome are able to assume the G4 conformation 89. 
 
2.3.2 G-quadruplex in the genome 
Bioinformatics analyses show that in human genome there are many sites which can 
fold into G-quadruplex structure 90,91. The most studied G4 conformation is the one 
formed by a single DNA strand (intramolecular G4). It has been reported that this 
structure is common in eukaryotic genomes and growing evidences indicate that it might 
have a role in transcription regulation, as oncogene promoters are rich in G-rich 
sequences  92–94. G4 is present also in telomeres and other biologically relevant genome 
regions  95–97. 
In the past years, several bioinformatics tools have been developed to predict the 
tendency of genome sequences to form a G-quadruplex. The consensus sequence for 
quadruplex formation commonly accepted is G3+N1-7G3+N1-7G3+N1-7G3+ but several 
variations have been proposed 89,98. Guanine runs are generally formed by 2-to-5 
consecutive guanines, whereas the loops comprise a number of nucleotides varying 
from 1 to 7 or more, but also longer loops have been found in G4 DNA. In general, the 
presence of a loop of 1 nucleotide increases the stability of the G4 99–101. Using 
algorithms scientists have predicted that in the human genome there are more than 
360.000 sequences capable of folding into a G-quadruplex. 
G-quadruplex structures are not randomly distributed, but often located in specific 
regions such as promoters, telomeres and 5’-UTRs, near or over transcription factor 
binding sites and in proximity of TSS 97,102. 
The presence of G4 forming sequence has been detected not only in human genome, 
but also in plants 103–105, viruses 106 and bacteria 107. Moreover, there are sequences in 
yeast which have the capability to fold into quadruplex and can be implicated in 
transcription regulation 108. 
The group of Li Ning performed experiments to analyse the distribution of quadruplex 





found a significant enrichment of G4 structures in transcriptional regulatory regions of 
warm-blooded animals 109. 
As these unusual folded DNA structures modulate transcription and translation, it is 
important to know their localization and their abundance inside the human genome. A 
significant step forward to the establishing of the location of G4 structures in vivo was 
obtained through the development of specific antibodies directed against telomeric 
G- quadruplex. One of these antibodies was selected from a synthetic library and used 
in an immunofluorescent assay showing the presence of G4 in a cellular contest 110. After 
these results, other antibodies were used to map the localization of G4 in the human 
genomic DNA. In particular, the antibody BG4, with a very high specificity for G4 
structures, was developed by the Balasubramanian’s group 111. Tests on human cells 
gave interesting results. BG4 confirmed the presence of G-quadruplexes in telomeric 
regions of chromosomes isolated from Hela cells, but some foci disseminated across the 
chromosomes were also detected, suggesting that G4 structures folds also in regions 
different from telomeres 111. 
New insights in detecting G4 localization in human genome were achieved using 
polymerase stop assay, which is used to measure the polymerase stalling at G4 sites, 
with the Illumina next-generation sequencing 112. This new method was called G4- seq 
and permitted to obtain a genome-wide distribution of G4s. The same group that 
developed the G4-seq experimental model, implemented the obtained results using the 
BG4 specific antibody as a probe to perform a G4-specific ChIP-seq, an 
antibody- dependent chromatin immunoprecipitation based on a high-throughput 
sequencing approach 113. Using this method, Balasubramanian and co-workers 
demonstrated the existence of 10.000 G4 structures in human chromatin, localized in 
regulatory regions (including the promoter of the c-MYC and KRAS genes). They reported 
that the number of G4 structures is lower compared to the predictions made by 
computational analyses or to the results obtained with G4-seq. This was explained by 
proposing a possible suppressive role played by heterocromatin in the formation of 
G- quadruplexes. They also reasoned that G4 ChIP-seq resulted to have higher sensibility 
and resolution than BG4 immunostaining because the peaks observed are more than 
the immunofluorescent foci 113. 





However, to understand the biological role of G-quadruplexes it is necessary to know 
their position and distribution, because the equilibrium between G4 folding and G4 
unfolding might act as a regulatory molecular switch. 
It has been reported that G4 folding occurs preferentially during DNA replication, 
transcription and repair because in these processes DNA assumes a transient single 
stranded form allowing Hoogsteen base paring instead of normal Watson-Crick base 
paring 114. In addition, superhelical stress, molecular crowding and specific proteins or 
transcriptional factors are expected to contribute to the stabilization of the G4 
structure  83. 
 
2.3.3 G4 in promoters: implication on transcription 
Several studies have demonstrated the presence of G4 structures in telomeric regions. 
Telomeres are regions made by repetitive (TTAGGG) motifs, located at the end of the 
chromosomes. G4 DNA protects the chromosomes from degradation and from fusion 
with other chromosomes 115. The role of telomeres in tumorigenesis is related to their 
capability to improve cellular immortalization, and their overexpression is founded in 
the majority of cancer cells, representing a hallmark of cancer 116,117. It has been 
reported that G-quadruplex can affect telomerase activity which is blocked by 
intramolecular G4 structure  95,118. 
In addition to the telomeres, G4 DNA is present also in the promoter of the genes. 
Small molecules binding to the G4 promoter show anticancer activity in mouse models, 
a finding that suggests that targeting critical promoter G4 structures may be a promising 
strategy to treat human cancers 119–121. 
Outside the telomeric regions, G4 is present with an average of about 1 quadruplex 
every 10.000 bases 122. Moreover, among all the human genes, about 50% have a 
PQS  (putative quadruplex sequence) in proximity of their promoter regions, suggesting 
that G-quadruplex could have a role in the regulation of gene expression 83. 
In 2007, Huppert and Balasubramanian published an article in which, thanks to an 
analysis carried out on 19.268 known human genes present in ENSEMBL, they found that 





demonstrated that the probability to find a G4 correlates with the distance to TSS: in 
particular the higher probability to find a PQS region is near the TSS (Figure 11) 122. 
 
 
Figure 11. Graphic showing the density of PQS relative to the distance from the TSS. (Huppert J, 
2007) 
 
Interestingly, other studies demonstrated that the G4 forming sequences are more 
abundant in oncogene promoters if compared to house-keeping or tumour suppressor 
genes 123. 
The effect of the G4 folded structure in or close to promoter regions could be both 
positive and negative. Maybe the type of response may be related to the strand position 
of the G4: on the template or coding strand of DNA. It has been reported that the 
presence of G4 motifs on the template strand results in the ending of transcription due 
to the fact that the transcription machinery is blocked; but, if the G-quadruplex is 
present on the non-template strand, it could maintain the template strand in a single 
strand  conformation promoting gene transcription 124. 
G4 structure can also function as a recruitment factor for specific proteins, which can 
unfold the G- quadruplex and activate transcription 125. 
Although several works in literature showed the inhibitory effect of G4 structures on 
DNA transcription, recently there is a growing amount of data demonstrating the 
positive effect on transcription induced by G4s 126. It is clear that is not possible to define 
a general function for G4 motifs, but we can only analyse each different situation and 





c- MYC and KRAS genes 1,127–129, but the evidence of the presence of G- quadruplexes 
has also been found in other genes such as VEGF, HIF-1, Bcl-2 and PDGF-A genes 130– 133. 
Balasubramanian and collaborators, studying the c-KIT promoter, demonstrated that a 
G- rich sequence of 21 nucleotides present upstream the transcription start site is able 
to fold into G4 motif under physiological conditions and is basically conserved between 
human, mouse, rat and chimpanzee 134. The c-KIT oncogene encodes for a tyrosine 
kinase receptor and its expression is critical for the development of mast cells, 
melanocytes and hematopoietic stem cells 135. It is aberrantly activated in 
Gastrointestinal Stromal Tumour (GIST) representing the main target of GIST 
therapies  136. The discovery that there is a sequence in the c-KIT promoter that is able 
to fold into three different G4 motifs may be an attractive starting point to develop 
specific targets in order to control c-KIT aberrant expression 137. 
C-MYC is another critical gene that results to be constitutively expressed in several types 
of cancer. Its activation leads to the overexpression of many other genes involved in cell 
proliferation. The regulation of the c-MYC protein level is complex and involves many 
factors; however, in 2002 the group of Hurley found that is possible to target a G4 motif 
present in the nuclease hypersensitive element (NHE). This G-quadruplex acts as a 
repressor element, thus its stabilization using specific ligands may lead to a decrease in 
transcription resulting in the reduced gene expression. This mechanism may display an 
alternative way to modulate c-MYC expression in cancers 129. 
The third most studied cancer related gene is KRAS. In the human and mouse KRAS 
promoters is present a nuclease hypersensitive polypurine/polypirimidine element 
(NHPPE) containing a G-rich region that is able to assume the G4 conformation. Through 
circular dichroism and NMR experiments, it has been possible to define that the 
structure forming in the KRAS promoter is an intramolecular parallel 
G- quadruplex  138,139. It has been demonstrated that it can adopt two conformations, 
called Q1 and Q2, which are recognized by different proteins such as PARP-1, Ku-70 and 
hnRNP  A1 138. hnRNP  A1 is a nuclear ribonucleoprotein which is able to unfold the G4 
and can have a role in several biological processes controlled by KRAS expression. In a 
recent work, it has been shown a possible link between KRAS, ILK, a mediator of an 





be involved in a loop with a regulatory effect on KRAS expression in pancreatic 





2.4 Reactive Oxygen Species 
In aerobic organism reactive oxygen species (ROS), which include anion superoxide 
(O2- ), hydrogen peroxide (H2O2) and hydroxyl radical (·OH), are continuously produced 
by metabolic reactions. The main sources of ROS are: (i) mitochondria, through electron 
leakage from the ubiquinone/ubiquinol shuttle; (ii) peroxisome, during -oxidation of 
long-chain fatty acids; (iii) cytochrome P-450 enzymes; (iv) nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidases of the NOX family (Figure 12). 
 
Figure 12. ROS production and regulation in cells. 
 
As high levels of ROS produce a negative impact on proliferation, cancer cells activate 
several defence mechanisms to keep oxidative stress at non-toxic levels. 
In fact, intracellular ROS can oxidize lipids, proteins and nucleic acids and severely 
damage the cells. 
Oxidative stress can act as a double-edge sword in PDAC. From one hand, the initiation 
of the carcinogenesis process and the malignant transformation of the cells are 
promoted by the damage to DNA caused by ROS. Moreover, a moderate increase of 
ROS, typically occurring in cancer cells, facilitates cell survival and cancer progression. 
On the other hand, an excessive amount of ROS activates apoptosis and leads to cell 
death. 
Therefore, the role of ROS in the development of cancer depends on the concentration 
of oxidative stress. It is noteworthy that the regulation of redox homeostasis is essential 






Figure 13. Effects and regulation of ROS production and stimulation on cell viability (Liou G Y, 2010)  
 
As stated above, there are different types of ROS among which the most important are 
represented by O2-, H2O2 and ·OH. 
Anion superoxide is generated by an incomplete reduction of molecular oxygen (O2) 
during the flux of electrons through the mitochondrial electron transport chain. 
O2- is reduced into H2O2 by superoxide dismutase and the H2O2 is then reduced to water 
by catalase (Figure 14) 141. 
 
Figure 14. Reactions and enzymes involved in reduction of anion superoxide 
 
Other sources of ROS inside the cells are xanthine oxidase, uncoupled endothelial nitric 
oxide synthase (eNOS), arachidonic acid and also metabolic enzymes like cytochrome 
P450 enzymes, lipoxygenase and cyclooxygenase 142,143. 
Hydrogen peroxide, which results from protein oxidation in the endoplasmic reticulum 
or as an end product in peroxisomal oxidation pathways, can diffuse through the 





H2O2 is the most stable form of ROS and can diffuse through membranes presenting a 
selective reactivity towards the thiol groups of proteins cysteine residues  144,145. 
In physiological conditions cysteine residues that exist as anion thiolates (Cys-S-) are 
more susceptible to oxidation if compared to the protonated thiol form Cys- SH. 
Oxidation of this protein residues results into the abundancy of the sulfenic form (SO-), 
which causes allosteric modification in protein conformation altering its function. High 
levels of hydrogen peroxide can lead to the formation of sulfinic (SO2-) or sulfonic (SO3-) 
species which, despite sulfenic modification, are irreversible and produce stable protein 
damage  144–147. In order to prevent irreversible protein alteration, the sulfenic 
intermediates react to form disulphide (S-S) bonds with nearby cysteines or are 
incorporated in sulfenic-amide (S-N) bonds and can be reduced to water by antioxidant 
systems as glutathione peroxidases (GPXs), peroxiredoxins (PRXs) and 
catalases  144,146,147. 
The third type of ROS is the hydroxyl radical, which is highly reactive and due to its very 
short half-life can cause oxidation of lipids, proteins and nucleic acids on the site where 
it is produced 148,149. In presence of ferrous ions, H2O2 is converted to hydroxyl radicals 
through the Fenton Reaction 142,144,145,148. 
Since hydroxyl radicals are deleterious for cell stability and uncontrolled levels of 
hydrogen peroxide lead to ·OH formation, a tight regulation of ROS detoxification is 
required 144. 
Among the detoxification enzymes mentioned above, the protein’s family of 
peroxiredoxin is considered the ideal hydrogen peroxide scavenger, due to its presence 
in different cell compartments and its high expression. H2O2 oxidizes the cysteine 
residues of PRXs; then they are reduced by thioredoxins (TRXs), which subsequently 
return to their reduced form using NADPH 148. 
Also GPXs can convert hydrogen peroxide to water and present a high constant rate, but 
they are less abundant in the cells if compared to PRXs. GPXs function through the 
reduction of glutathione (GSH) to glutathione disulphide (GSSG) 150. Thanks to NADPH, 
which function as an electron donor, glutathione reductase reduces GSSG back to 
GSH  144,148. 
NADPH resulted to be very important in the detoxification process; in fact, it provides 





sources of NADPH, which is produced both in the cytosol and in the mitochondria. Its 
major source in mammalian cells is the oxidative branch of the pentose phosphate 
pathway (PPP), through the action of the glucose-6-phosphate dehydrogenase 151,152. 
Anyway there are other enzymes generating NADPH such as isocitrate dehydrogenases, 
which catalyse the oxidative decarboxylation of isocitrate and seem to be the main 
source of NADPH in fat and liver cells, and malic enzymes, which transform malate to 
pyruvate 148,153. 
 
2.4.1 ROS and diseases 
As ROS are more reactive than molecular oxygen (O2), they are classified as toxic 
metabolic byproducts that cause damages to lipids, proteins and DNA. However, a lot of 
studies in the last two decades, found that ROS have a role in cell signalling pathways 
playing important roles in cell proliferation and growth, differentiation, metabolic 
adaptation and other biological responses 144,145. Thus, on one hand ROS are important 
signalling factors acting through reversible modification to proteins (i.e. kinases, 
phosphatases); on the other hand oxidative stress can cause cell damages leading to cell 
death 154. 
Several authors reported that ROS have a dual function. Low levels of intracellular ROS 
are required for normal cellular function and are associated to cell cycle progression and 
proliferation 142,155. It is known that H2O2 oxidizes the thiol groups of cysteine residues 
and this represents a critical event for the activation of protein kinase in cells. Some 
protein kinase involved in important signalling pathways are PTEN, PTP1B and 
MAPK  156–159. Other indirect target of ROS are transcription factors like NF-B, HIF-, 
ERK and PI3K 160–163. Through the regulation of all these factors, ROS can have a role in 
metabolism, apoptosis, immune signalling and aging 142. 
ROS level is tightly controlled in the cells. Aberrant intracellular ROS level associated to 
an inefficient function of the antioxidant machinery may lead to several disease. In fact, 
high levels of oxidative stress are implicated not only in carcinogenesis, but also in 
neurodegeneration, diabetes, aging and atherosclerosis or other cardiovascular 





2.4.2 ROS in cancer cells 
Cancer cells produce higher levels of ROS than healthy cells, as they have a higher 
metabolic rate than the latter. ROS can drive a constitutive activation of growth factors 
that sustains cellular growth and proliferation. 
Elevated ROS levels have been found in several cancers, and they are probably involved 
in the maintenance of the aggressive phenotype 164. 
Cancer cells acquire the ability to induce a new redox balance in order to maintain ROS 
at levels suitable for optimal cell grown. These adaptations to slightly higher oxidative 
stress allows cancer cells to proliferate despite enhanced ROS. Oxidative stress is the 
result of an equilibrium balance between antioxidant and oxidant (ROS) 
molecules  164,165. 
Even if different authors proposed a correlation between ROS and cancer, in the last 
years there were contradictory evidence about the role of ROS in tumorigenesis. Several 
studies show that mild-to-moderate increases of ROS promote cancer cell proliferation 
and metastasis both in human cells and mouse models 166–168. In contrast, treatments 
with anti-oxidants, such as N-Acetyl Cysteine (NAC) or vitamins A or E, are not 
particularly effective in reducing the incidence of cancer, for example the head/ neck 
cancers and lung cancers 148,169. 
However, the higher ROS levels observed in cancer cells cannot be ascribed only to an 
elevated metabolic rate. Probably, the genetic alterations in certain genes (oncogenes) 
can be directly or indirectly affected by ROS. In fact, ROS can activate several pathways 
and genes that have a role in tumour progression and aggressiveness 170. In particular 
ROS can (i) promote cellular proliferation through MAPK, activating ERK1/2 and NF-B 
key transcription factors 162; (ii) escape apoptosis by control c-SRC, NF-B, PI3K/AKT 160; 
(iii) support EMT (Epithelial to Mesenchymal Transition) leading to metastasis 
development 171; (iv) foster angiogenesis by promoting the release of VEGF  165. 
 
2.4.3 ROS in pancreatic cancer 
In PDAC a moderate increase of intracellular ROS is considered a hallmark of cancer and 





As high ROS levels are detrimental for the cells, in pancreatic cancer cells oncogenic 
KRAS is able to activate expression of several anti-oxidant genes through the Nuclear 
Factor erythroid 2-like 2 (NFE2L2 or Nrf2) 172,173. Nrf2 is a member of the 
Cap’ n’ collar  (CNC) family, a subfamily of basic region-leucine zipper (bZIP) 
transcription factors. This transcription factor is considered the master regulator of 
redox homeostasis 148,174–176. 
Under physiological unstressed conditions, inactive Nrf2 is sequestered into the 
cytoplasm bound to the repressor protein Kelch-like ECH-associated protein1 (KEAP1). 
KEAP1 is an adapter protein for the CUL3/RBX1 E3 ubiquitin ligase complex and mediates 
the ubiquitination of Nrf2 and its proteolytic degradation in 26S proteasome 173,177. 
In normal unstressed conditions, when the ubiquitination is not blocked, the half-life of 
Nrf2 is very short, from 10 to 30 minutes, and the protein is continuously directed to 
proteasome for degradation (Figure 15) 175,178. 
 
 
Figure 15. Under basal unstressed conditions Nrf2 is sequestered into the cytoplasm bound to 
KEAP1. The complex is directed to proteasome for degradation. Under oxidative stress conditions, 
the activated Nrf2 translocates into the nucleus where it activates the transcription of other 
antioxidant genes. 
 
On its surface KEAP1 presents some cysteine residues that function as redox sensors. 
Under oxidative stress conditions, the oxidation of cysteines produces a conformational 
change in KEAP1 protein resulting in the disruption of the bind with Nrf2. The free 
protein translocates into the nucleus where it heterodimerizes with small v-maf 
musculoaponeurotic fibrosarcoma oncogene homolog (Maf) regulator protein 179. Then 
the complex binds to the Antioxidant Response Element (ARE) on the DNA and this 





enzymes, as glutathione-S-transferase or NAD(P)H-quinone-oxidoreductase-1 
(hNQO- 1)  175,178. 
Some authors speculate on the dual role that Nrf2 seems to have in cancer 176,180–182. 
This important transcription factor has been considered for a long time as a tumour 
suppressor for its capacity to activate the antioxidant cellular response through the 
induction of the transcription of different genes involved in the response to oxidative 
stress or to xenobiotics 180,183. In the last years it has been pointed out the possible 
“dark  side” of Nrf2: there are growing evidences that Nrf2 activation is related to 
progression of tumours and operates as a chemoresistant agent 178,181,184. 
In 2011, the Tuveson laboratory demonstrated the correlation between oncogenic KRAS 
and Nrf2, showing that KRASG12D increases the level of Nrf2 in order to stabilize the redox 
balance in the cells, lowering intracellular ROS to sustain proliferation (Figure 16) 62. 
Another study on several pancreatic cancer cell lines reported that the dysregulation of 
the Nrf2/KEAP1 system leads to enhanced cell proliferation and contributes to the 
increase of chemo- and radio-resistance in pancreatic cancer cells 173. Moreover, in the 
same study, scientists demonstrated that pancreatic tumours are associated with an 
elevated expression of Nrf2, thanks to Nrf2 staining of both tumour and benign 
epithelium 173. 
Thus, in pancreatic cancer cells Nrf2 is overexpressed and KRAS mutations are directly 
correlated with enhanced expression of Nrf2, resulting in the promotion of the 
pancreatic intraepithelial neoplasia through the stimulation of proliferation and the 











Figure 16. Schematic representation showing how mutated KRAS controls ROS levels through Nrf2 





2.5 DNA oxidation 
Reactive oxygen species and nitrogen species can damage DNA modifying the bases: an 
event that can be rather harmful for the cell. Accumulation of DNA lesions can be 
deleterious for the genome integrity and for all the processes involving DNA. To prevent 
mutations, the damage caused by ROS must be repaired. 
There are two main pathways responsible for DNA repair lesions: NER, nucleotide 
excision repair pathway, and BER, base excision repair pathway 185,186. 
The first process generally recognizes DNA damages or modifications caused by 
xenobiotic agents. On the contrary, endogenously generated DNA lesions are recognized 
and removed by specific enzymes belonging to BER. During the process, BER proteins 
remove the modified base producing an abasic site (AP) that is then cleaved by an AP 
endonuclease which gives a single strand break. The process continues following two 
possible pathways: the short patch or the long patch BER. Finally, RNA polymerase and 
ligase add the missing nucleotides and seal the nick 187,188. 




Figure 17. ROS cause the transformation of guanine into 8-oxoguanine 
 
The result of oxidation is the formation of 7,8-dihydro-8-oxoguanine (8OG) which 
functions as an oxidative stress biomarker inside the cells (Figure 17) 189. 
The mutagenic effect of this lesion is due to the fact that 8-oxoguanine can coupled with 
adenine and this leads to a G:C to T:A transversion: a point mutation that can cause 
cancer 126,190. Although for a long time oxidative DNA lesions have been seen as 





large body of data suggest that oxidized bases, such as 8-oxoguanine, act as activators 
of key signalling pathways 191–193. 
It has been reported that the presence of 8OG in the genome may block the 
advancement of RNA polymerase, leading to a decrease in transcription 194. In contrast, 
several studies report a positive correlation between increased 8OG formation and gene 
expression 126. 
In order to better understand the role of 8OG in the genome, scientists performed 
several studies in which they tried to highlight the position of the lesion in DNA. 
Olinski and collaborators demonstrated that 8OG is not disposed randomly in the 
genome: the quantification of the oxidative lesion in heterochromatin and euchromatin 
from pig thymus extract showed that 8OG is more abundant in euchromatin 195. 
Other studies on the correlation between 8OG and gene expression, reported that the 
binding of several proteins is reduced when the 8-oxoguanine is present in the protein 
transcription factor binding sequence. These results are reported for specific 
protein  1  (SP1), NF-B and CREB 196–198. 
All these findings suggest that 8OG could have an epigenetic role and that its position in 
the genome may influence several cellular processes. 
As reported before, 8OG is a critical lesion for the DNA and must be repaired to avoid 
damages. The primary enzyme involved in the repair of 8-oxoguanine lesion is the 
glycosylase hOGG1 (8-oxoguanine DNA glycosylase-1), which recognizes the oxidized 
DNA base and excises it, leading to the formation of an abasic site 189. If a defect in OGG1 
repair activity occurs, the increased level of 8OG may enhances the raising of DNA 
mutations. It has been shown that in mice knock-out for OGG1 ( Ogg1-/-) a reduction in 
8-oxoguanine repair machinery lead to lesions accumulation in the genome; this causes 
an increased frequency of mutations which results to be 2-3 fold higher in liver of 
null- mice 199,200. Despite all these events, in the Ogg1-/- mice an increased tumour 
incidence was not detected, even if in a small number of human tumours has been 
reported the inactivation of OGG1 repair system 201,202. Therefore, previous study 
demonstrated that OGG1 null mice did not show substantial phenotype alterations or 
problems in embryonic development, and presented only a modest predisposition to 
tumorigenesis. But the most surprisingly event is that researches demonstrated an 





In the last years, it has been reported that the hOGG1 glycosylase may have a role going 
beyond BER. 
Boldogh and his co-workers hypothesized that the free 8OG, excised from the DNA, 
interacts with OGG1 to create an OGG1-8oxoG complex 193,204,205. They demonstrated 
that the complex OGG1-8oxoG acts as a guanine nucleotide exchange factor 
protein  (GEF). 
This complex shows affinity for all the three RAS proteins and enhances the release of 
GDP allowing the substitution with GTP, activating RAS protein 193. Boldogh 
demonstrated that the addition of supplemental 8OG in MCR5 cells results in an increase 
of RAS-GTP, the active form of RAS protein, that follows a dose and time response 
dependent manner. But, when the 8-oxoguanine is added to cells depleted for OGG1 
they did not see any significant change in RAS-GTP expression 205. 
Furthermore they studied the capability of the OGG1-8oxoG complex to function as a 
GEF protein also in another cell line (KG-1 cells) which express a mutant OGG1 193. 
KG- 1  cells are human myeloid leukemia cells expressing a 8OG repair deficient OGG1, 
called OGG1R229Q, which resulted to be inactive at the physiological temperature of 37°C 
either in vitro and in vivo. In physiological conditions the OGG1 inactivation results in 
the accumulation of 8OG 206. When the cells are cultured at lower temperature (25°C) 
the 8OG excision activity of OGG1 was rescued, showing an increase in p-MEK1/2 and 
p-ERK1/2 levels confirming the activation of RAS-GTPase 193. 
Although these data confirm that 8OG, ones excised from the DNA, can interact with 
OGG1 and can control RAS activation in cells, the 8-oxoguanine plays important role in 
gene activation also when it is present as lesion substitution of guanine in the genome. 
In particular, PQS regions in the DNA are sequences showing a high guanine density, and 
are therefore potential sites for guanine oxidation. 
Studying the sequence of the telomeric quadruplex, Szalai and her collaborators decided 
to investigate the effect of 8OG in that region through the substitution of different 
guanines present in the GGG triplet with 8-oxoguanine 207. As expected, they found that 
the position of 8OG can influence the formation of the quadruplex and can affect the 
telomerase activity. If the substitution occurs near the 5’-end, the presence of 8OG 





present in the middle of the sequence, the result is an undefined structure which has no 
impact on telomerase action 207. 
In 2011, Sagi presented another study on the effect of 8OG presence in quadruplex 
folded in telomeric DNA sequence 5’-dG3(TTAG3)3, in which he tested the stability of 
non-canonical structures folded both in NaCl or KCl solutions. Through CD experiments, 
they demonstrated that almost all the sequences tested fold into a hybrid 
parallel/antiparallel quadruplex. Analysing the thermal and thermodynamic stability of 
the sequences modified with 8OG in different positions, they concluded that the 
presence of a lesion in the middle tetrad destabilizes the quadruplex formation 190. 
Beside the studies made on telomeric regions, interesting results were found also in 
promoter regions of several genes that present G-rich elements able to fold into G4. 
G-rich region in the vascular endothelial growth factor (VEGF) gene promoter may fold 
into a G-quadruplex which is important for the transcriptional regulation of the 
gene  208,209. The Gillespie laboratory found that the guanine oxidation in the VEGF 
promoter induced by hypoxia increases gene expression, speculating that BER may be 
actively implicated in the process 210. Working on the same gene promoter, Burrows and 
colleagues, using a luciferase reporter plasmid, demonstrated that, in the VEGF 
G- quadruplex promoter region, the presence of 8OG activates the transcription of the 
gene 126,211. 
The role of 8OG in the genome is not completely clear, but all these data show that it 
can function through different mechanisms: (i) the presence of 8-oxoguanine in the G4 
motif can destabilize the structure giving the duplex DNA and leading to gene 
transcription; (ii) the oxidized guanine may function as a recruitment factor for several 
protein and transcription factors involved in the regulation of transcription; (iii) excised 
8OG can form a complex with OGG1 glycosylase which function as GEF protein favouring 






3. AIM OF THE WORK 
In this PhD program, I have focused my efforts on studying the biology of oncogenic 
KRAS in PDAC cells from a functional and therapeutic point of view. Many aspects of 
KRAS regulation are still unclear and this lack of information impedes the design of 
anticancer strategies against PDAC, a disease that unfortunately does not respond to 
the conventional therapies. 
To rationally design new therapeutic strategies for PDAC, we started from the 
observation that more than 90% of PDAC patients bear mutation in KRAS, in exon 1 at 
codons 12, 13 and 61. These mutations are detrimental for the patient’s health, as 
mutant KRAS is able to initiate and maintain pancreatic cancer 28,30. 
Previous works from our laboratory addressed the question on how KRAS expression is 
regulated. After years of investigation it has become clear that KRAS is under the control 
of a critical G-rich sequence located upstream of TSS 1,212,213. This DNA stretch of 120 nt 
embeds three G4 motifs – called on the basis of their distance from TSS, G4 near, G4 
mid and G4 far – that are sites where DNA is structurally polymorphic. In fact, the purine 
rich strand of G4 near and G4 far folds into stable G4 structures under physiological 
conditions. These unusual DNA conformations have drawn the attention of many 
scientists in the last two decades because compelling evidences that they are present in 
vivo have been provided by three independent methods: NMR 127,214, staining with 
fluorescent antibody highly specific for G4 DNA 111 and ChIP-Seq analyses of 
chromatin  113. 
The biological function of G4 DNA is still a matter of debate, and the research is still 
active in this field. 
Recent studies indicate that G4 DNA is a key element for transcription and evidence that 
its function is likely of recruiting transcription factors to the promoter is growing. Indeed, 
in the case of the KRAS gene, we have found that the proteins binding to G4 are 
transcription factors essential for activating transcription, such as PARP1, MAZ and 






We then asked ourselves if G4 DNA function as a recruiter of proteins is because of its 
non-canonical folded structure or because the G4 motifs are sites of epigenetic 
modifications. 
In my PhD work, in collaboration with my tutor, I have focused on this important aspect 
of the KRAS biology in PDAC. To address this point we started from two important 
observations: first, guanines present in G-clusters, as those that constitute the critical 
G4 motifs of KRAS, are susceptible to oxidation to 8-oxoguanine due to their low redox 
potential, compared to the other nucleobases; second, cancer cells, producing higher 
level of reactive oxygen species than healthy cells, have a high capacity of oxidation and 
probably a high level of 8-oxoguanine. With these premises, we have investigated the 
impact of 8-oxoguanine in the promoter of KRAS, by addressing important question such 
as: (i) does 8-oxoguanine alter the folding and the structure of the G4 which acts as an 
antenna for the transcription factors?; (ii) does 8-oxoguanine in the G4 motif of KRAS 
affects the recruitment of the transcription factors?; (iii) does the glycosidase OGG1 
repair the 8-oxoguanine lesion in the folded G4 motif? 
Another central point that we have been addressed is how the redox homeostasis is 
regulated in PDAC and if KRAS is involved in the control of it. In this regard, we have 
found that KRAS controls the expression of Nrf2, the master regulator that modulates 
the level of ROS in the cells 62. Since Nrf2 is enhanced by ROS and is stimulated by KRAS, 
we wondered if ROS stimulates KRAS too. The results of this research allowed us to 
propose an axis composed by ROS/Nrf2/KRAS that controls the redox homeostasis in 
PDAC. We also investigated the intersection of this axis with the survival and apoptosis 
pathways and found that low ROS levels favour the pro-survival Snail gene, while high 
ROS favours the pro-apoptotic RKIP gene. 
Another important point on this topic was to examine how ROS activate KRAS. To this 
regard, we have found that free oxygen radicals stimulates KRAS through a mechanism 
mediated by G4 DNA. This is quite a new aspect of the research that provides new 
evidences about the biological role of G4 DNA. 
Finally, considering that PDAC cells are addicted to KRAS and that the suppression of the 
oncogene triggers a cellular response that activates apoptosis, we have pursued a 





miRNAs in PDAC that are aberrantly downregulated as they behave as tumour 
suppressors. 
We have identified miR-216b as a strong therapeutic tool for suppressing KRAS in PDAC. 
We propose some chemical modifications to strengthen the activity of this particular 
miRNA and we have also tested different strategies for delivering miR-216b in PDAC 
cells. 
In conclusion, my PhD work focuses on oncogenic KRAS, as it has a central function on 
PDAC cells. Our main goal was to explore if KRAS has a role in the redox homeostasis, 
because the control of oxidative stress has a direct effect on the survival and apoptosis 
pathways in PDAC, as described in this work. The results of our research ended in three 
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KRAS is one of the most mutated genes in human 
cancer. It is controlled by a G4 motif located up- 
stream of the transcription start site. In  this  pa- per, 
we demonstrate that 8-oxoguanine (8-oxoG), be- ing 
more abundant  in G4 than in non-G4 regions,  is a 
new player in the regulation of this oncogene. We 
designed oligonucleotides mimicking the KRAS G4-
motif and found that 8-oxoG impacts folding and 
stability of the G-quadruplex. Dimethylsulphate- 
footprinting showed that the G-run carrying 8-oxoG 
is excluded from the G-tetrads and replaced by a 
redundant G-run in the KRAS G4-motif. Chromatin 
immunoprecipitation revealed that the base-excision 
repair protein OGG1 is recruited to the KRAS pro- 
moter when the level of 8-oxoG in the G4 region is 
raised by H2O2. Polyacrylamide gel electrophoresis 
evidenced that OGG1 removes 8-oxoG from the G4- 
motif in duplex, but when folded it binds to the G- 
quadruplex in a non-productive way. We also found 
that 8-oxoG enhances the recruitment to the KRAS 
promoter of MAZ and hnRNP A1, two nuclear fac- 
tors essential for transcription. All this suggests that 
8-oxoG in the promoter G4 region could have an epi- 
genetic potential for the control of gene expression. 
 
INTRODUCTION 
Cancer cells are characterized by high metabolic rates, nor- 
mally associated with an increased level of reactive oxygen 
species (ROS) (1,2). Anion superoxide (O2−), hydrogen per- 
oxide (H2O2) and hydroxyl radical ( OH) are produced by 
endogenous and exogenous sources (3). Among the endoge- 
nous sources, the mitochondrial electron transport chain, 
which reduces oxygen to water, is the major source of cellu- 
 
lar ROS (4). In suspended mitochondria about 0.12–2% of 
oxygen consumed in the respiration is converted into O2− 
(3,4). However, anion superoxide is also produced enzymat- 
ically in essential metabolic pathways, including NADH ox- 
idase, xanthine oxidase, lipo- and cyclo-oxygenases (5). Fur- 
thermore, O2− is reduced by superoxide dismutase to H2O2, 
which is then converted to OH via a non-enzymatic Fen- ton 
reaction (6). All these chemical and enzymatic reactions 
push the ROS level more up in high metabolic rate cancer 
cells than in normal cells. An enhanced ROS level may dam- 
age DNA, RNA, lipids and proteins, and may also alter the 
intracellular signal transduction, for instance through NF- 
kB (7,8). A key protein of the antioxidant network is Nrf2, a 
(b-Zip)-type transcription factor that binds to antioxidant 
response elements in gene promoters and induces the ex- 
pression of protective genes of the antioxidant response (9– 
11). Nrf2, being upregulated in pancreatic ductal adenocar- 
cinoma (PDAC) cells, increases the capacity of the cells to 
control oxidative stress, a necessary condition for optimal 
cell proliferation (12–14). 
The primary genetic lesions causing pancreatic cancer are 
somatic mutations in the KRAS gene. About 90% of PDAC 
carries KRAS G12D, i.e. a KRAS allele with a point mu- 
tation G D in exon 1, codon 12 (15–17). The activity of 
mutant KRAS G12D is required in all stages of carcinogen- 
esis (initiation, progression and metastasis) and the inacti- 
vation of mutant KRAS G12D reverses the transformation 
process (18–20). Recent studies have reported that KRAS 
G12D reduces the level of ROS in pancreatic cancer cells 
via Nrf2 (12,14). Since there is a correlation between mu- 
tant KRAS and Nrf2, we interrogated if in pancreatic cancer 
cells, the expression of KRAS is in some way influenced by 
oxidative stress. It is well known that oxidation of DNA oc- 
curs mainly at guanine, as it has the lowest oxidation energy 
among nucleobases (21). GG steps are preferred sites for 
oxidation, with 5j G being particularly reactive (22). In the 
promoter of the KRAS oncogene there is a G-rich element 
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called 32R that is critical for transcription and able to fold 
into a G-quadruplex structure (23). 32R is located between 
148 and 116 bp from transcription start site (TSS) and is 
recognized by several transcription factors including MAZ 
and hnRNP A1 (24–27). Polymerase-stop assays, footprint- 
ing and circular dichroism showed that 32R is highly poly- 
morphic in nature, as it can fold into three alternative G4 
structures (28,29). In this study, we have found by chromatin 
immunoprecipitation (ChIP) combined with quantitative 
polymerase chain reaction (qPCR) that the 32R region is 
more oxidized than other G-rich regions that are unable to 
fold into G4. The presence of 8-oxoG in 32R may lower the 
stability of the G-quadruplex, depending on where the dam- 
age is located inside the sequence. When the oxidation is sit- 
uated in the major 11-nt loop of the KRAS G4, the TM and 
folding are practically not affected. But when 8-oxoG is lo- 
cated in a G-tetrad, both TM and folding are strongly mod- 
ified. We also investigated how guanine oxidation impacts 
the binding of the transcription factors to the regulatory G4 
motif of KRAS. Our data show that 8-oxoG modulates the 
binding of the nuclear factors to the KRAS promoter and 
also strengthens the recruitment of MAZ and hnRNP A1 
to the promoter. Finally, the results are discussed in terms 
of possible role of 8-oxoG as an epigenetic regulator in the 
transcription of oncogenic KRAS. 
 
MATERIALS AND METHODS 
Oligonucleotides and reagents 
Unmodified oligonucleotides used in this  study  have  been 
obtained from Microsynth (CH). 8-oxoG-substituted 
oligonucleotides were synthesized from 8-oxo-dG CEP 
from Berry & Associates in 1-µmol scale on solid support by 
standard procedure, except using concentrated ammonia in 
the presence of 2-mercaptoethanol (0.25 M) in the deprotec- 
tion step as described by Bodepudi et al. (30). The oligonu- 
cleotides were purified by reverse-phase high pressure (or 
high performance) liquid chromatography on a Water sys- 
tem 600, equipped with a C18 column (XBridge OST C18, 
19 1000 mm, 5 µm). The composition of the oligonu- 
cleotides was verified by Matrix Assisted Laser Desorption 
Ionisation-Time of Flight (MALDI-TOF) (Supplementary 
Table S1). Luteolin, was purchased from Alfa Aesar (D), 8- 
oxoguanine (8-oxoG) and 8-oxodeoxyguanosine from Cay- 
man Chemicals (MI, USA), GTP from Euroclone (I), hy- 
drogen peroxide solution 30% (w/w) from BDH (UK). 
 
Cell cultures 
Human pancreatic cancer (Panc-1, MIA PaCa-2, BxPC3) 
and non-cancer human embryonic kidney 293 cells were 
maintained in exponential growth in Dulbecco’s modified 
Eagle’s medium (DMEM) containing 100 U/ml penicillin, 
100 mg/ml streptomycin, 20 mM L-glutamine and 10% 
foetal bovine serum (Euroclone, I). The cell lines have been 




Recombinant MAZ and hnRNP A1 were obtained with a 
high degree of purity as previously described (24,26). Re- 
 
combinant OGG1 with His-Tag at the N-terminus was ex- 
pressed in Escherichia coli bacteria transformed with plas- 
mid pET20 hOGG1. The bacteria were grown for 2 h at 
37◦C to an absorbance at 600 nm of 0.8–1 units before in- 
duction with isopropyl 1-thio-þ-d-galactopyranoside (0.4 
mM final concentration). The cells were allowed to grow 
overnight at 25◦C, and then centrifuged at 5000 rpm at 4◦C. 
The supernatant was removed and the pellet resuspended in 
Lysis buffer (50 mM NaH2PO4, 300 mM NaCl and 10 mM 
imidazole) added with 0.2 mM PMSF (phenylmethyl- 
sulphonyl fluoride). The bacteria were lysed by sonication 
[3 (30 s sonication/1 min off)], added with 0.05% Tween 20 
(Sigma-Aldrich, MO, USA) and the lysate centrifuged for 
10 min, 4◦C, 104 rpm. Ni-NTA resin (Qiagen, D) was added 
to the supernatant and the mixture was shaken for 1 h, 4◦C. 
The mixture was then centrifuged for 5 min at 1700 rpm and 
the pellet washed two times with Wash Buffer (50 mM 
NaH2PO4, 300 mM NaCl and 20 mM imidazole). The 
OGG1 bound to the resin was eluted with a buffer com- 
posed by 50 mM NaH2PO4, 300 mM NaCl and 600 mM im- 
idazole. OGG1 concentration was determined by Bradford 
method and the purity was confirmed by sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
(Supplementary Figure S1). Finally, the protein was con- 
centrated and desalted by using the Ultracel YM-3 Micro- 
con Centrifugal Filter Devices (Millipore, MA, USA). 
 
Chromatin immunoprecipitation (ChIP) and qPCR analysis 
ChIP was carried out as described in ref. 31, by using the 
ChIP-IT® Express Shearing Kit (Active Motif, CA, USA). 
In brief, Panc-1 cells (8 105) were seeded in 6-well plates 
and after 24 h some plates were treated with 10 µM luteolin 
for 24 h in DMEM or with 1 mM hydrogen peroxide for  15 
min in serum-free DMEM. The cells were then washed with 
phosphate buffered saline (PBS) and fixed for 10 min in 
serum-free DMEM containing 1% formaldehyde. After 
fixing, the cells were washed with cold PBS and added with 
Glycine Stop-Fix Solution to arrest the fixing reaction. The 
cells were washed again with cold PBS, treated with Scrap- 
ing Solution and centrifuged at 2500 rpm for 10 min at 4◦C. 
The pellet was resuspended in ice-cold lysis buffer supple- 
mented with PMSF, PIC (protease inhibitor cocktail) and 
incubated for 30 min on ice. The cells were transferred to 
an ice-cold dounce homogenizer for 20 strokes to release 
the nuclei. The homogenate was centrifuged for  10 min  at 
5000 rpm, 4◦C, to pellet the nuclei. The nuclei were 
resuspended in Shearing Buffer and the chromatin sheared 
by sonication [10 (30 s pulse on/30 s pulse off)] on 
Bioruptor Plus (Diagenode, BG) into DNA fragments of 
about 300–400 bp. The sheared chromatin was centrifuged 
at maximum speed for 15 min, 4◦C. The chromatin con- 
centration was determined with a spectrophotometer by 
ultraviolet (UV) absorption (260 nm) and 10 µg treated 
overnight at 4◦C with 1 µg antibody specific for 8-oxoG 
(Bioss Antibodies, MA, USA) or MAZ or OGG1 (Santa 
Cruz Biotechnology, TX, USA) or hnRNP-A1 (Sigma- 
Aldrich, MO, USA). In addition to the antibodies, the 
mixtures were added with Protein G Magnetic Beads, ChIP 
buffer-1 and PIC, following the Active Motif Kit protocol. 
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chromatin bound to the antibody collected with a magnetic 
bar. The collected beads were washed once with ChIP 
buffer-1 and twice with ChIP buffer-2. The beads were then 
re-suspended in Elution Buffer AM2 and let to incubate  on 
shaking for 15 min at room temperature. The beads were 
treated with Reverse Crosslinking Buffer and the 
supernatant with the chromatin was collected. The DNA 
fragments were amplified by qPCR using primers spe- cific 
for genomic KRAS (accession number NG 007524): G4-
plus      5j-GTACGCCCGTCTGAAGAAGA-3j     (nu- 
cleotides (nt) 4889–4908, 0.2 µM), G4-minus 5j- 
GAGCACACCGATGAGTTCGG-3j   (nt  4958–4977,  0.1 
µM), Ctr-1-plus 5j-ACAAAAAGGTGCTGGGTGAGA- 
3j  (nt 12–32, 0.2 µM), Ctr-1-minus 5j- 
TCCCCTTCCCGGAGACTTAAT-3j     (nt    248–268,  0.2 
µM), Ctr-2-plus 5j-CTCCGACTCTCAGGCTCAAG- 
3j (nt 7536–7555, 0.15 µM), Ctr-2-minus 5j- 
CAGCACTTTGGGAGGCTTAG-3j        (nt      7692–7711, 
0.15 µM). Ctr-1 is located in a non-coding region, G4- 
region is in the promoter, Ctr-2 is in an intron. qPCR 
reactions were carried out with a CFX-96 real-time PCR 
apparatus controlled by Optical System software (version 
3.1) (Bio-Rad Laboratories, CA, USA) on 1 µl of immuno- 
precipitated chromatin or input, which were mixed to Sybr 
Green mix following manufacturer instructions (Kapa Sybr 
Fast QPCR Mix, Kapa Biosystems, MA, USA) and primers. 
For G4-region amplification cycles were: 3 min at 95◦C, 40 
cycles 30 s at 95◦C and 40 s at 59◦C. For controls 
amplification cycles were: 3 min at 95◦C, 40 cycles 10 s  at 
95◦C and 30 s at 57◦C (control-1) or 61◦C (control-2). All 
reactions have been validated before amplification for each 
target and couple of primers. The Ct-values (number of 
cycles required for the fluorescent signal to cross the 
threshold) given by the instrument (Bio-Rad CFX-96) were 
used to evaluate the difference between sample and input. 
The adjusted Ct input was obtained by Ct input log2 (input 
dilution factor). Then OCt   Ct sample   Adjusted Ct input. The 
% Input for each sample was calculated as follows: % Input    
100    2   (-OCt). The % Input was obtained for   the G4 
region and also for the non-G4 regions (Ctr-1 and Ctr-2). 
The enrichment in 8-oxoG or MAZ or hnRNPA1  or OGG1 
of the G4 region respect to the non-G4 regions was 
determined by the ratio [% Input (G4 region))]/[% Input (non-G4 
region)]. In average, from three to seven samples were used 
for each experiment. The t-test analysis was performed with 
Sigma Plot 10.1(UK). 
 
Circular dichroism and UV-melting 
Circular Dichroism (CD) spectra were obtained on a 
JASCO J-600 spectropolarimeter, equipped with a ther- 
mostated cell holder, with 5 µM oligonucleotides solutions 
in 50 mM Tris–HCl, pH 7.4, 100 mM KCl. The spectra were 
recorded in 0.5 cm quartz cuvette at room temperature and 
90◦C. The spectra are reported as ellipticity (mdeg) versus 
wavelength (nm). Each spectrum was recorded three times, 
smoothed and subtracted to the baseline. 
UV-melting analysis was performed using the Jasco V- 
750 UV-visible spectrophotometer equipped with a Peltier 
temperature control system (ETCS-761) (Jasco, JP). The 
spectra were analyzed with Spectra Manager (Jasco, JP). 
Oligonucleotides (5 µM) were annealed in 100 mM KCl, 50 
mM Na-cacodylate pH 7.4 (10 min at 95◦C, overnight at 
room temperature). The melting curves were recorded at 
295 nm in a 0.5 cm path length quartz cuvette heating (20– 
90◦C) and cooling (90–20◦C) at a rate of 0.5◦C/min. The 
thermodynamic parameters for the folding of the wild-type 
and modified oligonucleotides into G4 were obtained from 
the UV-melting curves. The ‘DNA-Melting Analysis’ pro- 
gram (Jasco, JP), which analyzed the melting curves accord- 
ing to a standard all-or-none model, gave the OH ◦ and OS◦ 
values. The free energy of quadruplex formation was calcu- 
lated according to: OG ◦ = −RT ln K = OH ◦ − TOS ◦. 
PAGE assay 
8-OxoG-substituted oligonucleotides end-labeled with [μ- 
32P]adenosine triphosphate (ATP) (Perkin Elmer) and T4 
polynucleotide kinase (Thermo Fisher Scientific, USA), 
were annealed in duplex or quadruplex as follows: the du- 
plex was obtained annealing (5 min at  95◦C, overnight    at 
room temperature) the 8-oxoG-substituted oligonu- 
cleotides and 32R with complementary 32Y in 50 mM Tris– 
HCl, pH 7.4, 100 mM NaCl; the quadruplexes were ob- 
tained in 50 mM Tris–HCl, pH 7.4, 100 mM KCl  (5 min  at 
95◦C, overnight at room temperature). Radiolabeled du- 
plex and quadruplex (2 nM) were incubated at 37◦C with 
increasing amounts of OGG1 (1 and 5 µM), in 20 mM Tris–
HCl pH 8, 50 mM NaCl, 1 mM ethylenediaminete- 
traaceticacid (EDTA), 0.1 mg/ml bovine serum albumin, 1 
mM Na3VO4, 5 mM NaF and 0.01% Phosphatase In- hibitor 
Cocktail. After 15 min, the reactions were stopped by 
adding to the mixtures 8 µl stop solution (90% for- mamide, 
50 mM EDTA). The samples were then denatured for 5 min 
at 95◦C and run for 1 h on a denaturing 20% poly- 
acrylamide gel, prepared in Tris-borate-EDTA (TBE) and 7 
M urea, pre-equilibrated at 55◦C in an electrophoretic ap- 
paratus (C.B.S Scientific Company, CA, USA). After run- 
ning the gel was fixed in a solution containing 10% acetic 
acid and 10% methanol, dried and exposed to film for auto- 
radiography (Aurogene, I). 
Electrophoresis mobility shift assay (EMSA) 
Duplexes and quadruplexes have been prepared as de- 
scribed in previous section. PAGE purified 8-oxoG- 
substituted oligonucleotides were end-labeled with [μ-32P] 
ATP and T4 polynucleotide kinase (30 pmol). The cor- 
responding duplexes were obtained by annealing (10 min at 
95◦C and overnight at room temperature) the modified 
oligonucleotides with the complementary strand in 50 mM 
Tris–HCl pH 7.4, 100 mM NaCl. Protein–oligonucleotide 
interactions were analyzed by electrophoresis mobility shift 
assays (EMSA). End-labeled duplexes or G-quadruplexes 
were incubated in 20 µl solutions containing 50 mM Tris– 
HCl, pH 7.4, 100 mM NaCl (for duplexes) or 100 mM KCl 
(for G-quadruplexes), 1 mM EDTA, 0.01% Phosphatase In- 
hibitor Cocktail I (Sigma-Aldrich, MO, USA), 5 mM NaF, 
1 mM Na3VO4, 2.5 ng/µl poly [ dI dC], 1 mM Dithiothre- 
itol (DTT) and 8% glycerol with increasing amounts of re- 
combinant OGG1 (0.3 and 0.6 µg) or MAZ or hnRNP A1 
(2.5–5 µg), time and temperature are indicated in figure leg- 





− − − − 
664 Nucleic Acids Research, 2018, Vol. 46, No. 2 
 
 
prepared in TBE at 20◦C. After running, the gels were dried 
and exposed overnight to auto-radiography (Aurogene, I) at 
−80◦C. 
DMS-footprinting experiments 
Dimethylsulphate (DMS)-footprinting experiments were 
performed using PAGE purified 8-oxoG-substituted 
oligonucleotides (24 nM), end-labeled with [μ-32P] ATP. 
The oligonucleotides were incubated overnight at 37◦C, in 
50 mM Tris–HCl, pH 7.4, 1 µg sonicated salmon sperm 
DNA, 1 mM EDTA, 100 mM KCl or 100 mM LiCl, as 
specified in the figure legend. DMS dissolved in ethanol 
(DMS:ethanol, 2/38, vol/vol) was added to the DNA 
solution (2 µl to a total volume of 50 µl) and left to react 
for 1 min at room temperature. The reactions were stopped 
by adding to the mixtures 5 µl of stop solution (1.5 M 
sodium acetate, pH 5.2, 1 M þ-mercaptoethanol and 16 
ng/µl salmon sperm DNA). DNA was precipitated with 
four  volumes  of  ethanol  and  resuspended  in piperidine 
1 M. After cleavage at 90◦C for 20 min,  the  reactions were 
stopped on ice and the DNA precipitated with 0.3   M 
sodium acetate, pH 5.2 and three volumes of ethanol. The 
DNA samples were resuspended in 90% formamide and 50 
mM EDTA, denatured at  90◦C and run for 2 h on a 
denaturing 20% polyacrylamide gel, prepared in TBE and 
8 M urea, pre-equilibrated at 55◦C in a Sequi-Gen  GT 
Nucleic Acids Electrophoresis Apparatus (Bio-Rad, CA, 
USA), which was equipped with a thermocouple that allows 
a precise temperature control. After running, the gel was 
fixed in a solution containing 10% acetic acid and 10% 
methanol, dried at 80◦C and exposed to film (CL-XPosure 
Thermo scientific, MA, USA) for auto-radiography. Lane 
scan and analysis was performed with Image Quant TL 
software (Image Scanner, Amersham, UK). 
 
Pull-down assay with Panc-1 extract 
A total of 0.5 mg of nuclear Panc-1 extract (1.3 mg/ml) were 
incubated for 1.5 h at 37◦C with 80 nM biotinylated 32R or 
96 in 20 mM Tris–HCl, pH 7.4, 50 mM KCl, 8% glycerol, 1 
mM DTT,  0.1 mM ZnAc, 5 mM NaF,  1 mM Na3VO4 and 
2.5 ng/µl poly[dI-dC]. A total of 100 µg of Streptavidin 
MagneSphere Paramagnetic Particles (Promega, I) were 
added and let to incubate for 1 h at 4◦C. The beads were 
captured with a magnet and washed two times. The proteins 
were denatured and eluted with Laemmli buffer (4% SDS, 
20% glycerol, 10% 2-mercaptoethanol, 0.004% bromophe- 
nol blue and 0.125 M Tris–HCl). Then they were separated 
in 10% SDS-PAGE and blotted into nitrocellulose at 70 V 
for 2 h. The nitrocellulose membrane was blocked for 1 h 
with 5% fat dried milk in PBS and 0.05% Tween (Sigma- 
Aldrich, USA) at room temperature. The primary antibod- 
ies used were: anti-MAZ (clone 133.7, IgG mouse, Santa 
Cruz Biotechnology, USA) diluted 1:200, anti-hnRNP A1 
(clone 9H10, IgG mouse, Sigma-Aldrich, USA) diluted 
1:2000 and anti PARP-1 (polyclonal antibody, IgG rabbit, 
Cell Signalling Technology, USA) diluted 1:200. The mem- 
branes were incubated overnight at 4◦C with the primary 
antibodies, then washed with 0.05% Tween in PBS and in- 
cubated for 1 h with the secondary antibodies conjugated 
 
to horseradish peroxidase: anti-mouse IgG (diluted 1:5000) 
and anti-rabbit IgG (diluted 1:5000) (Calbiochem, Merck 
Millipore, D). The signal was developed with Super Signal 
®West PICO, and FEMTO (Thermo Fisher, USA) and de- 
tected with ChemiDOC XRS, Quantity One 4.6.5 software 
(BioRad Laboratories, USA). 
 
RESULTS AND DISCUSSION 
8-oxoG in KRAS is more abundant in G4 than in non-G4 re- 
gions 
Cancer cells have relatively high levels of ROS that may 
damage DNA, RNA and proteins. Oxidative damage to 
DNA occurs mainly on guanine (21), in particular at the 5j 
guanine of GG runs (22). G-rich quadruplex motifs, being 
composed by several runs of guanines, are effective hotspots 
for guanine oxidation (32). The formation of 7,8-dihydro- 
8-oxoguanine (or 8-oxoG) in these sequence motifs may 
be favored by the particular folded structure that they as- 
sume under physiological conditions (23,29). Indeed, four 
consecutive G-runs separated by few bases can form a G- 
quadruplex or G4 structure stabilized by tetrads of gua- 
nines. A G4-Seq conducted on the human genome found >7 
105 potential G4 motifs, mainly located in functional re- 
gions including promoters, 5j-Untranslated region (UTRs) 
and splicing sites (33). A subsequent G4-ChIP-Seq analysis 
conducted on chromatin revealed a lower number (about 
104) of G4 motifs folded into a G-quadruplex. The  critical 
point of these studies is that not all G4 motifs are folded un- 
der cellular conditions. Interestingly, many folded G4 mo- 
tifs are present in oncogenes including CMYC and KRAS 
(34). Recently, Burrows and co-workers developed an el- 
egant method, ‘8-oxoG-Seq’, to sequence 8-oxoG in the 
mouse genome. They found 104 regions of 8-oxoG en- 
richment in WT mouse embryonic fibroblast, in particular 
where there are G4 motifs (gene promoters and UTRs) (35). 
We therefore asked if 8-oxoG has an epigenetic potential in 
gene regulation and focused on the KRAS oncogene, which 
harbors upstream of the TSS a G-rich sequence with regu- 
latory functions. 
Human KRAS displays three G4-motifs that, according to 
their distance from TSS, can be named G4-proximal (pre- 
viously named 32R, 148/ 116), G4-middle ( 207/ 175) and 
G4-far ( 260/ 226) (23,25,28,29,36). Sequence 32R (69% 
GC), which has been extensively studied in our labo- ratory, 
is sensitive to nucleases and shows a complex struc- tural 
polymorphism (23,25,37). DMS-footprinting and CD 
experiments showed that 32R folds into a parallel G4 with 
a thymidine bulge in one strand and a (1/1/11) topology 
(23,25). Moreover, a truncated portion of 32R, comprising 
the first four G-runs from the 5j-end, folds into a (1/1/4) 
G-quadruplex (28,38). We reported that 32R is recognized 
by several nuclear proteins, including MAZ, PARP-1, Ku70 
and hnRNP A1 (25–27). The role of MAZ and/or hnRNP 
A1 on KRAS transcription regulation has been investigated 
in our laboratory and also by Chu et al. (24,26,27,39). The 
data showed that both transcription factors upon binding 
to 32R unfold the G4 structure and favor the transcription 
process. 
In order to understand, if the guanines of the G4 mo- 
tifs upstream TSS are prone to oxidation, we carried out 
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Figure 1. (A) Relative distance from TSS of G4 and non-G4 sequences used in quantitative real-time ChIP experiments. The length of each amplified DNA 
fragment is indicated. The structures of guanine and 8-oxo-7,8-dihydroguanine (8-oxoG) are shown; (B) ChIP qPCR showing the basal level of 8-oxoG 
in G4 and in non-G4 regions Ctr-1 and Ctr-2 in pancreatic cancer cells harboring mutated KRAS (Panc-1 and MIAPaCa-2) or wild-type KRAS (BxPC3) 
and in non-cancer HEK-293 cells. The histogram shows the fold enrichment of 8-oxoG in pancreatic cancer cells compared to 8-oxoG in G4 region of 293 
cells; (C) ChIP qPCR showing the relative level of 8-oxoG in G4 compared to non-G4 regions (Ctr-1 and Ctr-2). The ordinate reports the ratio between 
the level of 8-oxoG in G4 and in non-G4 region, in Panc-1 cells treated with 1 mM H2O2. The asterisk (*) means P < 0.05 (n 4), a Student’s t-test was 
performed. 
 
ChIP qPCR experiments. We measured the basal level of 8-
oxoG in the KRAS promoter region including 32R and 
compared it to other G-rich regions which are unable to fold 
into G4: Ctr-1 (containing a segment with 56% CG) and 
Ctr-2 (with 65% CG), both located >2000 bp from 32R 
(Figure 1A). Preliminary semi-quantitative ChIP PCR ex- 
periments carried out with pancreatic Panc-1 cancer cells 
clearly showed that 8-oxoG is more abundant in G4 than in 
non-G4 regions (Supplementary Figure S2). However, to 
determine the difference in guanine oxidation between G4 
and non-G4 regions, we performed quantitative ChIP qPCR 
in three pancreatic cancer cell lines (Panc-1 with KRAS 
G12D, MIA PaCa-2 with KRAS G12V and BxPC3 
with wild-type KRAS) and in one non-tumor cell line (hu- 
man embryonic kidney 293 cells, HEK-293) (Figure 1B). It 
turned out that the basal level of 8-oxoG in the cancer cells 
is up to 12-fold higher than in normal HEK-293 cells. This 
correlates with the fact that cancer cells have higher levels 
of ROS than normal cells (1,2). Our analysis also confirmed 
that in the three cancer cells analyzed, the G4-containing 
regions are more exposed to guanine oxidation (up to 4- 
fold) than the non-G4 regions Ctr-1 and Ctr-2. As Ctr-1 and 
Ctr-2 have a CG content >50% and contain several GG 
runs, the difference in 8-oxoG between G4 and non-G4 
regions cannot be ascribed to a low presence of guanines in 
the non-G4 regions. Previous studies reported that the 
secondary structure adopted by DNA affects the reactivity 
of guanine toward oxidative stress and that the guanines in 
a G-quadruplex are more keen to oxidation than the gua- 
nines in a duplex (40,41). Another interesting observation 
is the higher level of 8-oxoG in BxPC3 cells compared to 
Panc-1 and MIA PaCa-2 cells. This can be rationalized with 
the fact that only the latter cells carry a hyperactivated mu- 
tant KRAS which is known to constitutively stimulate the 
expression of Nrf2, a gene that activates the detoxification 
program bringing down ROS and thus 8-oxoG (9–11). As 
previously reported (12,14), we also found that there is a 
direct link between KRAS and Nrf2, as the overexpression 
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Figure 2. (A) Sequences of 32R and of the designed oligonucleotides with one or two 8-oxoG either in the major 11-nt loop of KRAS G4 (92, 93 and 94) 
or in G-tetrads (95, 96 and 97). The G-runs I–V are pointed out; (B) 20% PAGE of 32R and 8-oxoG-substituted oligonucleotides in denaturing (left) and 
native (right) gels. As reference oligonucleotides of 24, 30 and 36 nt have been loaded. G4-a and G4-b are due to G4 structures, ss indicates unstructured 
oligonucleotides. Gels were repeated three times; (C) Structure of a G-tetrad with 8-oxoG (left) and of a canonical G-tetrad (right). 
 
of KRAS in Panc-1 cells brought about an increase of Nrf2 
(Supplementary Figure S3). 
Finally, to make sure that the level of 8-oxoG correlates 
with the cellular amount of ROS, we performed ChIP qPCR 
assays with Panc-1 cells treated with H2O2. As expected, the 
treatment with H2O2 raised 8-oxoG in the G4 region 4- fold 
more than in the non-G4 regions Ctr-1 and Ctr-2 (Fig- ure 
1C). 
 
8-OxoG affects the folding of the G-rich 32R promoter se- 
quence 
DMS-footprinting and CD studies, reported by ourselves 
(23,25) and others (36), showed that 32R folds into a paral- 
lel G4 formed by the G-runs I, II, III and V (Figure 2A). 
Distinctive features of this G-quadruplex are a large 11- 
nt loop and a strand with a thymidine bulge (Supplemen- 
tary Figure S4). On the basis of this putative structure, we 
designed mimics of 32R, carrying 8-oxoG at specific posi- 
tions: in the G-tetrads (oligonucleotides 92, 93 and 94) or 
in the 11-nt loop (95, 96 and 97). Under denaturing condi- 
tions (7 M urea), the 8-oxoG-substituted oligonucleotides 
migrated expectedly as wild-type 32R or as its complemen- 
tary strand 32Y. By contrast, under native conditions (100 
mM KCl) the oligonucleotides carrying one or two 8-oxoG 
in the 11-nt loop (95, 96 and 97) migrated in the same way 
as 32R, with a single band running faster than the unstruc- 
tured oligonucleotide 32Y (Figure 2B). This suggests that 
when the oxidized guanine is in the 11-nt loop, the folding of 
the G4-motif is not affected [i.e. it is similar to that of wild- 
type 32R, (1/1/11) G4]. Instead, when 8-oxoG is placed in 
the G-runs II, III or V, which are involved in the formation 
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Figure 3. (A) Sequences of 32R, 92, 93 and 95 showing the G-runs involved in G4 formation (indicated in red). Compared to 32R, 92 and 93 undergo a 
different folding in order to exclude 8-oxoG from a G-tetrad; (B) Structure of the putative G-quadruplexes with 8-oxoG; (C) Comparison of the DMS- 
footprinting of unstructured 32R with those of structured 32R and 92, 93 analogs. Note that the fifth G-run of 32R replaces the G-run with 8-oxoG through 
an alternative folding. Experiment was repeated three times. 
 
of the G-tetrads (92, 93 and 94), the oligonucleotides mi- 
grated with 2-folded structures: one running as the G4 of 
wild-type 32R (band G4-a) and one running faster (band 
G4-b) (Figure 2B). It should be borne in mind that 8-oxoG 
is expected to destabilize the G-tetrad arrangement, as the 
N7 of diketo 8-oxoG becomes a hydrogen donor and steri- 
cally clashes with the amino group of a neighboring guanine 
(Figure 2C). This means that 8-oxoG can hardly stay in a G- 
tetrad, as the two H-bonding pattern is replaced by a single 
H-bonding pattern. It is therefore reasonable to assume that 
the incorporation of 8-oxoG in a G-tetrad destabilizes the 
G-quadruplex. Indeed, single substitutions of guanine with 
8-oxoG have been reported to do so (42). 
An insight into the structure of the human KRAS G- 
quadruplex with 8-oxoG substitutions was obtained by 
DMS-footprinting. As 32R contains 5 G-runs, it is likely 
that the G-run carrying 8-oxoG is excluded from the for- 
mation of the G-tetrads and replaced by the redundant fifth 
G-run present in 32R, as observed with G4 motifs found  in 
oncogene promoters and telomeres (Figure 3A and B) 
(43,44). This occurs through an alternative folding of 32R. 
As illustrated in Figure 3C, wild-type 32R shows its typical 
DMS footprinting in 100 mM KCl with all guanines pro- 
tected from DMS, except G16, G18–20 and G23. This cleav- 
age pattern is consistent with the formation of a (1/1/11)- 
G4 by the G-runs I, II, III and V (23,25). The DMS- 
footprinting of oligonucleotide 92, which was designed with 
8-oxoG in G-run II, clearly shows a different cleavage pat- 
tern. In keeping with the ‘fifth G-run’ hypothesis, its folding 
involves the G-runs I, III, IV and V, giving rise to (6/4/4) G- 
quadruplex. It can actually be seen that G-run II (G6-G7- 
G9) is reactive to DMS, while G-run IV (G18-G19-G20) is 
not. This DMS reactivity pattern demonstrates that the fifth 
G-run (G-run IV) has indeed replaced G-run II carrying 8- 
oxoG, through a re-modulation of the folding in order to ex- 
clude the oxidized guanine from the G4 scaffold. The result- 
ing (6/4/4) G4, having loops <11 nt, is more compact than 
wild-type (1/1/11) G4 and that explains why it runs faster 
in a polyacrylamide gel (band G4-b, Figure 2B). Oligonu- 
cleotide 93, carrying 8-oxoG in G-run III, shows a similar 
behavior as 92. In this case, G-run III is more reactive to 
DMS, suggesting that it is replaced by G-run IV (G18-G19- 
G20), which appears protected. We also analyzed oligonu- 
cleotide 95 with 8-oxoG in the 11-nt loop, that should not 
impact on the folding. In keeping with this prediction, the 
footprinting of 95 shows that the bases cleaved are those 
located in the 11-nt loop, as observed with the wild-type 
32R sequence (Supplementary Figure S5). A similar behav- 
ior has been observed with the critical G4 motif of CMYC 
(45). DMS footprinting and RNA polymerase stop assays 
showed that a simple 8-oxoG induces a change in the fold- 
ing to exclude the oxidized G-run from the formation of the 
G-tetrads. 
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Figure 4. CD spectra of 32R at 20◦C (black) and of 8-oxoG-substituted oligonucleotides at 20◦C (dotted spectra) and 90◦C (gray spectra), in 50 mM Tris–
HCl, pH 7.4, 100 mM KCl. Each panel compare the CD spectrum of 32R with that of an oligonucleotide with 8-oxoG. The ordinate reports the ellipticity 
signal expressed in mdeg. 
 
Fleming and co-workers have observed that there are 
many oncogenes with G4 motifs carrying an extra G-run 
that could relieve a damaged guanine through a structural 
transition (44). The authors hypothesized that the extrusion 
of the damage into a loop should be necessary for the acti- 
vation of the base excision repair mechanism. However, the 
evolutionary selection of a fifth G-run in regulatory G4 mo- 
tifs recognized by transcription factors might also find its 
rationale in the fact that 8-oxoG could act as a transcrip- 
tion regulator by modulating the binding and recruitment of 
transcription factors to promoter sequences (see infra). 
 
Circular dichroism and UV-melting of the G4 structures with 
8-oxoG 
Next, we asked if the presence of 8-oxoG in 32R may affect 
the strand directionality of the G-quadruplex. To address 
this question, we performed circular dichroism experiments, 
as CD is a spectroscopic technique sensitive to DNA sec- 
ondary structures. In Figure 4, we compared the CD spec- 
tra of each 8-oxoG-substituted sequence, obtained at 20 and 
90◦C, with the CD of 32R. At 20◦C, all the spectra are char- 
acterized by a strong and positive ellipticity at 264 nm and a 
negative ellipticity at 245 nm, which are typical of a parallel 
or type I G-quadruplex (46). At 90◦C, the intensity of the 
264-nm ellipticity is dramatically reduced, suggesting that 
at 20◦C the 8-oxoG-substituted oligonucleotides are struc- 
tured. Oligonucleotides 92 (6/4/4) and 94 (6/4/5) show also 
a weak ellipticity at 295 nm, that may point to the formation 
of an alternative parallel/antiparallel G4. Instead, the CD 
spectra of 95, 96, 97 and 32R, forming a G4 with the same 
(1/1/11) topology, exhibit almost identical CD spectra. 
As the thermal differential spectra of 32R and 8-oxoG- 
substituted oligonucleotides show a negative band at 295 
nm, we followed their melting by measuring the absorbance 
at 295 nm as a function of temperature (47). Typical melt- 
ing curves are shown in Figure 5. At heating/cooling rates 
of 0.5◦C/min, we obtained curves that are superimposable, 
indicating that the melting/annealing proceeded through 
equilibrium states. The TM’s, determined by the dAbs/dT 
versus T plots, are reported in Table 1. The data show that 
when the oxidized guanine is located in the 11-nt loop (95, 










Figure 5. Denaturing and annealing UV-melting curves of 32R and 8-oxoG substituted oligonucleotides in 50 mM cacodylate pH 7.4, 100 mM KCl. The 
curves have been obtained by measuring the absorbance at 295 nm as a function of temperature, at a heating/cooling rates of 0.5◦C/min. Denaturing, black 
filled curves; renaturing, dotted gray curves. 
 
show TM  values nearly similar to that of 32R (OTM 1– 
2◦C). So, in terms of stability, CD spectra, electrophoretic 
mobility and DMS-footprinting demonstrate that 32R and 
95, 96 and 97 form the same G-quadruplex. In contrast, 
when the oxidized guanine is inserted in a G-tetrad, the TM’s 
of the resulting G4s (92, 93, 94) are significantly lower than 
that of the wild-type G4 (OTM 10–11◦C), in agreement with 
previous data obtained with the telomeric sequence (42). 
However, in our case, the decrease of the TM’s is not due to 
altered stacking interactions between the G-tetrads, but to a 
change in the folding involving the fifth G-run. 
The thermodynamic parameters of G-quadruplex forma- 
tion were obtained from the melting profiles by using a 
‘DNA Melting Analysis’ software (Jasco, JP). As the melt- 
ing curves proceeded in a two-state manner, we could ana- 
lyze them with a standard all-or-none model. The data re- 
ported in Table 1 show that the OG of the G-quadruplexes 
with one or two 8-oxoGs in the major 11-nt loop (95, 96 and 
97) is 1–2 kcal/mol more favorable than the OG of wild- 
type G4. This increase of stability is enthalpic in origin, and 
may probably arise from more efficient stacking interactions 
between 8-oxoG and the surrounding bases in the loop. In 
contrast, when the damage is inserted in a G-tetrad (92, 93 
and 94) the sequences fold into an alternative G-quadruplex 
with a OG about 2 kcal/mol less favorable than the OG of 
wild-type G4. 
 
OGG1 is recruited to the KRAS G4 motif region carrying 
8-oxoG 
The enhanced level of 8-oxoG in the G4 region of KRAS 
upstream of TSS suggested to investigate whether the base- 
excision repair (BER) pathway is activated. BER is initiated 
by DNA glycosylases, which recognize and remove the ox- 
idized guanines. The resulting apurinic site is then cleaved 
and the single-strand break processed by a short- or long- 
patch BER. The first enzyme of this pathway is OGG1, 
which behaves in vitro as a bifunctional DNA glycosylase 
excising 8-oxoG and cleaving the abasic site, while in vivo it 
behaves as a monofunctional glycosylase, with APE1 per- 
forming the lyase function (48–52). In order to see if OGG1 
is recruited to the KRAS promoter when the level of 8-oxoG 
is increased by oxidative stress, we performed ChIP qPCR 
assays. We found that when Panc-1 cells are treated with 
H2O2 or luteolin, an inhibitor of Nrf2 that causes an in- 
crease of cellular ROS (53,54), the recruitment of OGG1 to 
the KRAS promoter increases more in G4 than in the non-
G4 regions Ctr-1 and Ctr-2 (Figure 6A). We then pro- duced 
and purified recombinant OGG1 to test its capac- 
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Figure 6. (A) ChIP qPCR showing that after treatment of Panc-1 cells with 1 mM H2O2 or 10 µM luteolin, the recruitment of OGG1 to the KRAS promoter 
increases more at G4 region than non-G4 regions (Ctr-1 and Ctr-2). Asterisk (*) indicate P < 0.05 (n 4), a Student’s t-test was performed; (B) Primary 
sequences of 32R and designed 8-oxoG-substituted oligonucleotides where the positions of 8-oxoG are indicated; (C) The panel shows in a denaturing 
PAGE that OGG1 excises 8-oxoG in the duplexes formed by the designed 8-oxoG oligonucleotides and the complementary strand; (D) Sequencing 18% 
PAGE showing that OGG1 (1 µM) cleaves the radiolabeled duplexes (2 nM) exactly at the positions where there is 8-oxoG. The experiments in (C) and 








94 52.6 9.5 2 in G-tetrad 
96   
−78.7 ± 1.0 −208 ± 1 −14.2 ± 
0.1
61.1 1.0 1 in 11-nt loop
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−74.2 ± 1.3 −202 ± 4 −11.5 ± 0.1 
95 61.5 0.6 1 in 11-nt loop 
−56.0 ± 0.9 −147 ± 3 −10.4 ± 0.2 
97 63.7 1.6 2 in 11-nt loop 
−80.1 ± 1.3 −215 ± 4 −13.4 ± 0.1 
−66.1 ± 1.3 −172 ± 4 −12.8 ± 0.2 
adata obtained in 50 mM cacodylate pH 7.4, 100 mM KCl. 
bOTM TM (32R) TM (8-oxoG oligo). 
cThermodynamic parameters obtained from analysis of melting cuves. 
dOG = OH − TOS, T = 310 K. 
 
ity to excise 8-oxoG and cleave the abasic site. Increasing 
amounts of enzyme were incubated, for 15 min at 37◦C, 
with 32P-ATP labeled 8-oxoG-substituted oligonucleotides, 
transformed into duplexes with the complementary strand 
and the products were analyzed in a denaturing PAGE gel 
(Figure 6B and C). The enzyme did not show any activity 
on the wild-type 32R duplex, but it cleaved the duplexes car- 
rying one or two 8-oxoGs. With duplexes 92, 93 and 95, 
which have only one 8-oxoG insertion, OGG1 gave only 
one main cleaved fragment; with duplexes 94, 96 and 97, de- 
signed with two 8-oxoG lesions, it produced two fragments, 
as expected. Note that the bands are doublets, because after 
having removed 8-oxoG, OGG1 cleaves the apurinic site by 
both þ and 6 eliminations (55). In a native gel, we detected 
only at 4◦C a weak binding of OGG1 to the designed du- 
plexes, because the enzyme destabilizes the complexes (Sup- 
plementary Figure S6) by cleaving the substrates. In order 
to confirm that the cleavage catalyzed by OGG1 occurs ex- 
actly at the duplex sites where guanine has been replaced 
with 8-oxoG, we analyzed the products of the enzymatic re- 
action in a sequencing gel (Figure 6D). In lane 1, we report a 
G-reaction that determines the sequence of the duplex sub- 
strate. The pattern obtained is in nice agreement with Figure 
6B and C. Each duplex substrate gave the fragment of the 
expected length, indicating that the cleavage occurs exactly 
at the place where the damaged guanine is. In the sequenc- 
ing gel, the doublets appear clearer showing that the two 
fragments differ for two/three nucleotides, as a results of 
successive þ and 6 eliminations (55). 
Then, we analyzed the catalytic activity of OGG1 on 32R 
and 8-oxoG- substituted oligonucleotides in the G4 confor- 
mation. The radiolabeled oligonucleotides were let to fold in 
KCl buffer and incubated with OGG1. Almost no cleaved 
products were detected in a denaturing gel, suggesting that 
the enzyme does have no or only slight activity against G4, 
as previously reported by Zhou et al. (56) (not shown). 
However, when we analyzed in a sequencing gel the mixtures 
between OGG1 and the designed 8-oxoG G-quadruplexes, 
we observed that the enzyme had a weak activity against 
specific guanines in the G4s (Figure 7A and B). The G- 
quadruplexes with 1/1/11 topology showed a small cleavage 
at G11 (a guanine of an external G-tetrad, Supplementary 
Figure S4), while G4s with 1/8/4 and 6/4/5 topologies (93 
and 94) showed a weak cleavage in the loop, at G16/A17. 
This cleavage activity does not occur at oxidized guanines, 
is G4 specific and was not detected in the duplexes (see Fig- 
ure 6C and D). To rule out that the OGG1 cleavage could be 
due to specific depurinations occurring during oligomer 
synthesis or handling (57), yielding abasic sites recognized 
by OGG1, we treated the oligonucleotides with hot piperi- 
dine and re-purified them by electrophoresis. The weak ac- 
tivity of OGG1 was detected even after this treatment (Sup- 
plementary Figure S7). On a native gel, OGG1 binds to the 
KRAS G-quadruplexes in a non-productive manner, form- 
ing stable G4-OGG1 complexes (Figure 7C). It is worth not- 
ing that oligonucleotides 92, 93 and 94, that fold in two G- 
quadruplexes (see infra), form two OGG1:G4 complexes: 
one involving the (1/1/11)-G4 and the other the (6/4/4)- 
G4 (92), 1/8/4 G4 (93) and (6/4/5) G4 (94). Together, these 
experiments demonstrate that OGG1 recognizes both the 
duplex and folded conformations of 32R, but only with the 
duplex substrate the enzyme is able to excise 8-oxoG. 
 
Guanine oxidation and DNA folding modulate the binding of 
MAZ and hnRNP A1 to the KRAS promoter 
We previously have demonstrated that 32R in G4 confor- 
mation is recognized by several transcription factors includ- 
ing MAZ and hnRNP A1 (25). The consensus sequence of 
MAZ is 5j-GGG(A/C)GG (58). There are two binding sites 
for MAZ at the 5j and 3j ends of 32R. We found that MAZ 
activates the transcription of KRAS and HRAS (24,59). The 
KRAS G4 is also recognized by hnRNP A1, a protein of 34 
kDa that has a wide range of functions including telomere 
biogenesis, RNA stability and control of transcription (60). 
The essential role of this nuclear factor in the transcription 
of KRAS has been demonstrated (26,27,39). Both MAZ and 
hnRNP A1, upon binding to the KRAS G4, destabi- lize the 
structure and facilitate, in the presence of the com- 
plementary strand, the transformation of G4 into duplex 
(26,59). As the guanines in 32R are exposed to oxidation, 
we asked if 8-oxoG modifies somehow the recruitment and 
binding of MAZ and hnRNP A1 to the KRAS promoter.   To 
address the first point, we performed ChIP qPCR with 
Panc-1 cells treated with H2O2. The results show that the 
treatment increases the recruitment of MAZ and hnRNP A1 
more to G4 than non-G4 regions, as a result of a cellu- lar 
increase of 8-oxoG (Figure 8A). These data suggest that an 
increase of oxidation favors the recruitment to the pro- 
moter of MAZ and hnRNP A1, two proteins that activate 
transcription. A ChIP–reChIP assay (61), based on two in- 
dependent rounds of immunoprecipitations with antibodies 
specific for MAZ/hnRNP A1 and 8-oxoG, was performed 
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Figure 7. (A) Sequencing 18% PAGE showing the effect of OGG1 (1 µM) on the G-quadruplexes. A very weak cleavage activity is detected at specific 
guanines: G11 in the G4s formed by 32R, 95, 96 and 97; G16/A17 in the G4s formed by 93, G4-(1/8/4) and 94, G4-(6/4/5). This cleavage activity is not 
correlated with 8-oxoG; (B) Sequences of the G4 motifs 32R, 92, 93, 94 and 95 showing the positions where the G4s are cleaved by OGG1 (96 and 97 
behave as 95); (C) Native PAGE showing that OGG1 binds to radiolabeled 32R and 8-oxoG oligonucleotides (20 nM) in the G-quadruplex form. Note that 
92, 93 and 94 form two complexes (c1 and c2) as they form in solution two quadruplexes. OGG1 (0.3 and 0.6 µg) and oligonucleotides (20 nM) have 
been incubated 45 min at 37◦C prior to PAGE. The experiment in A was repeated three times, that in C two times. 
 
to further confirm the co-localization of the transcription 
factors and 8-oxoG in the chromatinized DNA fragment 
carrying the G4 motif (Supplementary Figure S8). 
To know if the binding of  MAZ  and  hnRNP  A1  to the 
KRAS promoter is affected by 8-oxoG, we performed 
EMSA assays with recombinant proteins and 8-oxoG 
oligonucleotides in G4 or duplex conformation. Figure 8B 
reports native gels on the binding of MAZ and hnRNP A1 
to wild-type 32R and 8-oxoG-substituted oligonucleotides 
in the duplex conformation. It shows that the interaction 
between the proteins and the duplexes carrying one or two 
8-oxoG modifications is strongly inhibited. This is in keep- 
ing with the finding that the oxidation of both guanines    in 
the consensus sequence of cAMP responsive element- 
binding protein (CREB) strongly decreased the protein 
binding (62). In contrast, when 32R and 8-oxoG oligonu- 
cleotides are in the G4 conformation, MAZ and hnRNP A1 
bind to the DNA target despite it carries 8-oxoG lesions. It is 
worth noting that the binding of MAZ to 8-oxoG G- 
quadruplexes with (1/1/11) topology (95, 96, 97) increases 
by 5-fold compared to the binding of MAZ to 32R G4. The 
binding of hnRNP A1 also appears 4-fold more ro- bust 
with the G-quadruplexes bearing 8-oxoG in the 11-nt loop. 
To confirm the finding that the transcription factors have 
more affinity for KRAS G4 when it is oxidized in the major 
loop, we covalently linked biotin to 32R and 96, car- rying 
two 8-oxoGs in the 11-nt loop. We used the conjugates as 
DNA baits in streptavidin–biotin affinity precipitation 
experiments with a nuclear Panc-1 extract. The presence of 
MAZ and hnRNP A1 in the proteins binding to the DNA 
baits was detected and quantified by western blots (Figure 
8D). The results are in keeping with those obtained with 
the recombinant proteins: in the presence of all nuclear pro- 
teins, oxidized G4 (96) shows 2-fold higher affinity than 
wild-type G4 for MAZ and hnRNP A1 [also for PARP- 
1, a protein that binds to 32R (25)]. Considering the G4 
unfolding activity of MAZ and hnRNP A1, these findings 
are likely to have an impact on the transcription regulation 
mechanism, as proposed in the following paragraph. 
 
A transcription model for oncogene KRAS involving 8-oxoG, 
OGG1, hnRNP A1 and MAZ 
The results of this study, together with previously reported 
data, add a new element to the molecular mechanism con- 
trolling KRAS transcription in pancreatic cancer cells: the 
oxidation of guanine at the critical G4 motif upstream TSS. 
The high metabolic rate of cancer cells causes an enhanced 
level of ROS that favors the oxidation of guanine. An in- 
creased level of 8-oxoG going beyond the repairing capacity 
by the cell, would have a negative impact on KRAS expres- 
sion, as the binding of MAZ and hnRNP A1 to the pro- 
moter in the duplex conformation would be strongly inhib- 
ited. To prevent this, pancreatic cancer cells express high lev- 
els of Nrf2: a protein that stimulates the detoxification path- 
way to keep the oxidative damage at levels compatible with 
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Figure 8.  (A) ChIP qPCR showing that the recruitment of MAZ and hnRNP A1 to the promoter G4 region is higher than to non-G4 regions (Ctr-1    and 
Ctr-2), following cell treatment with 1 mM H2O2. Asterisk (*) indicates P < 0.05 (n 4), a Student’s t-test was performed; (B) The panels show the binding 
of MAZ and hnRNP A1 (2.5 and 5 µg) to 20 nM radiolabeled 32R and 8-oxoG oligonucleotides in duplex. The binding of MAZ and hnRNP  A1 to the 
duplexes bearing 8-oxoG is strongly inhibited; (C) The panels show the binding of MAZ and hnRNP A1 to G-quadruplexes 32R and analogs bearing 8-
oxoG. The proteins bind to the G4s, even though they harbor 8-oxoG. The G4s with 8-oxoG in the 11-nt loop (95, 96 and 97) bind MAZ much 
more than wild-type G4. Before EMSA, the G4s or duplexes have been incubated with MAZ for 1 h at 37◦C and with hnRNP A1 for 30 min at 25◦C; (D) 
Streptavidin-biotin pull-down assay with nuclear Panc-1 extract and biotinylated 32R and 96 used as DNA baits (the structure is shown). Cellular proteins 
bound to G4 were pulled down with streptavidin magnetic beads and analyzed by western blot. The experiments in (B) and (C) were repeated three times. 
 
an optimal cell growth. Indeed, in agreement with previous 
work (63), we found that the inhibition of Nrf2 brought 
about an increase of ROS in Panc-1 cells (Supplementary 
Figure S9). The damage caused to DNA by oxidative stress 
can modulate gene expression in different ways. While the 
insertion of a single 8-oxoG in a promoter non-G4 sequence 
of a reporter gene was found to affect negatively transcrip- 
tion (64), when the oxidized guanine was inserted in the 
G4-motif of VEGF composed of five G-runs, the expres- 
sion of Renilla luciferase increased by 3-fold. To rationalize 
this behavior, Fleming et al. (65) proposed that gene expres- 
sion increases because 8-oxoG is excised by OGG1, yield- 
ing an abasic site that would favor the folding into a G4 
looping out the oxidized G-run. This conformation should 
facilitate the binding of Ape1 to G4, but without cleaving 
efficiently the abasic site (66). Finally, the Ref-1 domain of 
Ape1 would recruit other nuclear factors and stimulate 
transcription. In addition to this interesting mechanism, 
Boldogh and co-workers (67) found that in the TNF-a pro- 
moter, ROS preferentially oxidizes the guanines in a G-rich 
region adjacent to a NF-kB-binding site. The authors sus- 
tained that the binding of OGG1 to the oxidized G-rich re- 
gion would promote the recruitment of NF-kB to its bind- 
ing site, with the consequence of activating transcription. 
The former mechanism has a more general character and 
could rationalize also the data of our study. However, also 
another mechanism can be postulated, in keeping with the 
original idea that G-quadruplex behaves as a transcription 
repressor (Figure 9). If we assume that the picture found 
for HRAS (59), based on a mutation analysis of the pro- 
moter, also holds for KRAS, the promoter G4 motif is nor- 
mally folded into G4 and transcription is kept to a basal low 
level. The folding of the G4 motif is favored by DNA super- 
coiling, which provides sufficient energy to locally unwind 
the double helix (68,69). This induces the formation of a G- 
quadruplex on the purine-rich strand and, most likely, an 
i-motif on the pyrimidine strand (70). Although the i-motif 
shows in vitro higher stability under slightly acidic condi- 
tions, both cellular crowding and supercoiling are expected 
to stabilize this unusual structure at physiological condi- 
tions too (69,71,72). The relatively high oxidative stress in 
pancreatic cancer cells may induce the oxidation of cer- 
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Figure 9. A model for KRAS transcription regulation involving 8-oxoG. 
A1 and Pol II stand for hnRNP A1 and RNA Pol II. 
 
 
tain guanines, particularly the DNA motifs composed by 
blocks of guanines (73) and folded into G4 (40). Our data 
show that the presence of one or two oxidized guanines in 
the major 11-nt loop of the KRAS G-quadruplex increases 
the binding of MAZ, hnRNP A1 and also PARP-1 to the G-
quadruplex. As hnRNP A1 recognizes also the i-motif (71), 
both strands of the G4 motif could interact with nu- clear 
proteins. The proteins upon binding should destabi- lize the 
folded structures and facilitate the reconstitution of the 
double helix (59,71). In this scheme, 8-oxoG would act as 
an epigenetic marker boosting the recruitment to the 
promoter of the nuclear factors essential for KRAS tran- 
scription. The oxidized guanines in the reconstituted duplex 
will be efficiently repaired via the BER pathway involving 
OGG1, that excises 8-oxoG, and Ape1, that cleaves the aba- 
sic site (48,74). The excision of 8-oxoG from the G4 motif in 
double helix will increase the affinity of the nuclear factors 
for the promoter, with the result of activating transcription. 
This mechanism is supported by the fact that KRAS tran- 
scription strongly depends on MAZ (24,59) and hnRNP A1 
(26,27,39). It also depends on OGG1, as its downregulation 
in Panc-1 cells by siRNA determines a parallel decrease of 
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Table S1. 8-oxoG substituted oligonucleotides with the sequence of the regulatory G4-
motif of the KRAS gene 
Oligo (a) 5’  3’  MW Calc.(b) MW Found (c) 
92 AGGGCoxGGTGTGGGAAGAGGGAAGAGGGGGAGG 10271.7 10275.2 
93 AGGGCGGTGToxGGGAAGAGGGAAGAGGGGGAGG 10271.7 10274.9 
94 AGGGCGoxGTGTGGGAAGAGGGAAGAoxGGGGGAGG 10287.7 10291.1 
95 AGGGCGGTGTGGGAAoxGAGGGAAGAGGGGGAGG 10271.7 10270.1 
96 AGGGCGGTGTGGGAAoxGAGoxGGAAGAGGGGGAGG 10287.7 10290.4 
97 AGGGCGGTGTGGGAAoxGAGGGAAoxGAGGGGGAGG 10287.7 10289.4 
32R AGGGCGGTGTGGGAAGAGGGAAGAGGGGGAGG   













Figure S1. SDS-PAGE showing the degree of purity of recombinant OGG1 used in this 
work. As for recombinant MAZ and hnRNP A1, we already reported in previous work that 
















Figure S2: Chromatin immunoprecipitation and PCR showing that the level of 8-oxoG in 
the G4 region close to TSS is higher than in the non-G4 region located about 4000 bp 
upstream TSS.  
 
 
Figure S3: Panc-1 cells transfected with vectors expressing wild-type KRAS, mutant 
KRAS G12D, KRAS G12V, empty vectors (control 1, control 2) showed increased levels of 
KRAS and Nrf2, 96 h after transfection, according to the Western blot analysis. As 






Figure S4. Putative structure of the G-quadruplex assumed by 32R determined by DMS-
footprinting experiments (Ref. 23 and 25).  
 
 
Figure S5. DMS-footprinting of unstructured 32R in LiCl-buffer (black) and 32R with G16 
replaced with 8-oxoG (oligonucleotides 95, Fig. 2, text) annealed in 100 mM KCl (red). It 
can be seen that, with respect to unstructured 32R, the G-runs I, II, III and V are protected 
from DMS, while the tract G16-A17-G18-G19-G20 inside the 11-nt loop is highly reactive, 
in particular the modified 8-oxoG base. The cleavage with piperidine occurs mainly at the 
modified base and that’s why the other guanines of the loop show a lower reactivity to 
DMS. By comparing these profiles with those reported in Fig. 3 of the text, one can 
conclude that when 8-oxoG is in the 11-nt loop, the folding of the modified oligonucleotide 




Figure S6: EMSA at 4 °C, under native conditions, showing that the complexes between 
OGG1 and 8-oxoG duplexes are not so stable and barely detectable in the gel, due to the 















Figure S7. (Left panel) Wild-type and 8-oxoG-substituted oligonucleotides purified by 
electrophoresis, folded in G4 in 100 mM KC, and treated with OGG1. The reaction 
products have been run in a sequencing gel. A weak cleavage activity at G11 is detected 
in the oligonucleotides assuming a (1/1/11) G4. Instead, oligonucleotides 93 and 94, 
showed a sligh cleavage at G16 and G23; (Right panel) Purified wild–type and 8-oxoG-
substituted oligonucleotides have been treated with hot piperidine, purified again by 
electrophoresis and folded in 100 mM KCL. The G4 oligonucleotides were used for a 
OGG1 assay. It can be seen that the piperidine treatment does not remove the cleavages 












Figure S8: ChiP-reChIP experiment. It is based on two independent rounds of 
immunoprecipitations with antibodies specific for MAZ/hnRNP A1 and 8-oxoG, was 
performed to further confirm the co-localization of the transcription factors and 8-oxoG in 
















Figure S9. (A) RT qPCR showing that the silencing of Nrf2 with a specific siRNA results in 
an increase of ROS in Panc-1 cells; (B) Level of ROS in Panc-1 cells treated with 0, 40 
and 80 nM of TmPyP4, followed by light treatment (15 min, fluence of 7.2 J/cm2). Only a 
slight increase of ROS (~ 30%) is observed as the increased ROS triggers the expression 
of Nrf2 activating the detoxification genes. When the cells are treated with TMPyP4 and 20 








Figure S10. Panc-1 cells treated for 24 h with OGG1 siRNA, then OGG1 and KRAS 
transcripts were measured by RT qPCR. The downregulation of OGG1 is accompanied by 













The ROS-KRAS-Nrf2 axis in the control of the redox homeostasis 
and the intersection with survival-apoptosis pathways 
 























The ROS-KRAS-Nrf2 axis in the control of the redox 




Annalisa Ferino, Giorgio Cinque, Valentina Rapozzi and Luigi E. Xodo* 
 
Department of Medicine, Laboratory of Biochemistry, University of Udine, P.le Kolbe 4, 
33100 Udine, Italy 
 
 
* To whom correspondence should be addressed: Luigi E. Xodo, Department of 
Medicine, Laboratory of Biochemistry, P.le Kolbe 4, University of Udine, 33100 Udine, 
Italy; Tel: (+39) 0432.494395; Fax: (+39) 0432.494301; E-mail: luigi.xodo@uniud.it 
 
Abstract 
In highly proliferating cancer cells, oncogenic mutations reprogram the metabolism 
and increase the production of reactive oxygen species (ROS). Cancer cells prevent ROS 
accumulation by upregulating antioxidant systems. We found that ROS stimulate the 
expression of KRAS, which in turn upregulates Nrf2, a master regulator of oxidative stress. 
ROS, KRAS and Nrf2 constitute a molecular axis controlling the redox homeostasis and 
the NF-kB/Snail/RKIP circuitry, which regulates the survival and apoptosis pathways. Our 
data show that low ROS levels result in the upregulation of prosurvival Snail and 
simultaneously downregulation proapoptotic RKIP. This gene expression pattern favours 
cell proliferation. By contrast, high ROS favour apoptosis by upregulating proapoptotic 
RKIP and downregulating prosurvival Snail. We also discuss the mechanism through 
which KRAS is upregulated by ROS. Lastly, we demonstrate that cancer cells can be 




KRAS, Kirsten ras; Nrf2, Nuclear factor (erythroid-derived 2)-like 2;  
G-quadruplex DNA, G4 DNA; PAGE, polyacrylamide gel electrophoresis 
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Introduction 
KRAS is mutated in about 30 % of all human cancers [1] and plays a key role in the 
pathogenesis of pancreatic ductal adenocarcinoma (PDAC). It has been reported that the 
ectopic expression of mutant KRAS G12D in mice is sufficient to initiate cancer [2, 3]. 
While the function of KRAS in the early steps of tumorigenesis has been addressed [4, 5], 
its role in later stages of the disease is still poorly understood. Recent studies have 
demonstrated that PDAC cells are addicted to oncogenic KRAS [6, 7]. This means that 
cancer cells require for proliferation the expression of a single oncogene, although they 
accumulate multiple genetic lesions [7]. In agreement with this important notion, De Pinho 
et al. [8] found that oncogenic KRAS reprograms the glucose metabolism in PDAC cells, in 
order to fuel a high anabolic demand, typical of rapidly dividing cells [9,10]. The metabolic 
rewiring induced by KRAS affects the glutamine (Gln) fate too, which does not follow its 
canonical oxidative pathway through the tricarboxylic acid cycle. By contrast, Gln is 
transformed into aspartate (Asp)  oxaloacetate  malate  pyruvate: a pathway that is 
accompanied by an increase of NADPH/NADP+, the reducing power necessary by cancer 
PDAC cells to maintain the redox homeostasis [11-14].  
As cancer cells produce higher levels of reactive oxygen species (ROS) [13], they 
activate a defence mechanism against oxidative stress. The major cellular response to 
oxidative stress is the activation of Nrf2 (nuclear factor erythroid 2-related factor 2), a 
redox-sensitive transcription factor that regulates the expression of antioxidant response 
element (ARE)-regulated genes [15-18]. While the knockout of Nrf2 in mice increased their 
susceptibility to a broad range of chemical toxicity, the pharmacological boosting of Nrf2 
protected the animals from oxidative damage [19]. Under basal redox conditions, 
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cytoplasmic Nrf2 is bound to Keap1 and subjected to proteosomal degradation. But, 
enhanced ROS cause a conformational change in Keap1, due to the oxidation of cysteine 
residues, resulting in the release of Nrf2 by the Nrf2:Kep1 complex. Free Nrf2 will then 
translocate into the nucleus and activate ARE-regulated genes [20].  
In this work we have analysed the impact of oxidative stress on the expression of 
KRAS and on its intersection with survival and apoptosis pathways. We found that 
enhanced ROS induce the expression of KRAS which, in turn, stimulates Nrf2. KRAS-
induced Nrf2 brings down the level of ROS, which results in the upregulation of prosurvival 
Snail and the downregulation of proapoptotic RKIP. By contrast, when ROS are generated 
and simultaneously Nrf2 is inhibited, proapoptotic RKIP is found upregulated while 
prosurvival Snail downregulated. Taken together, these data show that KRAS controls via 
Nrf2 the redox homeostasis and, through Snail and RKIP, the survival and apoptosis 
pathways. Finally, we address the issue of how ROS upregulate KRAS and propose a 
mechanism involving a G-quadruplex structure; we also demonstrate that the inhibition of 
Nrf2 strengthen the capacity of porphyrin TMPyP4 to act as a PDT photosensitizer for 
PDAC cells. 
 
Materials and Methods 
Oligonucleotides and Reagents 
Oligonucleotides used in this study have been obtained from Microsynth (CH). 8-
oxoG-substituted oligonucleotides were synthesized using 8-oxo-dG CEP (Berry & 
Associates) in 1-μmol scale on solid support by standard procedure, except using 
concentrated ammonia in the presence of 2-mercaptoethanol (0.25 M) in the deprotection 
step. The oligonucleotides were purified by reverse-phase HLPC equipped with a C18 
column (XBridge OST C18, 19 × 1000 mm, 5 μm). Oligonucleotide composition was 
verified by Matrix Assisted Laser Desorption Ionisation-Time of Flight (MALDI-TOF) 
(Spectra reported in ref. [21]). Luteolin, was purchased from Alfa Aesar (D), 8-oxoguanine 
(8-oxoG) and 8-oxodeoxyguanosine from Cayman Chemicals (MI, USA), GTP from 




Cell Cultures  
Human pancreatic (Panc-1, MIA PaCa-2, BxPC3) and bladder T24 cancer cells as well 
as non-cancer human embryonic kidney 293 cells were maintained in exponential growth 
in Dulbecco’s modified Eagle’s medium (DMEM) containing 100 U/ml penicillin, 100 mg/ml 
streptomycin, 20 mM L-glutamine and 10 % foetal bovine serum (Euroclone, IT).  
Western blots 
Total protein lysates (15 μg) were electrophoresed on 12 % SDS-PAGE and 
transferred to a nitrocellulose membrane at 70 V for 2 h. The filter was blocked for 1 h with 
5 % nonfat dried milk solution in PBS 0.1 % Tween (Sigma-Aldrich, USA) at room 
temperature. The primary antibodies used are anti-beta actin (clone JLA20, IgM mouse, 
1x10-4 , Calbiochem, Merck Millipore, Germany), anti-KRAS (Sigma Aldrich, clone 
3B10-2F2), anti Snail (Cell Signalling, C115D3 Rabbit mAb), anti RKIP (Cell Signalling 
G38 Ab), anti NF-kB p65 (Santa Cruz, C-20), PARP-1 (Cell Signalling, PARP-1 Ab), MAZ 
(Santa Cruz, MAZ-133.7) and hnRNP A1 (Sigma, clone 9H10). Membranes with the 
samples were incubated overnight at 4 °C with primary antibodies. The filters were 
washed with a 0.1 % Tween in PBS and subsequently incubated for 1 h with the 
secondary antibodies horseradish peroxidase conjugated: anti-mouse IgM (diluted 
1:5000), anti-rabbit IgG (diluted 1:5000) and anti-mouse IgG (1:5000) (Calbiochem, Merck 
Millipore, Germany). The signal of the proteins was developed with Super Signal ®West 
PICO, and FEMTO (Thermo Fisher, USA) and detected with ChemiDOC XRS, Quantity 
One 4.6.5 software (BioRad Laboratories, USA). 
 
RNA extraction and quantitative real-time PCR 
Panc-1 and T24 cancer cells were plated in a 96-well plate (18 x 103 cells/well). The 
following day (24 h), we treated the cells with P4/ (40 or 120 nM P4, 7.2 J/cm2 white light) 
and total RNA was extracted using iScript TM RT-qPCR Sample Preparation Reagent 
(BioRad, USA) 2, 8 or 33 hours after treatment, following the manufacturer’s instructions. 
For the cDNA synthesis, 1.25 µl of RNA, added with 3.75 ml DEPC water, were heated at 
70 °C for 5 min. The solution was added with 7.5 µl of a mix containing: 1x buffer, 0.01 M 
DTT (Invitrogen, USA), 1.6 µM primer dT [MWG Biotech, Germany; d(T)16], 1.6 µM 
random hexamer primers (Mycrosynth, Switzerland), 0.4 mM dNTPs solution containing 
equimolar amounts of dATP, dCTP, dGTP and dTTP (Euroclone, Italy), 0.8 U/µl RNase 
OUT, 8 U/µl of M-MLV reverse transcriptase (Invitrogen, USA). The mixtures were 
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incubated for 1 h at 37 °C and stopped by heating at 95 °C for 5 min. As a negative control 
the reverse transcription reaction was performed with a sample containing DEPC-treated 
water. 
To determine the levels of Nrf2, Snail, RKIP, KRAS and housekeeping genes 
hypoxanthine-guanine phosphoribosyltransferase (HPRT) and β2-microglobulin, 
quantitative real-time multiplex reactions were performed. We used sensi FASTTM syBR 
(No-ROX kit, Bioline, UK), 2.2 µl of cDNA and primers/probes. The PCR cycle was: 3 min 
at 95 °C, 50 cycles 10 s at 95 °C, 60 s at 58 °C (RKIP, KRAS, HPRT and 2 
microglobulin), 61 °C (Snail) and 62 °C (Nrf2). PCR reactions were carried out with a CFX-
96 real-time PCR apparatus controlled by an Optical System software (version 3.1) (Bio-
Rad Laboratories, USA). The KRAS transcript level was normalized with the housekeeping 
genes. The primer sequences are reported in Table 1. 
As for ChIP experiments, we followed the protocol reported in Ref. [21] and used the 
ChIP-IT® Express Shearing Kit (Active Motif, CA, USA). qPCR was performed with the 
following primers specific for genomic KRAS (accession number NG_007524): G4-plus 5’-
GTACGCCCGTCTGAAGAAGA-3’ (nucleotides (nt) 4889-4908, 0.2 M), G4-minus 5’-
GAGCACACCGATGAGTTCGG-3’ (nt 4958-4977, 0.1 M), Ctr-1-plus 5’-ACAAAAAG-
GTGCTGGGTGAGA-3’ (nt 12-32, 0.2 M), Ctr-1-minus 5’-TCCCCTTCCCGGAG-
ACTTAAT-3’ (nt 248-268, 0.2 M), Ctr-2-plus 5’-CTCCGACTCTCAGGCTCAAG-3’ (nt 
7536-7555, 0.15 M), Ctr-2-minus 5’-CAGCACTTTGGGAGGCTTAG-3’ (nt 7692-7711, 
0.15 M). Ctr-1 is located in a non-coding region, G4-region is in the promoter, Ctr-2 is in 
an intron. A detailed description of the method of analysis is reported in Ref. [21]. 
Pull-down assay with Panc-1 extract 
A total of 150 g of nuclear Panc-1 extract (1.3 mg/ml) were incubated for 0.5 h at 
25°C with 80 nM biotinylated 32R, ODN-92 and ODN-96 in 20 mM Tris–HCl, pH 7.4, 50 
mM KCl (oligos in G4) 8% glycerol, 1 mM DTT, 0.1 mM ZnAc, 5 mM NaF, 1 mM 
Na3VO4 and 2.5 ng/μl poly[dI-dC]. A total of 80 μg of Streptavidin MagneSphere 
Paramagnetic Particles (Promega, I), previously washed in buffer, were added and let to 
incubate for 0.5 h at 25°C. The oligonucleotides were used also in the duplex conformation 
in the same buffer but in 150 mM NaCl (incubation with extract was carried out at 37°C for 
1 h). The beads were captured with a magnet and washed three times. The proteins were 
denatured and eluted with Laemmli buffer (4% SDS, 20% glycerol, 10% 2-
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mercaptoethanol, 0.004% bromophenol blue and 0.125 M Tris–HCl). Then they were 
separated in 10% SDS-PAGE and blotted into nitrocellulose at 70 V for 2 h. The 
nitrocellulose membrane was blocked for 1 h with 5 % non fat dried milk in PBS and 0.1% 
Tween (Sigma-Aldrich, USA) at room temperature. The primary antibodies used were: 
anti-MAZ (clone 133.7, IgG mouse, Santa Cruz Biotechnology, USA) diluted 1:200, anti-
hnRNP A1 (clone 9H10, IgG mouse, Sigma-Aldrich, USA) diluted 1:2000 and anti PARP-1 
(polyclonal antibody, IgG rabbit, Cell Signalling Technology, USA) diluted 1:200. The 
membranes were incubated overnight at 4°C with the primary antibodies, then washed 
with 0.1% Tween in PBS and incubated for 1 h with the secondary antibodies conjugated 
to horseradish peroxidase: anti-mouse IgG (diluted 1:5000) and anti-rabbit IgG (diluted 
1:5000) (Calbiochem, Merck Millipore, D). The signal was developed with Super 
Signal ®West PICO, and FEMTO (Thermo Fisher, USA) and detected with ChemiDOC 
XRS, Quantity One 4.6.5 software (BioRad Laboratories, USA). 
Measurement of intracellular ROS  
Panc-1 and T24 cells were plated in 6-well plate (2.0 x 105 cells/well). The following 
day we treated the cells with 20 M luteolin and after 4 h with TMPyP4 (P4) (40 or 80 nM). 
We irradiated the cells with white light (fluence of 7.2 J/cm2), 24 h after luteolin treatment.  
The following day, the medium was removed and the cells washed twice with PBS. After 
washing, the cells were incubated with 500 l of 10 M CM-H2DCFDA (Invitrogen) in 
DMEM-free serum for 40 min. After two washes with PBS, the cells were trypsinized and 
transferred into FACS tubes containing 1 ml of PBS. The suspension was centrifuged at 
1200 rpm for 3 min. The pellet was resuspended in 300 l of PBS and the ROS signal was 
measured by flow cytometer. In some experiments intracellular ROS levels were 
determined in a 96-well plate using EnSpire 2300 Multilabel Reader (Perkin Elmer).  
Cell transfection with KRAS expression vectors  
Panc-1 cells were plated in a 6-well plate (5 x 105 cells/well) or in 96-well plate (9 x 103  
cells/well) and the following day transfected with plasmids encoding WT, G12D, G12V 
KRAS protein and control plasmid (empty vector) using jetPEI (Polyplus, France) as 
transfectant reagent. For Western blot total protein lysates were obtained after 96 h in 
Laemmli Buffer and quantified using a Markwell Test. ROS was determined by treating the 
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cells with 10 M H2DCFDA in DMEM-free serum for 40 min and reading the fluorescence 
at 515 nm (Ex 495 nm).  
 
PAGE for enzymatic reactions with DNA glycosylases 
Oligonucleotides 32R and 8OG-substituted analogues ODN-92 and ODN-96 end-
labelled with [γ-32P] ATP (Perkin Elmer) and T4 polynucleotide kinase (Thermo Fisher 
Scientific, USA), were annealed in duplex with complementary 32Y strand in 50 mM Tris-
HCl, pH 7.4, 100 mM NaCl (5 min at 95°C, overnight at room temperature). Radiolabelled 
duplex (2 nM) was incubated at 37 °C with increasing amounts of recombinant hOGG1 or 
NEIL1 (1 and 5 M), in 20 mM Tris-HCl pH 8, 50 mM NaCl, 1 mM EDTA, 0.1mg/ml BSA, 1 
mM Na3VO4, 5 mM NaF and 0.01 % Phosphatase Inhibitor Cocktail. After 15 min the 
reactions were stopped by adding 2 l stop solution (90 % formamide, 50 mM EDTA). The 
samples were then denatured for 5 min at 95 °C and run for 1 h on a denaturing 20 % 
polyacrylamide gel, prepared in TBE and 7 M urea, pre-equilibrated at 55 °C in an 
electrophoretic apparatus (C.B.S Scientific Company, CA, USA). After running the gels 
were fixed in a solution containing 10 % acetic acid and 10 % methanol, dried and 
exposed to film for autoradiography (Aurogene, IT). 
Statistical analysis 
Data are reported as the mean ± standard error (SE). Statistical analysis was carried out 
using Sigma Plot software. Group differences were analyzed by Student’s t-test or one-
way analysis of variance (ANOVA). Groups are considered different when P< 0.05. 
 
Results  
Oxidative stress in pancreatic cancer cells and role of Nrf2. In aerobic organisms, 
ROS, which include anion superoxide (O2-), hydrogen peroxide (H2O2) and hydroxyl radical 
(·OH), are continuously produced as byproducts of metabolism. Their main sources are: (i) 
mitochondria, through electron leakage from the ubiquinone/ubiquinol shuttle; (ii) 
peroxisomes, during -oxidation of long-chain fatty acids; (iii) cytochrome P-450 enzymes; 
82 
 
(iv) nicotinamide adenine dinucleotide phosphate (NADPH) oxidises of the NOX family [22, 
23] [Suppl. Inf. S1]. One of the most injurious consequences of oxidative stress is its 
impact on DNA. Due to its low redox potential, guanine tends to oxidize to 7,8-dihydro-8-
oxoguanine (8OG) [24] [Suppl. Inf. S2]. As there is a direct correlation between 8OG and 
ROS, the level of 8OG in the genome is a useful cell biomarker for oxidative stress [25]. To 
evaluate the intrinsic level of oxidative stress in cancer (Panc-1, MIA PaCa-2 and BxPC-3) 
and non-cancer (embryonic human kidney 293) cells, we measured 8OG by chromatin 
immunoprecipitation, using an antibody specific for 8OG. Fig. 1A shows that the level of 
8OG in cancer cells is significantly higher than in non-cancer 293 cells. This is due to the 
fact that cancer cells display a higher metabolic rate and thus a higher ROS production 
than normal cells [10, 13, 14]. A recent study showed that in cancer cells the metabolism is 
reprogrammed by the KRAS oncogene [8, 11]. We measured the basal level of KRAS in 
cancer and non-cancer cells and found that it is expressed more in the former than the 
latter [Suppl. Inf. S3]. Besides regulating the metabolism, KRAS seems to control the 
redox homeostasis too [15]. A master regulator of the redox homeostasis is Nrf2, a 
transcription factor that activates the expression of antioxidant response element (ARE)-
bearing genes [26, 27]. In response to enhanced ROS, cancer cells strengthen their 
antioxidant capacity by raising the basal expression of Nrf2 to bring down oxidative stress 
to levels favouring cell growth [15-17]. To test the response of Nrf2 to an increase of 
oxidative stress, we used Panc-1 cells, which harbour KRAS G12D (G12D, GlyAsp), the 
most frequent mutation occurring in PDAC. We treated the cells with porphyrin TMPyP4 
(hereafter called P4), a cationic photosensitizer that generates ROS upon light irradiation 
[28], and measured Nrf2 by Western blot [Fig. 1B]. It can be seen that when the cells are 
treated with P4 (20, 40 and 80 nM) and light (7.2 J/cm2), in order to produce ROS through 
a photodynamic effect (we call the treatment P4/), Nrf2 increased in a dose-response 
manner up to ~ 2-fold compared to untreated cells. A similar result was obtained by 
quantitative RT-PCR (qRT-PCR), showing that the mRNA of Nrf2 increased ~ 3-fold 
compared to untreated cells, following a P4/ treatment (40 nM P4, 7.2 J/cm2) [Fig. 1C]. A 
strong inhibitor of Nrf2 is luteolin, a tetrahydroxyflavone that reduces Nrf2 expression [29, 
30] [Suppl. Inf. S4]. When Panc-1 cells are treated with P4/40 and 80 nM P4, 7.2 
J/cm2) ROS increase in a dose-response manner. However, when the cells are treated 
with P4/ and luteolin (20 M Lu) (treatment called P4/Lu), a higher increase of ROS is 
observed, as the detoxification program mediated by Nrf2 is inhibited by luteolin (Fig. 1D). 
This seems to be a general response of cancer cells, as it is observed not only in 
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pancreatic Panc-1 but also in bladder T24 cancer cells [Fig. 1E]. These data suggest that 
there is a close correlation between Nrf2 and intracellular ROS.  
The ROS-KRAS-Nrf2 axis in the control of the ROS homeostasis. As KRAS 
reprograms the metabolism in pancreatic cancer cells [8], we asked if there is a link 
between KRAS, Nrf2 and ROS. First, we investigated if enhanced ROS stimulates the 
expression of KRAS. We gradually increased ROS in Panc-1 cells with three distinct 
treatments: luteolin; P4/ and P4/ u (Fig. 2A). By qRT-PCR we measured KRAS 
mRNA and observed an increase of transcript in a dose response manner: P4/  
> Lu, i.e proportional to the amount of ROS generated. The increase of KRAS expression 
induced by ROS was confirmed by Western blot, using a monoclonal antibody specific for 
protein KRAS [Fig. 2B]. The results showed that ROS caused a ~ 2-fold increase of 
protein in Panc-1. This cellular response was observed also in T24 bladder cancer cells 
harbouring wild-type KRAS [Fig. 2C]. These findings demonstrate that ROS stimulate the 
expression of KRAS in cancer cells bearing either wild type or mutant KRAS alleles. A 
possible mechanism through which KRAS is upregulated by ROS will be discussed next. 
As Nrf2 is overexpressed in pancreatic cancer cells [16], we interrogated how this 
redox-sensing factor is upregulated. A first hint that KRAS controls the expression of Nrf2 
was reported by De Nicola et al. [15], who found that the ectopic expression of KRAS 
G12D in mouse embryonic fibroblasts promoted a 60 % increase of Nrf2. To test if a 
similar behaviour is observed in pancreatic cancer cells, we transfected Panc-1 cells with a 
vector expressing either wild-type (pWT) or mutant (pG12D or pG12V) KRAS protein. As a 
control we used a vector lacking the KRAS coding sequence (pEmpty). After transfection, 
we measured the levels of proteins KRAS and Nrf2 by Western blot [Fig. 2D]. The ectopic 
expression of KRAS G12D or KRAS G12V caused a ~ 2-fold increase of Nrf2, while the 
control vector did not. In agreement with previous data obtained with embryonic fibroblasts 
[15], our finding supports the notion that in pancreatic cancer cells the expression of Nrf2 
is under the control of KRAS. The upregulation of Nrf2 induced by the ectopic expression 
of KRAS G12D or KRAS G12V is expected to lower the level of intracellular ROS. To 
prove this, we transfected Panc-1 cells with the expression vectors pG12D, pG12V and 
pEmpty and measured ROS with dichlorofluorescein (DCF). Fig. 2E shows that ROS are 
reduced to 45 % of the control (empty vector), which is in nice accord with our hypothesis. 
Together our data support the notion that KRAS governs the redox state in cancer cells 
through the ROS/KRAS/Nrf2 axis (Fig. 2F).  
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Intersection between ROS-KRAS-Nrf2 axis and survival/apoptosis pathways. As the 
ROS-KRAS-Nrf2 axis controls the redox homeostasis, we wondered if it also affects the 
survival and apoptosis pathways. In a previous study we demonstrated that in melanoma 
B78-H1 cells, a moderate increase of ROS generated by pheophorbide/ caused the 
upregulation of NF-kB and prosurvival Snail and the downregulation of proapototic RKIP 
[31, 32]. NF-kB, Snail and RKIP are interconnected in a circuitry modulated by ROS, that 
regulates the signalling for cell survival and apoptosis. Pancreatic cancer cells 
overexpress Snail and Nrf2 [33, 34], therefore we asked if there is a link between Nfr2 and 
the NF-kB/Snail/RKIP circuitry. To address this question we first measured by qRT-PCR 
the levels of Nrf2, Snail and RKIP mRNAs in Panc-1 [Fig. 3A)] cancer cells, untreated or 
treated with two doses of P4/ (40 and 120 nM P4, light at 7.2 J/cm2) generating a 
moderate increase of ROS. The cells responded to the treatment by upregulating Nrf2 
(from 20 to 40 %) and prosurvival Snail (up 6-fold), and simultaneously downregulating 
proapoptotic RKIP (~ 30 %) compared to untreated cells. Snail is a zinc-finger transcription 
factor with a central role in cell survival and metastasis [35, 36]. When this protein is 
ectopically expressed in Panc-1 cells, their invasive property increases dramatically [35]. 
Panc-1 cells, expressing Snail, implanted into nude mice metastasized more efficiently 
than the unmodified cells [33], thus supporting the notion that Snail plays a key role in 
PDAC progression. It has been reported that Snail is transcriptionally regulated by NF-kB 
[37] and capable to induce phenotypic changes in cells. For example, Snail represses the 
epithelial marker E-cadherin and pushes up the mesenchymal marker Vimentin [38]. Snail 
is also a potent repressor of the RAF kinase inhibitor protein (RKIP): a metastasis 
suppressor protein that acts through the inhibition of RAS/MEK/ERK signalling [39, 40]. 
The effect of ROS on the NF-kB/Snail/ RKIP circuitry was also examined by Western blots 
[Fig. 3B]. In agreement with qRT-PCR, after P4/ (80 nM P4, light 7.2 J/cm2) Nrf2 and 
Snail were found upregulated while RKIP downregulated. Also NF-kB was strongly 
upregulated by P4/, in accord with previous work [31]. Collectively, these data show that 
a moderate increase of ROS shifts NF-kB/Snail/ RKIP towards cancer progression. The 
link between KRAS-Nrf2 and the propapototic/prosurvival NF-kB/Snail/ RKIP circuitry was 
observed also in T24 bladder cancer cells [Fig. 4A,B]. 
Next, we investigated how NF-kB/Snail/ RKIP responds to high ROS levels, obtained 
by generating ROS under conditions in which Nrf2 and thus the detoxification capacity of 
the cells were repressed. We compared the response of the cells to low ROS generated 
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by P4/ and high ROS generated by P4/Lu. Fig. 5A-D shows the expression of 
prosurvival Snail and proapoptotic RKIP measured by Western blots. The average result of 
two similar treatments (40 and 80 nM P4, light 7.2 J/cm2 ), performed with and without 10 
M luteolin, show that the cells exposed to ROS while Nrf2 is inhibited (high ROS), have 
prosurvival Snail downregulated and proapoptotic RKIP upregulated. As expected, the NF-
kB/Snail/ RKIP circuitry assumes a configuration favouring apoptosis. It has been 
demonstrated that a decreased level of RKIP in cancer cells is associated with invasion 
and metastasis, while an increase of RKIP promotes anticancer effects [41]. In PDAC cells 
RKIP is normally underexpressed and this closely correlates with patient outcomes [42]. 
The overexpression of RKIP in PDAC cells suppresses proliferation and activates 
apoptosis [41].  
ROS activate KRAS through a mechanism mediated by G4 DNA. To explore how ROS 
upregulate KRAS we focused on the promoter region of the gene which contains between 
-144 and -117 relative to the transcription start site, a G-rich element called 32R. This 
sequence is composed of runs of guanines and folds into a G-quadruplex (G4) stabilized 
by G tetrads, with a TM of 62.1 °C in 100 mM KCl. The CD spectra of 32R at 25 °C is 
indicative of the formation of a G4 with a parallel topology [43-45] (Fig. 6A-C) (Suppl. Inf. 
S5). By streptavidin-biotin pull-down assays and mass spectrometry we found that the G4 
formed by 32R is recognized by several transcription factors (TFs) including MAZ, hnRNP 
A1 and PARP1, which are essential for transcription  [44,46-48]. We also found that the 
guanines in this promoter region, due to their low redox potential, are prone to oxidation to 
8OG [21]. ChIP experiments showed that an intracellular increase of ROS boosts the 
recruitment of the TFs to the 32R promoter region [21] (Fig. 6D). To confirm that the TFs 
and 8OG co-localize on the same 32R-containing region, we firstly performed a double 
chromatin immunoprecipitation experiment (ChIP-reChIP) (Suppl. inf. S6) (Fig. 6E). Panc-
1 cells were treated with hydrogen peroxide and the chromatin was extracted and sheared 
into fragments of about 300 bp. Sheared chromatin was immunoprecipitated with an 
antibody specific for MAZ or hnRNPA1 and the precipitated chromatinized DNA recovered 
and used for a second immunoprecipitation with an antibody specific for 8OG. After the 
second ChIP, the DNA was recovered and analysed by qPCR. The results showed that 
the occupancy of MAZ and hnRNP A1 is higher on the chromatin fragment containing 32R 
than on the control sequence, in keeping with the co-localization of the TFs and 8OG on 
the same promoter sequence. Secondly, we demonstrated that there is co-localization also 
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between 8OG and G4 DNA. Sheared chromatin from hydrogen peroxide-treated cells was 
pulled down with a biotinylated ligand G4-specific (anthrathiophenedione [49]) (Fig. 7A) 
(Suppl. Inf. S7). The precipitated chromatin was recovered and then immunoprecipitated 
with an antibody specific for 8OG. The DNA recovered after the second precipitation was 
analysed by qPCR. The level of 8OG was higher in the 32R region compared to the 
control regions. Together, the two immunoprecipitation experiments show that 8OG and 
TFs co-localize on the same promoter region containing 32R. 
Finally, to provide direct evidence that the TFs bind to oxidized G4, we performed 
pulldown/WB experiments with wild-type 32R or oxidized analogues (ODN-92 with one 
8OG and ODN-96 with two 8OG) as a bait (Fig. 7B) The presence of 8OG in 32R does not 
inhibit the folding into a G4 but it can inhibit the topology depending on its position within 
the sequence. This is described in detail in Ref. [21] (Suppl. Inf. S8). The results show that 
the G4 structures, either the wild type or those oxidized, form a multiprotein complex with 
the above TFs. How G4 and ROS favour transcription of KRAS will be addressed in  
Discussion. 
Photodynamic treatment in the presence of luteolin: clonogenic assay. Finally, the 
results of this study may be useful to design efficient photodynamic therapy (PDT) for 
cancer [50]. PDT is a slightly invasive therapeutic approach involving the administration of 
a photosensitizer and its activation with light in order to generate ROS killing cancer cells 
[51]. The treatment can be strengthened if Nrf2, the gene that activates the cellular 
response to oxidative stress, is inhibited. In fact, the data of Fig. 5 show that when PDT 
(the P4/treatment) combined with an inhibitor of Nrf2 such as luteolin (adjuvant), the 
cells become more sensitive to PDT by up-regulating proapoptotic RKIP and down-
regulating prosurvival Snail: i.e. creating intracellular conditions favouring apoptosis 
modulated by ROS. To assess the effect of P4 and luteolin on cell growth, we carried out a 
colony formation assay with pancreatic Panc-1 and BXPC-3 cancer cells. The cells were 
seeded in a medium containing either P4, luteolin or a mixture between P4 and luteolin 
and irradiated with light at a fluence of 7.2 J/cm2. After 8 days of growth the colonies were 
counted and the results plotted in a histogram. Fig. 8 shows that the number of colonies in 
the plates treated with only 20 M luteolin (Lu blocks Nrf2 and increases the basal level of 
ROS) or P4/ (40 nM) is 20-25 % lower than the number of colonies in untreated cells. In 
contrast, the combined treatment, P4/+ luteolin, reduce the number of colonies to ~ 50 % 
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of the control. These results strongly support our hypothesis that when Nfr2 is inhibited, 
the cells are more sensitive to PDT as the Nrf2-directed antioxidant program is inhibited.  
Discussion  
As any actively dividing cells, cancer cells have a high demand of biomass to fuel their 
rapid proliferation. To satisfy this requirement, cancer cells reprogram the metabolism and 
KRAS induces the metabolic changes occurring in PDAC (8). A comprehensive review 
summarizing the metabolic requirements of cancer cells is reported in ref [10]. Cancer 
cells produce higher amounts of ROS than healthy cells (13). ROS can oxidize lipids, 
proteins and nucleic acids and their accumulation may severely damage the cells. To 
protect macromolecules from oxidative damage, cancer cells activate a complex network 
of enzymatic and non-enzymatic antioxidants [52]. The antioxidant response is regulated 
by Nrf2, which is activated by ROS. As KRAS reprograms the metabolism in PDAC, we 
asked if there is a correlation between KRAS and Nrf2. In agreement with the work of De 
Nicola et al. [15], we found that the ectopic expression of KRAS G12D or G12V in PDAC 
cells pushes up Nrf2 by nearly 2 folds, thus confirming a direct correlation between KRAS 
and Nrf2. Our data show that ROS, KRAS and Nrf2 form a molecular axis preventing ROS 
accumulation to toxic levels that could inhibit cell cycle progression and proliferation. We 
also found that the ROS/KRAS/Nrf2 axis intersects with survival and apoptosis pathways. 
By controlling the redzsox homeostasis, the ROS/KRAS/Nrf2 axis regulates via NF-kB the 
expression of prosurvival Snail and proapoptotic RKIP (Fig. 9A,B). Low ROS, occurring 
when Nrf2 is active, results in upregulation of NF-kB and prosurvival Snail and 
downregulation of proapoptotic RKIP: survival/proliferation overcomes apoptosis. In 
contrast, high ROS, occurring when Nrf2 is inhibited, results in downregulation of NF-kB 
and prosurvival Snail and upregulation of proapoptotic RKIP: in this case apoptosis 
overcomes proliferation.  This behaviour provides an explanation, in terms of molecular 
pathways, why a combined treatment, PDT and Nrf2 inhibitior, is more effective than only 
PDT.  
Next, an important issue regarding the ROS/KRAS/Nrf2 axis is how KRAS is 
upregulated by ROS. To this end, we focused on the KRAS promoter containing upstream 
of TSS a regulatory G-rich element called 32R, which forms a G4 structure recognized by 
transcription factors MAZ, PARP-1 and hnRNP A1 [43, 44-48, 53]. Due to its low redox 
potential, guanine in the G4 motif is inclined to oxidation to 8OG. Recent data suggest that 
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oxidized guanine is likely to be an epigenetic modification stimulating gene expression [54, 
55]. ChIP experiments showed that when intracellular ROS is increased with hydrogen 
peroxide, MAZ, hnRNP A1 and PARP1 are recruited to the promoter 32R region more 
than in other G-rich regions [21]. PARP1 is likely to play a critical role in the recruitment. 
This 110 kDa protein has a high affinity for G4 DNA (Kd ~ 10-9 M-1) and the tendency to 
undergo auto poly(ADP-ribosyl)ation following the binding to G4 [56]. So, the protein, 
displaying on its surface ADP-ribosyl units, becomes anionic and favours the recruitment 
of MAZ and hnRNP A1, as these TFs having a pI > 7.4 (8.11 and 9.45, respectively) are 
cationic under physiological conditions. This is consistent with the finding that the G4 
structure, with or without 8OG, pulls down from a total Panc-1 extract the three TFs (Fig. 
7B).  
In conclusion, our data suggest that an increase of cellular ROS favours the oxidation 
of guanine at the G-rich promoter region of KRAS located upstream of TSS. This 
increases the recruitment of the TFs to the promoter and the subsequent activation of 
transcription. Our data support the notion that 8OG is not a detrimental by-product of 
oxidative processes, but an epigenetic modification with gene regulatory functions. A 
recent study by Fleming et al [57] reported that the presence of 8OG in the VEGF G4 motif 
increases indeed transcription.  
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Table 1: DNA primers and oligonucleotides used in this study 
  
KRAS forward 5’-CGAATATGATCCAACAATAGAG  
KRAS reverse 5’-ATGTACTGGTCCCTCATT  
2-microgobuline forward 5’-CCCCACTGAAAAAGATGA  
2-microglobuline reverse 5’-CCATGATGCTGCTTACAT  
HPRT forward 5’-CTTGATTGTGGAAGATATAATTG  
HPRT reverse 5’-TATATCCAACACTTCGTGG  
Nrf2 forward 5’ TCAGCGACGGAAAGAGTATGA  
Nrf2 reverse 5’-CCACTGGTTTCTGACTGGATGT  
Snail forward 5’-GAGGCGGTGGCAGACTAG  
Snail reverse 5’-GACACATCGGTCAGACCA  
RKIP forward 5’-AGACCCACCAGCATTTCGTG  
RKIP reverse 5’-GCTGATGTCATTGCCCTTCA  
G4 near  b-AGGGCGGTGTGGGAAGAGGGAAGAGGGGGAGG 
ODN-92* b-AGGGCGGTGTGGGAAGAGGGAAGAGGGGGAGG 
ODN-96* b-AGGGCGGTGTGGGAAGAGGGAAGAGGGGGAGG 
















Figure 1. (A) Level of 8-oxoguanine (8OG), determined by ChIP-qPCR assays, in PDAC 
cells (Panc-1, MIA PaCa-2, BxPC-3) and non-cancer 293 cells. Error bars (± SE) obtained 
from 3 experiments. Student’s t-test, (*)= P< 0.05; (B) Level of Nrf2 in Panc-1 cells 48 h 
after treatment with P4/ (P4= 0, 20, 40 and 80 nM, light 7.2 J/cm2); (C) Levels of Nrf2 
mRNA respect to HPRT and 2 microglobulin mRNA in untreated cells (NT) and in cells 
treated with 40 nM P4 and light 7.2 J/cm2 (P4/); (D, E) Levels of ROS in Panc-1 (D) and 
T24 (E) cells untreated (NT) or treated with P4 (P4, 40 and 80 nM, light 7.2 J/cm2) or 20 
M Lu or P4//Lu (P4, 40 and 80 nM, 20 M Lu, 7.2 J/cm2). Analysis performed 24 h after 







Figure 2. (A) Levels of KRAS mRNA in Panc-1 cells untreated (NT) or treated for 1 h with 
20 M Lu, P4/ (40 nM P4, light 7.2 J/cm2), P4//Lu (40 nM P4, 20 M Lu, light 7.2 J/cm2). 
Student’s t-test, (*)= P< 0.05, error bars (± SE) obtained from 3 experiments; (B and C) 
Western blots showing the level of KRAS in Panc1 (B) and T24 (C) cancer cells ~ 2 days 
after treatment. Error bars (± SE) obtained from 2 experiments, Student’s t-test, (*)= P< 
0.05; (D) Western blot showing the expression of KRAS in Panc-1 cells untreated (NT) or 
treated with vectors encoding WT, G12D, G12V KRAS protein and a control vector, 
pEmpty (a vector without KRAS coding sequence). The histograms show the relative 
levels of KRAS and Nrf2. Error bars (± SE) obtained from 2 experiments; (E) Fluorescence 
of 2',7'-dichlorofluorescein (DCF) in Panc-1 cells treated with pEmpty and vectors pG12D 
and pG12V encoding for KRAS protein. Student’s t-test, (*)= P< 0.05, error bars (± SE) 
obtained from 3 experiments; (F) The ROS-KRAS-Nfr2 axis which regulates the ROS 





Figure 3. (A) Quantitative RT-PCR determination of Nrf2, Snail and RKIP mRNAs in Panc-
1 cells treated for 8 h with P4/(40 and 120 nM P4, light 7.2 J/cm2). Student’s t-test, (*)= 
P< 0.05, error bars (± SE) obtained from 3 experiments; (B) Western blot determination of 
Nrf2, NF-kB, Snail, RKIP and -actin in Panc-1 cells treated with P4/ (80 nM P4, light 7.2 
J/cm2). Analysis was carried out 48 h after treatment. The histograms report the levels of 
proteins Nrf2, NF-kB, Snail and RKIP in untreated (NT) and P4/ treated cells compared to 




Figure 4. (A) Quantitative RT-PCR determination of Nrf2, Snail RKIP mRNAs in T24 
bladder cancer cells treated for 8 h with PS/(40 and 120 nM P4, light 7.2 J/cm2). 
Student’s t-test, (*)= P< 0.05, error bars (± SE) obtained from 3 mRNA experiments; (B) 
Western blot determination of Nrf2, NF-kB, Snail, RKIP and -actin in T24 cells treated 
with P4/ (80 nM P4, light 7.2 J/cm2). ). Analysis was carried out 48 h after treatment; (C) 
Histograms reporting the levels of proteins Nrf2, NF-kB, Snail and RKIP in untreated (NT) 







Figure 5. (A, B) Western blots showing the levels of Snail, RKIP and -actin in Panc-1 (A) 
and T24 (B) cancer cells treated with three doses of P4/(20, 40 and 80 nM P4, light 7.2 
J/cm2) or P4/Lu (20, 40 or 80 nM P4, light 7.2 J/cm2, 20 M Lu). ). The analysis was 
carried out 48 h after days after treatment; (C, D) The histograms report the levels of RKIP 
and Snail compared to -actin in cells treated P4/and P4/Lu (80 nM P4, 20 M Lu, light 







Figure 6. (A) Sequence of the KRAS G-rich motif located upstream of TSS, embedding 
the 32R sequence (signed with a solid line), forming a G4 with the G-runs shown in red. 
The sequences of oligonucleotides 32R, ODN-92 and ODN-96 with 8OG modifications 
(indicated with underlined G in blue) are shown; (B) Structure of KRAS G4 characterized 
by two 1-nt and one 11-nt loops and a T-bulge in one strand (Suppl. Inf. S5); (C) CD 
spectra  for 32R in 50 mM cacodylate pH 7.4, 100 mM KCl at 25 and 95 °C; (D) ChIP and 
EMSA experiments showed that hnRNP A1 (abbreviated A1), MAZ and PARP-1 are 
recruited to the G4 motif; (E) Double chromatin immunoprecipitation (ChIP-reChIP) and 
qPCR showing that MAZ and hnRNPA1 co-localize on the G4 region harbouring 8OG. 
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Figure 7. (A) Pull-down chromatin with a G4-ligand and immunoprecipitation with 8OG Ab 
show that 8OG and G4 DNA co-localize on the G4 region located in the KRAS promoter. 
Student’s t-test, (*)= P< 0.05, error bars (± SE) obtained from one experiment in triplicate; 
(B) Pulldown/Western blot assay carried out with a Panc-1 extract and 32R conjugated to 
biotin. Sequence 32R was also designed with one (ODN-92) or two (ODN-96) 8OGs. The 
pulldown proteins were analysed by Western blot with specific Ab for MAZ, hnRNP A1 and 
PARP1. G4 32R and the oxidized analogues form a multiprotein complex with the 
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Figure 8. Clonogenic assays. (A) Pancreatic Panc-1 and BXPC3 cancer cells were treated 
with P4/(40 nM P4, light 7.2 J/cm2), luteolin (20 M) and P4/Lu( 40 nM P4, light 7.2 
J/cm2, 20 M Lu. The histogram shows the % colonies in untreated and treated cells. 
Error bars have been obtained from three independent experiments. A Student’s t-test was 
performed, (*)= P < 0.05. 
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Figure 9. (A and B) The ROS-KRAS-Nrf2 axis and its intersection with NFkB-Snail-RKIP. 
When Nrf2 is upregulated by KRAS, the ROS level is low and NF-kB and Snail are 
upregulated while RKIP is downregulated. This expression profile favour cell growth. In 
contrast, when Nrf2 is inhibited by luteolin, the ROS level is increased. This results in 
downregulation of NF-kB and Snail and upregulation of RKIP. This expression profile 
favours apoptosis; (C) Proposed mechanism for KRAS transcription activation by ROS. 
The promoter G-rich G4 motif undergoes oxidation and folding. Oxidized G4 favours the 
recruitment of TFs (PARP1, hnRNP A1 and MAZ). PARP1 binds to G4 with a high affinity 
and becomes anionic through auto poly(ADP-ribosyl)ation. Anionic PARP1 stimulates the 
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S1: Cellular reactions generating ROS; 
S2: Oxidation of guanine to 7,8-dihydro-8-oxoguanine (8OG); 
S3: KRAS expression in PDAC cells; 
S4: Nrf2 is inhibited by luteolin; 
S5: G-quadruplex DNA in the KRAS promoter; 
S6: ChiP-reChIP experiment;  
S7: Pull-down chromatin with G4 ligand and ChIP with Ab specific for 8OG; 



















Suppl. Inf. S1: In aerobic organisms, ROS – including anion superoxide (O2-), hydrogen 
peroxide (H2O2) and hydroxyl radical (·OH) – are continuously produced by metabolic 
reactions. The main sources of ROS are: (i) mitochondria, through electron leakage from 
the ubiquinone/ubiquinol shuttle; (ii) peroxisomes, during -oxidation of long-chain fatty 
acids; (iii) cytochrome P-450 enzymes; (iv) nicotinamide adenine dinucleotide phosphate 





















Suppl. Inf. S2: Due to its low redox potential, guanine is prone to oxidation to 7,8-dihydro-
8-oxoguanine (8OG). The presence of 8OG in the G4 motif and in control G-rich 
sequences Ctr-1 and Ctr-2, unable to form a G-quadruplex, was analysed by ChiP assays 






Suppl. Inf. S3: Western blot showing the basal level of KRAS protein in cancer 













Suppl. Inf. S4: Luteolin is a tetrahydroxyflavone that reduces Nrf2 expression. When 
Panc-1 cells are treated with luteolin, the expression of Nrf2 is significantly reduced, as 
shows by the western blot reported below. In this experiment the cells were treated with 20 
M luteolin (lane 2) and Nrf2 is significantly reduced. Luteolin downregulates Nrf2 also 
when it is stimulated by a P4/treatment that pro 
duces ROS: lane 3, 20 nM P4 and light (8 J/cm2); lane 4, 20 nM P4, light 8 J/cm2, 20 M 

























Suppl. Inf. S5: The G4 structure formed by 32R. DMS footprinting and CD support a G- 
quadruplex with a parallel topology and a strand containing a T-bulge. Typical melting 
curves of 32R in 50 mM cacodylate pH 7.4 and 100 mM KCl. The heating and cooling 
curves show that the melting and annealing are reversible, with TM is 61.6 °C.  
 
32R          5’-AGGGCGGTGTGGGAAGAGGGAAGAGGGGGAGG 










Suppl. Inf. S6. ChiP-reChIP is a strategy useful to determine in vivo the co-localization of 
proteins in a chromatinized DNA fragment on the basis of two independent 
immunoprecipitations with specific antibodies. In our experiment we first obtained the 
chromatin from Panc-1 cells treated with hydrogen peroxide. Then the chromatin was 
fragmented into pieces of about 300 bp by sonication. The sonicated chromatin was 
immunoprecipitated with an antibody specific for MAZ or hnRNPA1. The precipitated 
chromatinized DNA was recovered and used for a second immunoprecipitation with an 
antibody specific for 8-oxoG. After the second ChIP, the DNA was recovered and analysed 
by qPCR, in order to see if an enhanced level of 8-oxoG was present in the G4 motif 
region compared to control region. The ChIP-reChIP showed that MAZ and hnRNP A1 are 
localized in the same chromatin fragment harbouring a higher level of 8-oxoG compared to 












Suppl. Inf. S7. To demonstrate that there is co-localization between 8OG and the G4 
structure we carried out a pull-
down/ChIP experiment.  
 (A) Pull-Down Panc-1 chromatin 
with biotin-streptavidin technology. 
Panc-1 cells (8 x 105) were seeded in 
a 6-well plate and after 24 h some 
wells treated with 1mM H2O2 for 30 
min in serum-free DMEM. The 
chromatin was collect by using the 
ChIP-IT® Express Shearing Kit (Active 
Motif, USA), following the 
manufacturer instructions. 
Then 
incubated for 6 
biotinylated ligand (anthrafuranedione 2a, J Med Chem 2017, 60, 9448-61) in water. A 
Paramagnetic Particles (Promega, Italy), 
previously washed in 50 mM Tris-HCl, pH 7.4, 50 mM KCl and incubated with Salmon 
Sperm DNA in a thermomixer for 30 min at 25 °C and 600 rpm, was added and let to 
incubate for 30 min at 25 °C. The beads were captured with a magnet and the DNA was 
eluted by an incubation for 30 min at 25 °C with 0,8 M NaCl. 
Chromatin Immunoprecipitation (ChIP) 
The concentration of DNA eluted from the Pull-down assay was determined on a 
 of antibody specific for 8-oxoG (Bioss Antibodies, USA). In 
addition to the antibody the mixtures were added with Protein G Magnetic Beads, ChIP 
Buffer-1 and PIC, as indicated in the Active Motif Kit protocol. After incubation, the 
mixtures were span and the chromatin bound to the antibody collected with a magnetic 
bar. The collected beads were washed once with ChIP Buffer-1 and twice with ChIP 
Buffer-2. The beads were then re-suspended in Elution Buffer AM2 and let to incubate on 
shaking for 15 min at room temperature. The Reverse Crosslinking Buffer was added to 
the mixture and the supernatant with the chromatin was collected. The DNA fragments 
were amplified by qPCR. 
111 
 
In J Med Chem 2017, 60, 9448-61, we have demonstrated that the biotinylated G4 ligand 
2a efficiently pulls down a G4 DNA in a streptavidin-biotin assay. 
 
Suppl. Inf.S8  
CD spectra at 20 and 90 °C of 32R and oxidized analogues ODN-92 and ODN-96 in 50 
mM Tris-HCl, pH 7.4, 100 mM KCl. Melting curves of 32R, ODN-92 and ODN-96 in 50 mM 
cacodylate  pH 7.4, 100 mM KCl. 
When 8OG is located in the major 11-nt loop, the topology of the G-quadruplex does not 
change, neither the TM (see 32R and ODN-96). In contrast, when 8OG is in a G-run, the 



























 5’-AGGGCGGTGTGGGAAGAGGGAAGAGGGGGAGG       32R 
 5’-AGGGCGGTGTGGGAAGAGGGAAGAGGGGGAGG       ODN-92 
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Pancreatic ductal adenocarcinoma (PDAC) is one of the 
major causes of death in western countries [1,2]. As current 
treatments are not effective, there is an urgent need to develop 
new therapies [3]. The main genetic lesion present in > 90% of 
PDAC patients is a mutation in the KRAS proto-oncogene, 
mainly in exon 1 at codon 12, G12D (Gly→Asp) or G12C 
(Gly→Cys) [4]. It has been demonstrated that mutant KRAS 
is the major driver of PDAC and that the expression of KRAS 
G12D  in transgenic mice pancreas causes intraepithelial  neo- 
plastic lesions progressing into full malignancy [4–6]. The 
expression of KRAS G12D is necessary for tumour maintenance 
and its extinction leads to a rapid tumor regression [6]. 
Recent work has demonstrated that pancreatic cancer cells 
are ‘addicted’ to mutant KRAS, as this oncogene reprograms 
the metabolism of tumor cells, in particular the glucose and 
glutamine pathways, in order to fuel a higher proliferation 
rate [7,8]. 
It is known that several properties of cancer cells, including 
proliferation, migration, invasion and gene expression, are 
regulated by small noncoding microRNAs [9–14]. These 
molecules are synthesized as long RNA strands folding into 
hairpin-loop structures processed by Drosha and Dicer into 
mature duplexes ranging from 17 to 26 nt in length [9–14]. 
The guide strand of the mature RNA duplexes forms a com- 
plex with argonaute proteins that bind to a 3ʹ-untraslated 
region (3ʹ-UTR) mRNA target. This mediates two modes of 
gene silencing: translation repression and/or RNA decay 
[12–15]. Synthetic double-stranded (ds) miRNAs have given 
encouraging results as antigene molecules [16] and recent 
studies have demonstrated that single-stranded (ss) RNAs, 
mimicking the guide strand of miRNAs, can also mediate an 
Ago-dependent inhibition of the target gene [17–21]. These 
findings provided new perspectives on the use of synthetic 
miRNAs as therapeutic agents. 
In an attempt to inhibit KRAS in pancreatic cancer cells, 
we started from the observation that certain small noncoding 
RNAs are aberrantly expressed in cancer tissues [22]. In 
cancer, miRNAs inhibiting the expression of tumor suppres- 
sor genes are often upregulated, and this favors the develop- 
ment of the tumor. Instead, miRNAs behaving as tumor 
suppressors are downregulated and inhibit cancer growth 
[22–27]. Two miRNA-based therapeutic approaches have 
been developed: miRNA antagonists and miRNA mimics. 
MiRNA antagonists are single-stranded oligonucleotides that 
bind to oncogenic miRNAs and ablate their function. MiRNA 
mimics instead are used to restore a miRNA that is down- 
regulated in the tumor, normally behaving as a tumor sup- 
pressor (replacement strategy) [23]. 
In our study we focused on a miRNA aberrantly down- 
regulated in PDAC, miR-216b, in order to design therapeutic 
agents suppressing KRAS in these tumor cells [28]. We 
designed single-stranded (ss) miR-216b mimics with unlocked 
nucleic-acid modifications, with or without a 5ʹ phosphate, 
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ABSTRACT 
Datasets reporting microRNA expression profiles in normal and cancer cells show that miR-216b is 
aberrantly downregulated in pancreatic ductal adenocarcinoma (PDAC). We found that KRAS, whose 
mutant G12D allele drives the pathogenesis of PDAC, is a target of miR-216b. To suppress oncogenic KRAS 
in PDAC cells, we designed single-stranded (ss) miR-216b mimics with unlocked nucleic acid (UNA) 
modifications to enhance their nuclease resistance. We prepared variants of ss-miR-216b mimics with 
and without a 5ʹ phosphate group. Both variants strongly suppressed oncogenic KRAS in PDAC cells and 
inhibited colony formation in pancreatic cancer cells. We observed that the designed ss-miR-216b mimics 
engaged AGO2 to promote the silencing of KRAS. We also tested a new  delivery strategy  based on the 
use of palmityl-oleyl-phosphatidylcholine (POPC) liposomes functionalized with ss-miR- 216b conjugated 
with two palmityl chains and a lipid-modified cell penetrating peptide (TAT). These versatile nanoparticles 
suppressed oncogenic KRAS in PDAC cells. 




and found that they strongly suppress oncogenic KRAS in 
PDAC cells. We also tested the activity of miR-216b conju- 
gated to two palmityl chains and fixed on the surface of 
palmityl-oleyl-phosphatidylcholine (POPC) liposomes, func- 
tionalized with the trans-activator of transcription of the 
human immune-deficiency virus (TAT) cell penetrating pep- 
tide [29–32]. The results of our study may have relevance in 
cancer therapy, for designing single-stranded UNA-modified 
miRNA mimics against therapeutically important genes. 
 
Results and discussion 
We consulted miRNA expression profiles relative to PDAC 
and adjacent non-tumor tissues, deposited in the Array 
Express Archive of Functional Genomics. The three datasets 
analyzed, whose accession number are E-MTAB-753, 
GSE43796 and GSE41372 [28], showed that several miRNAs 
are differently expressed when the tumor PDAC tissue was 
compared with adjacent non-tumor tissue. Among the abnor- 
mally downregulated miRNAs, miR-216b showed an expres- 
sion fold change of 27.95 (GSE43796) (Figure 1). Similar data 
were observed with E-MTAB-753 and GSE41372 (Fig. S1). In 
keeping with these data, Liu et al [33] have recently reported 
that the level of miR-216b in PDAC cells (Panc-1, BxPC3 and 
SW 1990) is 3- to 4-fold lower than in non-cancer cells. The 
targets of miR-216b in PDAC cells include TPT1, a gene 
encoding for the translationally-controlled tumor protein 
[34], and ROCK1, the ρ-associated coiled-coil containing 
protein kinase 1 [33]. In addition, miR-216b targets the 
KRAS oncogene in nasopharyngeal tumor cells [35]. MiR- 
216b plays a critical role in PDAC, as in a transgenic mouse 
model this miRNA is downregulated in all steps of tumori- 
genesis, suggesting that it behaves as a tumor suppressor [36]. 
Considering that PDAC cells are addicted to KRAS, we asked 
if KRAS is a target of miR-216b even in this lethal cancer and 
if miR-216b mimics, properly modified, may be a valuable 
therapeutic tool to suppress mutant KRAS in PDAC cells. 
 
Design of single-stranded miRNA mimics specific for 
oncogenic KRAS 
Synthetic miRNA mimics are normally double-stranded RNA 
molecules imitating mature microRNA duplexes [16]. 
Synthetic double-stranded miRNA mimics are incorporated 
into the miRNA-induced silencing complex (miRISC) that 
directs miRNA to its mRNA target in a sequence-specific 
manner for translation inhibition or mRNA degradation. 
Interestingly, previous studies have showed that both double- 
and ss-siRNAs act through the RNAi pathway and silence 
gene expression [20,21]. This led to the hypothesis that ss- 
miRNAs might also suppress gene expression. Indeed, ss- 
miRNAs are loaded into miRISC and inhibit gene expression 
[18]. Against this background, we designed synthetic ss- 
miRNA mimics to attempt KRAS suppression in pancreatic 
cancer cells. One might wonder why to use ss-miRNAs, con- 
sidering that ds-miRNAs are potent tools for gene silencing. 
Two reasons have been put forward [18]: (i) ds-miRNAs, 
being more complex molecules than ss-miRNAs, are expected 
to be transported into the cells less efficiently than the single- 
stranded analogues [37]; (ii) ds-miRNAs are composed of the 
guide and passenger strands, and the latter may be a source of 
undesired off-target effects [38]. Figure 2(a) shows the pri- 
mary sequence of the designed miR-216b mimics and their 
target in the 3ʹ-UTR of KRAS mRNA. At the 5ʹ-end the miR- 
216b sequence, UCUCUAAA-5ʹ, is perfectly complementary 
to mRNA and represents the ‘seed region’. Some complemen- 
tarity with the target is also present at the 3ʹ-end of miR-216b, 
where 5ʹ-UAAAC is base-paired with mRNA. This should 
improve the interactions between miRNA and the target 
gene [39,40]. To increase their nuclease stability, we designed 
miR-216b mimics with one or two unlocked nucleic acid 
(UNA) modifications [41,42]. The key feature of UNA is the 
loss of C2ʹ-C3ʹ bond of the ribose, a modification that 
increases the flexibility of the RNA strand [43] (Figure 2(b)). 
A single UNA modification in the middle of a RNA/RNA 
duplex can lower the Tm by 5–10 °C, but when the UNA 
modification is placed near the duplex end, it causes a rather 
modest drop in Tm of 1–3 °C [43,44]. 
We designed two UNA-modified miR-216b mimics: 
compound U1 with one modified adenine (uA) at the 3ʹ- 
end; compound U2 with two uAs, at the 3ʹ-end and in the 
middle of the oligoribonucleotide, but outside the seed 
sequence (Figure 2(a)). The uA at the 3ʹ-end is also located 
in a portion of miR-216b that does not pair with the 
mRNA target. Therefore, these modifications should not 
affect the hybridization of the UNA-modified mimics to 
the RNA target. Previous studies have reported that: (i) 
ss-miRNAs with 2ʹ-methyl, 2ʹ-fluoro, 2ʹ-O-methoxyethyl 
and with a phosphorothioate backbone are fairly active 
[17,45]; (ii) the binding of Argonaute 2 (AGO2) to mod- 
ified siRNAs (including UNA-modified siRNAs) is not 
affected by chemical modifications [18,21]. Another impor- 
tant element in designing synthetic ss-miRNAs is the pre- 
sence of a phosphate at the 5ʹ-end. Lima et al. found that a 
5ʹ phosphate is a critical determinant for ss-siRNAs 
[17,18,21]. Yet, ss-siRNAs function through the RNAi path- 
way and require protein AGO2 [21]. Recently, Chorn et al. 
have compared the activity of ss-2ʹF-miRNAs against ss- 
2ʹOH-miRNAs [17]. They observed that the former had a 
higher capacity to suppress CD164 in HCT-116 cells than 
the latter. Moreover, with both types of miRNA the phos- 
phorylation at the 5ʹ end was irrelevant. In contrast, when 
the ss-miRNAs contained both 2ʹ-F and 2ʹ-OH riboses, the 
5ʹ phosphorylated analogues showed higher activity [17]. 
This suggests that the 5ʹ phosphorylation has a complex 
effect on miRNA activity. We thus designed UNA-modified 
ss-miRNAs with and without a 5ʹ phosphate group 
(Figure 2(a)). To investigate the gain in stability obtained 
with the UNA insertions, we treated the wild-type and 
UNA-modified miRNA mimics with cellular nucleases 
from a total Panc-1 extract. Figure 3(a) shows the integrity 
of the designed ss-miRNA mimics with a 5ʹ phosphate after 
incubation with a total Panc-1 extract for 1, 2 and 4 h, at 
37°C. After 4 h, only ~ 10% of miR-216b-P was still intact. 
This percentage increased to ~ 20 and ~ 65%, respectively, 
when one or two UNA modifications were introduced in 
the oligonucleotide. Figure 3(b) shows that the non-phos- 
phorylated analogues are slightly more resistant: after 4 h, 











Figure 2. (a) Sequence of the KRAS 3ʹ-UTR recognized by miR-216b. We designed single-stranded UNA-modified miR-216b mimics with and without a 5ʹ phosphate: 
wild-type miR-216b and miR-216b-P; miR-216b with one UNA (U1 and U1-P) or two UNAs (U2 and U2-P). Mutated miRNAs with and without a 5ʹ phosphate (mut-P, mut) 
were used as a control (Supplementary S3); (b) The structures of RNA and UNA, lacking the covalent bond between C2ʹ and C3ʹ of the ribose, are shown. 
 
~ 27% of miR-216b was intact, while the percentage of 
undigested U1 and U2 was ~ 30 and ~ 80%, respectively. 
This proves that UNA insertions at the 3ʹ end and in the 
middle of the sequence boost the resistance of the designed 
mimics to PDAC cellular nucleases. 
Anti KRAS activity of UNA-modified miR-216b mimics 
in PDAC cells 
To suppress oncogenic KRAS in Panc-1 cells we employed a 
replacement strategy. A previous study reported that miR- 







Figure 3. Denaturing (7 M urea) polyacrylamide gel showing the integrity of  wild-type and UNA-modified mimics with (a) and without (b) a 5ʹ  phosphate, after incubation 
for 1, 2 and 4 h with 2 μg Panc-1 cellular extract (E) at 37 °C. The mobility of E is shown in each panel. The arrow shows the undegraded miRNA. The % of undegraded 
miRNA at the various times is shown in the histograms. 
 
216b down-regulates KRAS in nasopharyngeal cancer cells 
[35]. Although miR-216b is aberrantly downregulated in 
PDAC, its therapeutic potential in pancreatic cancer cells 
has not yet been investigated. Our first step was to demon- 
strate that miR-216b is indeed KRAS-specific in PDAC. To 
this end, we hybridized wild-type and UNA-modified miR- 
216b mimics to their complementary sequence and obtained 
22-mer ds-mimics with or without UNA insertions and 5  ́
phosphate in the guide strand (ds-216b, ds-U1, ds-U2 and 
ds-U2-P) (Figure 4). We also obtained a mutated ds-UNA- 
modified miRNA that was used as a control. Panc-1 cells were 
transfected two times with the duplexes and after an incuba- 
tion of 48 h, a Western blot was performed to measure the 
level of KRAS protein (Figure 4). Duplexes ds-U1 and ds-U2 
dramatically reduced the level of KRAS protein to ~ 10% of 
the control (ds-mut). Instead, duplex wild-type (ds-216b) 
produced a weaker protein suppression (~ 35% of the con- 
trol). Duplex ds-U2-P, in which the guide strand bears a 5  ́
phosphate, reduced protein KRAS to ~ 40% of the control. 
This experiment clearly demonstrates that in PDAC cells 
oncogenic KRAS is a target of miR-216b. 
Next, we designed ss-miR-216b mimics, with and without 
a 5ʹ phosphate, and examined their capacity to suppress KRAS 
in Panc-1 cells. As miRNAs inhibit gene expression either by 
translation repression and/or by mRNA decay [12–14], we 
measured by quantitative RT-PCR the level of KRAS tran- 
script in Panc-1 cells treated with the designed ss-miR-216b 
mimics. As in the case of nasopharyngeal cells [35], we did 
not notice any significant reduction of KRAS mRNA at 16, 40 
or 72 h (Fig. S2). Instead, when we measured by Western blot 
the level of the KRAS protein in Panc-1 cells treated the ss- 
miRNAs, we observed a dramatic suppression of the protein 
(Figure 5(a,b)). In keeping with the nuclease stability data, the 
compound showing the highest capacity to suppress protein 
KRAS was U2, the ss-miRNA with two UNA modifications. 
We found that both 5ʹ phosphorylated and non-phosphory- 
lated single-stranded mimics caused a strong suppression of 
translation. UNA modifications turned out to be essential for 
the activity of the ss-miRNA mimics, which brought the 
protein down to < 10% of the control. The phosphorylation 
at the 5ʹ end did not seem to be an essential determinant, at 
least with these miRNAs containing UNA modifications. As a 
next issue, we wondered what the specificity of miR-216b for 
KRAS is, since this oncogene is highly homologous to HRAS 
and NRAS. As illustrated in Figure 5(c,d) none of the designed 
miR-216b mimics had any impact on HRAS and NRAS pro- 
teins. This was expected, as the matching between the seed 
region of the designed mimics and the 3ʹ-UTR sequence in 
these genes is suboptimal. In these cases, the base pairing in 
the miRNA 3ʹ half would have importance for stabilizing the 
interaction [12–14]. The lack of complementarity at the 3ʹ end 
makes the mimics ineffective against HRAS and NRAS. We 
can therefore conclude that, at least in pancreatic cancer cells, 
miR-216b regulates only the KRAS member of the ras family. 
 
 
Single-stranded miR-216b without 5ʹ phosphate is 
AGO-dependent 
Previous studies have demonstrated that AGO2 is a protein 
involved in RNAi gene silencing activated by ss-siRNAs [46] 
or ss-miRNA mimics with a 5ʹ phosphate [18]. On this basis, 







Figure 4. Effect of double-stranded UNA-modified mimics (ds-216b, ds-U1, ds-U2, ds-mut, ds-U2-P, ds-mut-P) on KRAS expression in Panc-1 cells. MiR-216b, U1, U2 
and mut were hybridized to the complementary strand; Western blots were performed 48 h after the second transfection. The histogram shows the % KRAS protein 
determined as T/C x 100 where T = (KRAS/β-actin) in cells treated with ds-216b, ds-U1, ds-U2 and ds-U2-P, C = (KRAS/β-actin) in cells treated with ds-mut. The values 
are the average of three independent Western blot experiments, error bars represent ± SE. A Student’s t-test was performed, the asterisk (*) means P < 0.05 (n = 3). 
 
 
we asked if the activity of UNA-modified ss-miR-216b with- 
out a 5ʹ phosphate is also mediated by AGO2. To address this 
point, we silenced in Panc-1 cells AGO2 by siRNA and one 
day after we treated the cells with the designed ss-miR-216b 
mimics. The levels of proteins AGO2 and KRAS were mea- 
sured by Western blot (Figure 6(a,b)). The results show that 
when protein AGO2 is suppressed, the designed miR-216b 
mimics are unable to knock out KRAS. In contrast, when the 
designed ss-miRNA mimics suppressed KRAS, AGO2 was 
expressed in the cells, as expected (Figure 6(c)). Together 
these results suggest that the silencing mechanism promoted 
by the ss-miR-216b mimics lacking a 5ʹ phosphate is clearly 
AGO2 dependent. The crystal between AGO2 and miR-20a 
showed that besides the 5ʹ phosphate, also the phosphates and 
ribose 2ʹ-OHs of the seed sequence promote contacts with the 
protein [46]. This suggests that in the absence of a 5ʹ phos- 
phate, ss-miR-216b will only have more freedom to adopt a 
position within the binding site of AGO2. 
 
 
Luciferase and clonogenic assays 
To obtain further experimental evidence that the designed 
UNA-modified ss-miR-216b mimics lacking a 5ʹ phosphate 
are active and specific for KRAS, we tested them in a luciferase 
assay (Figure 7(a,b)). We used plasmid pGL4.75-KRAS 
LCS6m, carrying Renilla luciferase driven by the CMV pro- 
moter and the human KRAS 3ʹ UTR (3200 bp) containing 
 
downstream of luciferase the KRAS 3ʹ UTR. Panc-1 cells were 
treated with 10 nM miRNA mimics (complexed with 
Interferin), with 30 ng pGL4.75-KRAS LCS6m and 70 ng 
pGL3-Control Vector carrying Firefly luciferase driven by 
the SV40 promoter. When the cells were transfected only 
once with the miRNA mimics, the reduction of luciferase 
was proportional to the modifications introduced in ss-miR- 
216b. The molecule with the strongest anti-KRAS activity was 
U2, which decreased luciferase to ~ 60% of the control (luci- 
ferase expressed in mut-treated Panc-1 cells). Instead, when 
the cells were transfected twice with the single-stranded miR- 
216b, U1 and U2 (one treatment 24 h after the other) the 
suppression of luciferase was stronger: it was reduced to ~ 60, 
~ 50 and ~ 40% by miR-216b, U1 and U2, respectively. A 
roughly similar result was obtained with the 5ʹ phosphory- 
lated mimics (not shown). The luciferase experiment unam- 
biguously proved that oncogenic KRAS can be downregulated 
by miR-216b. The luciferase assay gave a weaker effect than 
the western blot assay, probably because CMV is a stronger 
promoter than the KRAS promoter, and also because in the 
luciferase assay the target is not in its natural context. 
Since KRAS stimulates the pathway controlling cell growth, 
the suppression of protein KRAS should result in the inhibi- 
tion of proliferation. To assess the effect of miR-216b, U1 and 
U2 on the growth of PDAC cells, we carried out a colony 
formation assay with Panc-1 and MIA PaCa-2 cells, carrying 
the KRAS mutations G12D and G12C, respectively. The 
PDAC cells were seeded in a medium after being diluted in 







Figure 5. (a, b) Effect of single-stranded miRNA mimics with and without a 5ʹ phosphate on the expression of KRAS in Panc-1 cells. The cells, 24 h after seeding, were 
treated with the mimics, using Interferin. A second treatment was carried out 24 h after the first treatment. A Western blot was carried out 48 h after the second treatment; 
(a) Base-pairing between KRAS 3ʹ-UTR mRNA and miR-216b. The Western blot shows the impact on protein KRAS of the designed ss-miR-216b mimics with a 5ʹ 
phosphate. Histograms show the % KRAS protein in miRNA-treated cells compared to mut-treated cells is reported; (b) as in a but with single-stranded mimics without a 
5ʹ phosphate; (c) and (d) match between HRAS and NRAS 3ʹ-UTR mRNA and miR-216b. The Western blots show the levels of HRAS and NRAS proteins in Panc-1 cells 
treated with the designed ss-miR-216b mimics. Results obtained from three independent Western blot experiments, error bars represent ± SE. A    Student’s t-test was 
performed, the asterisk (*) means P < 0.05 (n = 3). 
 
a way that a single colony could be formed by each cell. After 
10 days of growth, the colonies of at least 50 cells were 
counted and the results plotted in a histogram. Figure 8(a, 
b), show the data of a typical colony-formation assay obtained 
with Panc-1 and MIA PaCa-2 cells. The number of colonies 
on the untreated plate shows to be similar to the number on 
the plate treated with the control single-stranded mut 
sequence, which does not suppress oncogenic KRAS. In con- 
trast, miR-216b and the UNA-analogues strongly reduced the 
number of colonies with both types of cells. U2 reduced the 
number of MIA PaCa-2 colonies to ~ 40% of the control. As 
KRAS controls cell adhesion via the integrin-linked kinase 
(ILK) [47–49], its suppression in Panc-1 cells resulted in cell 




Lipid-modified miR-216d and POPC liposomes 
In the experiments described above, the miRNA mimics 
were delivered to the cells complexed with Interferin, a 
commercial polyethyleneimine-based transfectant agent. 
To improve miRNA delivery, we used as a transporter 
palmityl-oleyl-phosphatidylcholine (POPC) liposomes in 
combination with surface attached functionalities [29,30]. 
POPC liposomes were functionalized with a cell-penetrating 
peptide, the trans-activator of transcription of the human 
immune-deficiency virus (TAT), and with miR-216b, as 
previously reported [29,30,50,51]. Both miR-216b and 
TAT were chemically modified with a palmityl membrane 
anchor to allow their rapid attachment to the liposome 
surface. This strategy, illustrated in Figure 9(a), has been 
recently adopted to suppress KRAS in Panc-1 cells with 
POPC liposomes functionalized with G4-decoy oligonucleo- 
tides and TAT [29]. In the present work, bioactive nano- 
particles were obtained by treating POPC liposomes with 
lipid-modified miR-216b (216b-Pal) and TAT (TAT-Pal). 
The effector molecules spontaneously anchored to the lipo- 
some surface. Oligonucleotide 216b-Pal being not cova- 
lently attached to the liposomes can move freely on the 
lipid surface and interact efficiently with the mRNA target. 
The membrane anchor of miR-216b consists of a 3-amino- 
1,2-propanediol unit with two saturated palmityl chains 
(membrane anchor X) [29,30]. We treated two pancreatic 
cancer cells (Panc-1 and MIA PaCa-2) twice with POPC 
liposomes functionalized with TAT-Pal and 216b-Pal and 
then measured the level of KRAS protein by Western blot. 
It was observed that KRAS protein is reduced to about 
~ 30–40% of the control (cells treated with empty lipo- 
somes or with 216b-mut) (Figure 9(b)). This supports the 
conclusion that POPC liposomes are an attractive vehicle to 
deliver miR-26b. Lastly, the bioactivity of 216b-Pal deliv- 
ered via POPC liposomes was tested in a colony formation 
assay.  The  lipid-modified  216b-Pal  fixed  on   POPC 







Figure 6. (a) Scheme showing the function of AGO2 in the silencing mechanism mediated by ss-miRNA; (b) Western blot showing that the silencing of AGO2 by a specific 
siRNA, results in the inactivation of the designed ss-miR-216b mimics. The histograms show the % of KRAS and AGO2 proteins in the cells treated with the designed ss-
miR-216b mimics lacking a 5ʹ phosphate and with AGO2 siRNA as indicated; (c) histograms show the levels of AGO2 and KRAS proteins in Panc-1 cells treated with the 




Figure 7. (a) Plasmids used for the luciferase experiments; (b) Outline of the luciferase experiments. T1: plasmids transfection and first miRNA treatment; T2: second 
miRNA treatment; (c) Histograms show the levels of Renilla luciferase in Panc-1 cells treated with miRNAs mut, 216-b, U1 and U2. The histograms report the % luciferase 
in Panc-1 cells treated with the designed ss-miRNAs (% luciferase = T/C x 100 where T = Renilla/Firefly in miRNA treated cells, C = Renilla/Firefly luciferase  in controlled 
miRNA treated cells (mut)). Error bar is obtained from three independent experiments. A Student’s t-test was performed, the asterisk (*) means P < 0.05    (n = 3). 







Figure 8. Clonogenic assays. MiRNAs 216-b, U1 and U2 decrease the % of colonies in Panc-1 (a) and Mia PaCa-2 (b) pancreatic cancer cells, while miRNA mut did not. 
NT = untreated cells. Histogram shows the % colonies in miRNA-treated cells compared to NT. Error bar is obtained from three independent experiments. A Student’s t-
test was performed, the asterisk (*) means P < 0.05 (n = 3). 
 
 
liposomes reduced Panc-1 and MIA PaCa-2 colony forma- 
tion to about 60% of the control (Figure 10). 
 
Conclusion 
The aim of this study was to design oligoribonucleotides 
combining the potency of the RNAi pathway with the 
versatility of single-stranded RNA, in order to prepare 
antigene molecules specific for the KRAS oncogene, the 
main causative agent for pancreatic cancer. To this purpose 
we focused on miR-216b, a miRNA that is aberrantly 
downregulated in PDAC. We found that double–stranded 
miR-26b mimics, with UNA-modifications in the guide 
strand, specifically down regulate the KRAS gene but not 
the NRAS and HRAS analogues. We also observed that 
UNA-modified single-stranded miR-216b mimics exhibit a 
formidable inhibitory activity against oncogenic KRAS in 
pancreatic cancer cells. The designed ss-miRNAs acted 
through an AGO2-dependent mechanism, in keeping with 









Figure 9. (a) Sequence of miR-216b with two palmityl chains (216b-pal) and of TAT peptide with two X insertions containing two saturated palmityl chains (TAT-pal). 
MiRNA 216b-pal and TAT-pal attached through their lipid modifications to the surface of POPC liposomes; (b) Western blot showing the reduction of KRAS protein in Panc-
1 and MIA PaCa-2 cells treated with the POPC liposomes functionalized with TAT-pal and miR-216b-pal. 
 
 
studies showing that ss-miRNAs may act as gene silencing 
agents [17,18]. Our study provides further evidence in 
support of this conclusion. We designed ss-miRNAs with 
and without a 5ʹ phosphate: in both cases the effector 
molecules suppressed the KRAS target gene with similar 
strength. Western blots showed that the designed ss-miR- 
216b mimic with two UNA modifications reduced drama- 
tically (by 90%) the KRAS protein in Panc-1 cells as well as 
the capacity of colony formation (by 50%). To our knowl- 
edge, this is the first report showing that miR-216b targets 
oncogenic KRAS in PDAC cells. As a proof-of-principle we 
conjugated miR-216b with two palmityl chains and fixed it 
on the surface of POPC liposomes, functionalized with the 
TAT cell-penetrating peptide, which was also conjugated 
with two palmityl chains. The results obtained with two 
PDAC cell lines showed that the nanoparticle functiona- 
lized with TAT-Pal and 216b-Pal caused ~ 70% decrease of 
protein KRAS and ~ 40% inhibition of colony formation. 
This delivery strategy may have a interesting potential for 









Figure 10. Clonogenic assays. Effect of functionalized POPC liposomes on colony formation in Panc-1 and Mia PaCa-2 pancreatic cancer cells. NT = untreated cells, 
216-pal = cells treated with POPC liposomes functionalized with 216b-pal and TAT-pal; Liposome = cells treated with POPC non-functionalized with the effector 
molecules. Histogram shows the % colonies in miRNA-treated, liposome-treated and non-treated (NT) cells. Error bar is obtained from three independent 
experiments. A Student’s t-test was performed, the asterisk (*) means P < 0.05 (n = 3). 
 
Experimental 
Synthesis of UNA-modified miRNAs 
The synthesis of the UNA-modified miRNA miR-216b 
mimics (216b, U1, U2, mut, U1-P, U2-P) was performed on 
an automated nucleic acid synthesizer as previously reported. 
The oligonucleotides were purified by HPLC by using a C18 
3 µm 300 Å reversed phase column. Maldi MS analyses were 
carry out to confirm the structure of the designed UNA- 
modified miRNAs and evaluate their purity. Calculated and 
experimental masses were almost identical for all the oligo- 




Synthesis of lipid-conjugated TAT and miR-216b 
The oligonucleotide was synthesized on an ExpediteTM 8900 
nucleic acid synthesis system (Perceptive Biosystems Inc.). 
The synthesis was performed on a 1.0 µmol scale on GE 
Healthcare Custom Primer SupportTM T40s using standard 
conditions for automated synthesis with DCI as activator. 
However, the lipid modified phosphor amidite was dissolved 
in 2:1 DCE:MeCN at a concentration of 0.1 M, 42® was used 
as activator (Proligo reagent/Sigma-Aldrich) and the coupling 
time was increased to 20 min. The DMT protecting group on 
the last nucleotide in the sequence was removed. After depro- 
tection and cleavage from the solid support using standard 
conditions (conc. NH3(aq.) over night at 55 ºC), the oligonu- 
cleotides were purified by HPLC. 
TAT was synthesized on a Liberty 1 Microwave Peptide 
Synthesizer using a Rink Amide resin and an amino acid 
concentration of 0.2 M for unmodified amino acids and 
0.1 M for the lipid-modified amino acids. After synthesis, 
the peptide was cleaved from the resin, deprotected and 





The cells used in this study are the human pancreatic adeno- 
carcinoma cells Panc-1 with a KRAS G12D (12 Gly→Asp) 
mutation and MIA PaCa- 2 with a KRAS G12C (12 Gly→Cys) 
mutation. The cell lines have been genotyped by Microsynth 
(CH) to verify their identity. As expected, they matched 100% 
to the DNA-profiles of the cell line of Panc-1 (ATCC® CRL- 
1469TM) and MIA PaCa-2 (ATCC® CRM-CRL-1420TM). 
 
 
Preparation of POPC liposomes 
Liposomes were prepared as previously described [31]. They 
were extruded on a LIPIX Extruder, Northern Lipids. 114 mg 
1-palmityl-2-oleyl-sn-glycero-3-phosphocholine (POPC) was 
suspended in 1.5 mL 10 mM phosphate buffer (10 mM 
NaH2PO4. 2 H2O, 5 mM Na2HPO4, 140 mM Na+, pH 7.4) 
(100 mM POPC) and the resulting solution was extruded 10 
times through two stacked polycarbonate filters with a pore 






liposomes, determined using Nanoparticle Tracking Analysis, 
was about 80 nm. 
 
Transfection experiments 
The cells were transfected twice with the designed ds- or ss- 
miRNAs. When the cells were about 65% confluent, 10 nM ss- 
or ds-miRNAs were transfected in the cells in the presence of 
Interferin (Polyplus, France), following the manufacturing 
instructions. After 24 h of incubation a second transfection 
was performed. The double-stranded miRNA mimics have 
been prepared in DEPC water containing 100 mM NaCl, 
50 mM Tris-HCl pH 7.4, heating the solution for 5 min at 
80 °C and let the molecules to anneal overnight at room 
temperature. 
Transfections with POPC liposomes were carried out as 
previously reported [29]. Briefly, Liposomes (2.8 μl, liposome 
stock solution ~ 10−12 moles/L) were mixed with 110 pmol ss/ 
ds-miRNA in 200 μl phosphate buffer (10 mM NaH2PO4, 
5 mM Na2HPO4, 140 mM NaCl pH 7.4). After overnight 
incubation at room temperature, 2.3 μg of peptide were added 
to the solution and let to incubate for 30 minutes (liposome 
mix). For all liposome formulations a statistic distribution of 
miRNA and CPPs during membrane anchoring to the surface 
of the liposomes was assumed. Finally, the liposome mix 
(200 μl) was added to the cells in 2 ml DMEM. 
As for the clonogenic assays, the liposome mix was 
obtained by adding 100 pmol miRNA in 50 μl buffer (lipo- 
some and peptide were scaled down accordingly). Then 50 μl 
of liposome mix were in this case added to 120 μl cell med- 
ium. A second transfection was performed 24 h following the 
first. Then, 48 h after the second transfection the cells in each 
well were divided in 3 parts and seeded again in 3 wells. 
Anti AGO2 siRNA (10 nM, OriGene, USA) were trans- 
fected in Panc-1 cells using Interferin (PolyPlus, France) 
according to manufacturing instructions. 
 
Stability of miRNAs in cellular environment 
To determine their nuclease resistance, the designed miRNAs 
(3 µM) have been incubated for 1, 2 and 4 h in a total extract 
from Panc-1 cancer cells (2 μg). After incubation the oligo- 
nucleotides have been run in a denaturing 20% polyacryla- 
mide gel (7 M urea, 1 x TBE), which was stained with 
‘stains all’. 
 
Dual luciferase assays 
Panc-1 cells were plated (15 x 103) in 96-well plate and after 
one day transfected with miR-216b or UNA-analogues and 
with plasmids pGL4.75-KRAS LCS6m (a gift from Frank 
Slack, Plasmid # 44,571, Addgene) and pGL3 Control Vector 
(Promega, USA). Transfection was performed by mixing 
70 ng of pGL3 Control Vector (Firefly luciferase) with 30 ng 
of pGL4.75-KRAS LCS6m (Renilla luciferase), by using jet-PEI 
(Polyplus) as a transfectant agent. A second miRNA transfec- 
tion was performed 24 h after the first transfection and the 
luciferase assays were performed 48 h after the second trans- 
fection. A Dual-Glo Luciferase Assay System (Promega, USA) 
was used. Samples were read on a Turner Luminometer and 
the relative luminescence expressed as T/C x 100, where 
T = Renilla luciferase/Firefly luciferase in miRNA treated 





Total cell protein lysates (15–20μg) extracted from Panc-1 
cells were sonicated for 10 minutes and the lysates were 
electrophoresed on 12% SDS-PAGE and transferred into a 
nitrocellulose membrane, at 70 V for 2 h. The filter was 
blocked for 1 h with 5% nonfat dry milk solution in PBS 
0.05% Tween (Sigma-Aldrich, Italy) at room temperature. 
Membranes were incubated overnight at 4 °C with the pri- 
mary antibodies: monoclonal anti-KRAS (clone 3B10-2F2, 
IgG1 mouse, 2.5 μg/mL, Sigma-Aldrich, USA), polyclonal 
anti-HRAS (IgG rabbit, diluted 1:300, Santa Cruz 
Biotechnology Inc, USA), monoclonal anti-NRAS (clone 
F155-227, IgG1 mouse, 2.5 μg/mL) and monoclonal anti- 
actin (clone JLA20, IgM mouse, 1x10−4 μg/mL, Calbiochem, 
Merck Millipore, Germany). The membranes were washed 
with a 0.05% Tween in PBS and then incubated 1 h with the 
secondary antibodies horseradish peroxidase conjugated: anti- 
mouse IgG (diluted 1:5000) and anti-mouse IgM (diluted 
1:2000) (Calbiochem, Merck Millipore, Germany) and anti- 
rabbit IgG (diluted 1:5000) (Calbiochem, Merck Millipore, 
Germany). To detect the protein we used Super signal ® 
West PICO and FEMTO (ThermoFisher Scientific Pierce, 
USA). The exposure time depended on the antibody used 
and was usually between 30 s and 5 min. The protein levels 




Colony forming assay 
To assess the effect of miR-216b, U1 and U2 on the growth of 
PDAC cells we carried out colony formation assays with 
Panc-1 and MIA PaCa-2 cells, carrying the KRAS mutations 
G12D and G12C, respectively. The PDAC cells, treated with 
the designed miRNAs, were seeded in a medium after being 
diluted in a way that a single colony could be formed from 
each cell. After 7–13 days of growth, the colonies of at least 50 
cells were counted and the results plotted in a histogram. 
NT = untreated cells. Histogram shows the % colonies in 
miRNA-treated cells compared to NT. Values obtained from 
three independent experiments. A Student’s t-test was per- 
formed, (*) = P < 0.05. 




PDAC pancreatic ductal adenocarcinoma 
KRAS Kirsten ras 
UTR untranslated region 
POPC palmityl-oleyl-phosphatydilcholine 
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Supplementary data, S1. miRNA and FC values calculated for three dataset (GSE43796, E-





Three miRNA expression datasets (GSE41372, GSE43796, E-MTAB-753) of pancreatic cancer were 
retrieved from GEO (Barrett, 2011) and ArrayExpress (Parkinson, 2007). The available raw files have 
been downloaded. As for the affymetrix platform, the CEL files were processed using standard tools 
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available within the affy package in R (Gautier, 2004), they were normalized using the standard RMA 
algorithm (Irizarry, 2003). The Agilent raw data text files were normalized between arrays by quantile 
normalization using the limma library (Ritchie, 2015). A statistical analysis was performed using the 
standard t-test for unpaired samples (tumour samples and non-tumour samples were unrelated). 
Differentially expressed miRNAs in the malignant tissues were defined as those characterized by a P 
<0.05 and a fold change FC >1.5 or FC < -1.5. We searched for a correlation between KRAS and the 
differentially expressed miRNAs by using miRGate (Andrés-León et al., 2015), Targetscan (Lewis 
et al., 2005) and Miranda (Betel et al., 2010).  
 
 
Supplementary data, S2. Levels of KRAS mRNA in Panc-1 cells measured by quantitative real-time 
PCR. The assay has been performed 16, 40 and 72 h after the second treatment with 10 nM single-








RNA Extraction and Real-time PCR 
Panc-1 cells (15x103) were transfected in a 96-well plate with 10 nM miRNA 216b as described 
above. RNA was extracted 16, 40 and 72 h after the second transfection by using iScript™ RT-qPCR 
Sample Preparation Reagent (Bio Rad) following the manufacturer’s instructions. For cDNA 
synthesis 1.25  μl of RNA (extracted from about 103 cells) was heated at 55 °C and placed in ice. The 
solution was added to 11.25 μl of mix containing (final concentrations) 1 x buffer, 0.01 M DTT 
(Invitrogen), 1.6 μM primer dT (MWG Biotech, Ebersberg, Germany; d(T)16), 1.6 μM Random 
hexamer primers (Microsynth), 0.4 mM dNTPs solution containing equimolar amounts of dATP, 
dCTP, dGTP, and dTTP (Euroclone, Pavia, Italy), 0.8 units/μl RNase OUT, and 8 units/μl of Maloney 
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murine leukemia virus reverse transcriptase (Invitrogen). The reactions were incubated for 1  h at 
37 °C and stopped with heating at 95 °C for 5 min. 
Real-time PCR multiplex reactions were performed with 1 x Kapa Probe fast qPCR kit (KAPA 
Biosystems, Wilmington, MA, USA) for KRAS and housekeeping genes β2-microglobulin and 
HPRT, 1.0 μl of cDNA in 10 μl final and primers/probes at the following concentrations: for KRAS, 
the probe was FAM-TACTCCTCTTGACCTGCTGTG-BHQ1 (accession No. NM_033360, from 
352 to 372, 90 nM), the sense primer was 5′-CGAATATGATCCAACAATAGAG (from 271 to 292, 
180 nM) and the antisense primer was 5′-ATGTACTGGTCCCTCATT (from 379 to 396, 180 nM). 
For β2-microglobulin accession n. NM_004048 probe ROX-TATGCCTGCCGTGTGAACC-BHQ2 
(from 352 to 370, 60 nM), the primer sense was 5′-CCCCACTGAAAAAGATGA (from 333 to 350, 
100 nM), the primer antisense was 5′-CCATGATGCTGCTTACAT (from 415 to 432, 100 nM). For 
HPRT accession n. NM_000194 probe 5′-Cy5-CTTGCGACCTTGACCATCTT-BHQ2 (from 633 to 
652, 180 nM), the primer sense was 5′-CTTGATTGTGGAAGATATAATTG (from 557 to 575, 
210 nM), the primer antisense was 5′-TATATCCAACACTTCGTGG (from 672 to 690, 230 nM). 
The PCR cycle was: 3 min at 95 °C, 50 cycles 10 s at 95 °C, 60s at 58 °C. PCR reactions were carried 
out with a CFX-96 real-time PCR apparatus controlled by an Optical System software (version 3.1) 













Table 1. Molecular masses of UNA-modified RNAs by MALDI MS 
miRNA sequence* Name Calculated Found 
5’-rArArArUrCrUrCrUrGrCrArGrGrCrArArArUrGrUrGuA U1 7051,4 7051,3 
5’-rArArArUrCrUrCrUrGrCuArGrGrCrArArArUrGrUrGuA U2 7053,4   7053,4 
5’-rArArArCrUrGrUrGrGrCrArGrGrCrArCrCrUrGrUrGuA mut 7082,4   7082,7 
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5’P-rArArArUrCrUrCrUrGrCrArGrGrCrArArArUrGrUrGuA U1-P 7131,3  7131,3 
5’P-rArArArUrCrUrCrUrGrCuArGrGrCrArArArUrGrUrGuA U2-P 7133,3 / 7133,6   
* uA= unlocked nucleic acid  
 
 





































Table 2. Oligonucleotides used in this study. 








complementary-216b  5’-rCrArCrArUrUrUrGrCrCrUrGrCrArGArGrArUrUrUrU 
complementary-mut: 5’-rCrArCrArGrGrUrGrCrCrUrGrCrCrArCrArGrUrUrUrU 




Barrett T, Troup DB, Wilhite SE, et al. NCBI GEO: archive for functional genomics data sets—10 
years on. Nucleic Acids Res. 2011 Jan; 39: D1005–1010.  
 
Parkinson H, Kapushesky M, Shojatalab M, et al. Array Express a public database of microarray 
experiments and gene expression profiles. Nucleic Acids Res. 2007; 35:D747–750.  
 
Gautier L, Cope L, Bolstad BM, et al., Affy--analysis of Affymetrix GeneChip data at the probe level. 
Bioinformatics. 2004; 20:307-315. 
 
Irizarry RA, Bolstad BM, Collin F, et al., Summaries of Affymetrix GeneChip probe level data. 




Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-
sequencing and microarray studies. Nucleic Acids Res. 2015; 43:e47.   
 
Andrés-León E, González Peña D, Gómez-López G, et al., MiRGate: a curated database of human, 
mouse and rat miRNA-mRNA targets. Database (Oxford) 2015; 2015:bav035.  
 
Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that 
thousands of human genes are microRNA targets. Cell 2005; 120:15-20. 
 
Betel D, Koppal A, Agius P, et al. Comprehensive modeling of microRNA targets predicts functional 







Mutant KRAS is present in more than 90% of pancreatic tumours where it plays an 
important role in the initiation and progression of the disease. Despite the important 
achievements of the last years, several aspects on KRAS biology are not yet clear and 
further studies are needed to develop targeted strategies against this oncogene for the 
treatment of PDAC. 
Previous work from our laboratory showed that the KRAS promoter contains a G- rich 
region located upstream of the transcription start site (TSS). This sequence being 
composed by runs of guanines (G4 motif) folds into a G-quadruplex (or G4) structure 
that, according to recent studies, is present in the cell 1. This unusual conformation is 
recognized by several transcription factors such as MAZ, PARP-1 and hnRNP A1 and the 
most likely function of the G4 structure is to recruit to the KRAS promoter the nuclear 
proteins essential for activating transcription. 
Recent studies have reported that pancreatic cancer cells are addicted to KRAS because 
it reprograms the metabolism in order to sustain a high metabolic rate, typical of cancer. 
An interesting byproduct of the metabolism are the so-called ROS species: free radical 
reactive oxygen species that are cytotoxic. Because of the rapid metabolism of cancer 
cells, their level of ROS is higher than in normal cells. ROS are strong oxidizing agents 
and may affect the cellular biomolecules including DNA. It is worth noting that, among 
the nucleobases, guanine, in particular when present in a G- rich sequence, is the most 
oxidizable of the nucleobases, due to its low redox potential. The main product of 
guanine oxidation is 8-oxoguaine (8OG). 
We discovered by ChIP experiments performed with an antibody specific for 8OG, that 
this oxidized base is more abundant in the KRAS G4 region than in genomic non- G4 
regions. Starting from this finding, we investigated if 8OG in the promoter G4 motif of 
KRAS can somehow affect the transcription of the gene. To address this point we start 
by designing oligonucleotides mimicking the KRAS G4 motif, carrying 8OG modifications 
in different positions, either in the G- tetrads or in the 11-loop. The synthesis of these 
modified oligonucleotides was carried at the University of Odense (DK), with which we 





We discovered that 8OG can modulate the folding of the KRAS G4 motif. Circular 
dichroism experiments and UV-melting curves showed that 8OG strongly destabilizes G4 
when the lesion is present in a G-tetrad, whereas, if it is located in a loop, it does not 
affect the stability of the structure. Moreover, DMS-footprinting assays confirmed that 
when 8OG is located in a G-run, the oxidized G-run is excluded from the formation of 
the G4 structure and replaced by the extra G-run present in the G4 motif (the KRAS G4 
motif is composed by 5 runs of guanines). The reason why the oxidized G-run is excluded 
is due to the fact that N7 of 8OG becomes a donor of H-bond, whereas in wild type 
guanine is an acceptor. So, the presence and position of the oxidized guanine plays a 
crucial role in the folding of the G4 motif and in the topology of the G4 structure, which 
can affect its stability, interaction with transcription factors and gene transcription. 
In addition to its impact on DNA folding, 8OG affects the recruitment and binding of the 
transcription factors to the KRAS promoter, as stated above. ChIP assays showed that, 
when the cells are treated with hydrogen peroxide (H2O2) - a molecule that increases 
the oxidative stress in the cells – the level of 8OG increases more in the G4 motif than 
in non-G4 motif regions. We also found that the recruitment of the above transcription 
factors to the promoter is increased, suggesting that 8OG can be an important marker 
for transcription. Together our data suggest that in pancreatic cancer cells a moderate 
increment in the level of ROS affects favourably transcription in the sense that ROS 
stimulate the expression of KRAS, which is necessary for cell growth. 
So, we can conclude that ROS may be an important player in KRAS expression and 
tumour progression. However, high levels of ROS can be cytotoxic and even if ROS are 
upregulated in cancer cells, their level is strictly controlled by the cells to avoid cellular 
conditions that may favour apoptosis instead of proliferation. It is known that the redox 
homeostasis is regulated by Nrf2 which maintains the ROS equilibrium at levels suitable 
with cell growth. In the light of data reported in literature 62, we investigated the 
response of Nrf2 expression from ROS and found that there is a strict correlation 
between ROS and Nrf2 in pancreatic cancer cells. Interestingly, we also found that KRAS 
controls the expression of Nrf2 as the ectopic expression of mutant KRAS upregulates 
Nrf2. Since Nrf2 is stimulated by both ROS and KRAS, we asked if ROS upregulates KRAS 
as well. We discovered by Western blots and RT-PCR experiments that when the level 





suggesting that ROS function as KRAS stimulators. In the light of these data, we asked 
how ROS upregulate KRAS. We have hypothesized that this occurs through a mechanism 
involving oxidation at the G4 motif, which is known to play an essential role in the 
transcription of the gene. We reasoned that the relatively high level of oxidative stress 
present in pancreatic cancer cells favours the oxidation of guanine, in particular in the 
G-runs of the G4 motif, as supported by ChIP data. This oxidative event stimulates the 
recruitment to the promoter of the transcription factors essential for transcription, 
suggesting that 8OG may function as an epigenetic marker for transcription. But it 
should be noted that 8OG is a mutagenic DNA lesion that is repaired by glycosylase 
hOGG1 when the G4 motif leaves the G4 conformation and assumes the canonical 
duplex conformation. This occurs when the transcription factors binds to the oxidized 
G4 structure. We surprisingly found that upon binding they unfold the structure and 
promote the transition of the G4 motif from the folded to the duplex form. In the duplex 
form, hOGG1 excises 8OG creating an apurinic site that is repaired by BER system. After 
BER, a transcription machinery involving RNA Pol II is formed at the promoter and 
transcription is activated. As proposed by Boldogh and co-workers 205,215, hOGG1 excises 
8OG and binds tightly to it, forming a complex that acts as a guanine nucleotide 
exchange factor. This complex contributes to the activation of protein KRAS by 
promoting the transformation of KRAS-GDP to KRAS-GTP. It is possible that this 
mechanism play an important role in KRAS activation in tumour cells, but further work 
is necessary to fully address this issue. 
In addition to the control of the redox homeostasis, we found that the ROS/KRAS/Nrf2 
axis is also linked to survival and apoptosis pathways. This involves NF-B, Snail and RKIP. 
The expression of these proteins are sensitive to ROS. In fact, our data show that low 
ROS levels result in the upregulation of NF-B and pro-survival Snail and in the 
simultaneous downregulation of pro-apoptotic RKIP. This gene expression pattern 
favours cell proliferation. By contrast, high ROS favour apoptosis by upregulating pro-
apoptotic RKIP and downregulating NF-B and pro-survival Snail. There is a clear 
interconnection between the ROS-KRAS-Nrf2 axis and the NF B-Snail-RKIP pathway. 
Considering that KRAS controls the ROS homeostasis via Nrf2 and that the ROS-
homeostasis controls, in turn, the survival and apoptosis pathways, KRAS is a key gene 





results in the inhibition of cell proliferation and activation of apoptosis. Now we can 
understand the molecular basis of this behaviour. When KRAS is inhibited, Nrf2 is not 
stimulated and endogenous ROS increases to higher levels. Enhanced ROS inhibits NF-
B which in turn downregulates Snail and simultaneously upregulate RKIP. As RKIP is a 
pro-apoptotic gene, the gene expression profile activated by enhance ROS is consistent 
with apoptosis. 
Finally, the data of this PhD work are useful in the design of effective PDT treatments 
for pancreatic cancer. PDT is a treatment modality involving a photosensitizer that, upon 
irradiation at a given wavelength, generates ROS that can kill cancer cells. Since ROS 
stimulates Nrf2, the ROS produced by PDT are partly detoxified by the anti-ossification 
programs activated by Nrf2. In the presence of active Nrf2, PDT will be effective if it 
overcomes the action of Nrf2. In the light of this behaviour, the generation of ROS in the 
presence of an inhibitor of Nrf2, i.e. under conditions in which the cellular defences 
against oxidative stress are suppressed, may render PDT more efficient. To support this 
prove-of-concept we performed some preliminary experiments by treating 
photodynamically (fluence 7.2 J/cm2) Panc-1 and BX-PC3 cells with a cationic porphyrin 
(TMPyP4) or with TMPyP4 and luteolin, an inhibitor of Nrf2. We found indeed that when 
PDT is combined with luteolin (adjuvant), the cells become more sensitive to PDT 
treatment. By measuring the number of cell colonies after 8 days of growth, TMPyP4 + 
Luteolin reduced the colonies by 50 %, while TMPyP4 alone by only 25 %. These results 
strongly support our hypothesis that when Nfr2 is inhibited, the cells are more sensitive 
to PDT as the Nrf2-directed antioxidant program is inhibited. These results provide the 
molecular basis for the design of innovative PDT treatment by using a photosensitizer 
and an adjuvant molecule that reduces the detoxification pathways of cancer cells. 
 
Another topic of this PhD program was to find out molecules that specifically suppress 
KRAS. I have investigated the capacity of a miRNA aberrantly downregulated in PDAC 
(miR-216b) to inhibit the expression of KRAS in pancreatic cancer cells. We focused on 
miR-216b, which has been identified in three different databases. In collaboration with 
the University of Odense (DK), we designed single-stranded miRNA mimics modified 
with unlocked nucleic acid (UNA) in order to improve their resistance in the cells. We 





through on AGO dependent mechanism. We also modified miR- 216b with a palmityl 
chain in order to anchor it to the surface of palmitoyl- oleyl- phosphatidylcholine (POPC) 
liposomes, which in turn were functionalized with cell penetrating peptides. These 
nanoparticles were tested in two different pancreatic cancer cell lines and efficiently 
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